

10/25/01

1-10-52 JC10 Rec'd PCT/PTO 25 Oct 2001

FORM PTO 25 (10-95) (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER <b>BB-1355</b>	
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>					
INTERNATIONAL APPLICATION NO. <b>PCT/US00/12061</b>		INTERNATIONAL FILING DATE <b>3 MAY 2000 (03.05.00)</b>		U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR) <b>10/030884</b>	
				PRIORITY DATE CLAIMED <b>7 MAY 1999 (07.05.99)</b>	

TITLE OF INVENTION  
**AUXIN TRANSPORT PROTEINS**

APPLICANT(S) FOR DO/EO/US  
**OROZCO, EMIL M., JR. ET AL.**

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to being national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b)) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19<sup>th</sup> month from the earliest claimed priority date.
5. ☒ A copy of the International Application was filed (35 U.S.C. 371 (c) (2))
  - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau.
  - b. ☐ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ A translation of the International Application into English (35 U.S.C. 371 (c) (2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c) (3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409)
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).


Items 13 to 18 below concern document(s) or information included :

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A FIRST preliminary amendment.  
A SECOND or SUBSEQUENT preliminary amendment.
16. ☐ A substitute specification.
17. ☒ A change of power of attorney and/or address letter.
18. ☒ Certificate of Mailing by Express Mail.
19. ☐ Other items or information:

17. General Power of Attorney  
18. Express Mailing Label No.: EJ376014453US

531 Rec'd PCT

25 OCT 2004

APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.53) <b>10/030881</b>		INTERNATIONAL APPLICATION NO. <b>PCT/US00/12061</b>		ATTORNEY'S DOCKET NUMBER <b>BB-1355</b>	
20. The following fees are submitted  <b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) – (5)) :</b> <input checked="" type="checkbox"/> Search Report has been prepared by the EPO or JPO \$890.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) \$710.00 <input type="checkbox"/> No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$740.00 <input type="checkbox"/> Neither international preliminary examination fee paid to USPTO (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,040.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) And all claims satisfied provisions of PCT Article 33(2)-(4) \$ 100.00  <b>ENTER APPROPRIATE BASIC FEE AMOUNT = \$890.00</b>				<b>CALCULATIONS PTO USE ONLY</b>	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	24 - 20 =	4 x	\$18.00	\$72.00	
Independent Claims	6 - 3 =	4 x	\$80.00	\$252.00	
Multiple Dependent Claims (check if applicable)			<input type="checkbox"/>	\$0.00	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$324.00</b>	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).			<input type="checkbox"/>	\$0.00	
<b>SUBTOTAL =</b>				<b>\$324.00</b>	
Processing Fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)).			<input type="checkbox"/> 20 <input type="checkbox"/> 30	\$0.00	
<b>TOTAL NATIONAL FEE =</b>				<b>\$1,214.00</b>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).			<input type="checkbox"/>	\$0.00	
<b>TOTAL FEES ENCLOSED =</b>				<b>\$1,214.00</b>	
				Amount to be : Refunded	\$
				Charged	\$
<input type="checkbox"/> A check in the amount of _____ to cover the above fees enclosed. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <b>04-1928</b> in the amount of <b>\$1,214.00</b> to cover the above fees. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. <b>04-1928</b> a duplicate copy of this sheet is enclosed.					
<b>NOTE :</b> Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (CFR 1.37(a) or (b)) must be filed and granted to restore the application to pending status. <b>SEND ALL CORRESPONDENCE TO:</b>					
<b>RIZZO, Thomas M.</b> <b>E. I. DU PONT DE NEMOURS AND COMPANY</b> <b>Legal Patent Records Center</b> <b>1007 Market Street</b> <b>Wilmington, Delaware 19898</b> <b>United States of America</b>			<div style="text-align: center;">             SIGNATURE         </div> <div style="text-align: center;"> <b>RIZZO, THOMAS M.</b>            NAME         </div> <div style="text-align: center;">           41,272            REGISTRATION NUMBER         </div> <div style="text-align: center;"> <i>October 19, 2001</i>            DATE         </div>		

101544384, 2002-05-28



PCT10

## RAW SEQUENCE LISTING

DATE: 06/21/2002

PATENT APPLICATION: US/10/030,884

TIME: 11:44:56

Input Set : A:\BB1355 USPCT Corrected Seq List.txt

Output Set: N:\CRF3\06212002\J030884.raw

3 <110> APPLICANT: Emil M. Orozco, Jr.  
4 Zude Weng  
5 Wesley B. Bruce  
6 Rebecca E. Cahoon  
7 Yong Tao  
9 <120> TITLE OF INVENTION: Auxin Transport Proteins  
11 <130> FILE REFERENCE: BB1355  
13 <140> CURRENT APPLICATION NUMBER: 10/030,884  
C--> 14 <141> CURRENT FILING DATE: 2002-05-28  
16 <150> PRIOR APPLICATION NUMBER: 60/133,040  
17 <151> PRIOR FILING DATE: 1999-05-07  
19 <160> NUMBER OF SEQ ID NOS: 48  
21 <170> SOFTWARE: Microsoft Office 97  
23 <210> SEQ ID NO: 1  
24 <211> LENGTH: 629  
25 <212> TYPE: DNA  
26 <213> ORGANISM: Zea mays  
28 <220> FEATURE:  
29 <221> NAME/KEY: unsure  
30 <222> LOCATION: (413)  
31 <223> OTHER INFORMATION: n=a,c,g or t  
33 <220> FEATURE:  
34 <221> NAME/KEY: unsure  
35 <222> LOCATION: (466)  
36 <223> OTHER INFORMATION: n=a,c,g or t  
38 <220> FEATURE:  
39 <221> NAME/KEY: unsure  
40 <222> LOCATION: (526)  
41 <223> OTHER INFORMATION: n=a,c,g or t  
43 <220> FEATURE:  
44 <221> NAME/KEY: unsure  
45 <222> LOCATION: (535)  
46 <223> OTHER INFORMATION: n=a,c,g or t  
48 <220> FEATURE:  
49 <221> NAME/KEY: unsure  
50 <222> LOCATION: (549)  
51 <223> OTHER INFORMATION: n=a,c,g or t  
53 <220> FEATURE:  
54 <221> NAME/KEY: unsure  
55 <222> LOCATION: (560)  
56 <223> OTHER INFORMATION: n=a,c,g or t  
58 <220> FEATURE:  
59 <221> NAME/KEY: unsure

ENTERED

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/030,884

DATE: 06/21/2002

TIME: 11:44:56

Input Set : A:\BB1355 USPCT Corrected Seq List.txt

Output Set: N:\CRF3\06212002\J030884.raw

```

60 <222> LOCATION: (601)..(602)..(603)
61 <223> OTHER INFORMATION: n=a,c,g or t
63 <220> FEATURE:
64 <221> NAME/KEY: unsure
65 <222> LOCATION: (628)
66 <223> OTHER INFORMATION: n=a,c,g or t
68 <400> SEQUENCE: 1
69 gctaaaattg ctaatatcttcc tccaaaggaa acaagatata taatgtttat cttcagacag 60
70 catgaagcaa gataagatat atatataatcg attcttcgac cgcagtcagc atgtttgaca 120
71 gatcgcaatg cctcactcac tgaatcactg aatagatcgc tgcgtcgcga gctatctttc 180
72 gtttccctac ctaagctaata agtaatcgct aatgctcatc agaaatttca tgtggggccg 240
73 atacaccaca gcatggcgcc ttccgcacgc tgaagaagcg agcgagagag gctcacagcc 300
74 ccagcaagat gtagtagacc aggggtgatgg gcagagcgat gagcatcccg aagatcacgg 360
W--> 75 ctgtgctcag gatgtcgagg tgaacgccgt actccttggg cgaacacgaa cgngcacgat 420
W--> 76 cccctgaggc agagcagcct ggacgatggc gatgtggagg aggagncgcg cagaccgacg 480
W--> 77 gcgatggaag cggcgcccat gaccgcgggg gctgcgaaga aaccgnacgc ccatnccgat 540
W--> 78 ggccgccanc ttgttcccg n aagcgatgat cctcgggtgc agcgccatga acaggcctag 600
W--> 79 nnngaacatg gccatccgag accgcgtnc 629
81 <210> SEQ ID NO: 2
82 <211> LENGTH: 171
83 <212> TYPE: PRT
84 <213> ORGANISM: Zea mays
86 <400> SEQUENCE: 2
87 Pro Leu Ala Ile Pro Pro Ala Gly Val Met Thr Arg Leu Ile Leu Ile
88 1 5 10 15
90 Met Val Trp Arg Lys Leu Ile Arg Asn Pro Asn Thr Tyr Ser Ser Leu
91 20 25 30
93 Ile Gly Val Val Trp Ser Leu Val Ser Tyr Arg Trp Gly Ile Glu Met
94 35 40 45
96 Pro Ala Ile Ile Ala Arg Ser Ile Ser Ile Leu Ser Asp Ala Gly Leu
97 50 55 60
99 Gly Met Ala Met Phe Ser Leu Gly Leu Phe Met Ala Leu Gln Pro Arg
100 65 70 75 80
102 Ile Ile Ala Cys Gly Asn Lys Leu Ala Ala Ile Ala Met Gly Val Arg
103 85 90 95
105 Phe Val Ala Gly Pro Ala Val Met Ala Ala Ala Ser Ile Ala Val Gly
106 100 105 110
108 Leu Arg Gly Val Leu Leu His Ile Ala Ile Val Gln Ala Ala Leu Pro
109 115 120 125
111 Gln Gly Ile Val Pro Phe Val Phe Ala Lys Glu Tyr Gly Val His Pro
112 130 135 140
114 Asp Ile Leu Ser Thr Ala Val Ile Phe Gly Met Leu Ile Ala Leu Pro
115 145 150 155 160
117 Ile Thr Leu Val Tyr Tyr Ile Leu Leu Gly Leu
118 165 170
120 <210> SEQ ID NO: 3
121 <211> LENGTH: 1088
122 <212> TYPE: DNA
123 <213> ORGANISM: Zea mays

```

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/030,884

DATE: 06/21/2002

TIME: 11:44:56

Input Set : A:\BB1355 USPCT Corrected Seq List.txt

Output Set: N:\CRF3\06212002\J030884.raw

125 &lt;220&gt; FEATURE:

126 &lt;221&gt; NAME/KEY: unsure

127 &lt;222&gt; LOCATION: (110)

128 &lt;223&gt; OTHER INFORMATION: n=a,c,g or t

130 &lt;400&gt; SEQUENCE: 3

W--> 131 gggacgggaa agccgcggcg gcgggcgggg accccagcac ggtggccgcg ccgacggcga 60  
 132 tggcgccgac gaggctcatg acccggtga tcctgatcat ggtgtggcgn caactcatcc 120  
 133 gcaacccaaa cactactcc agcctcatcg gcgtcatctg gtcgctcgtc tgcttcaggt 180  
 134 ggaacttcca gatgccggcc atcgctcctgc agtccatctc catcctgtcg gacgcggggc 240  
 135 tgggatggc catgttcagt ctggggctgt tcatggcgct gcagccgcgg atcatcgct 300  
 136 gcggaacaa ggtggcgacg ttgcctatgg cggcgcgctt cctgaccggt ccggcggtta 360  
 137 tggcgccgcg gtccttcgcc gtgggcctcc gcggcacgct tctgcacgtc gccatcgctc 420  
 138 aggcagctct gcctcagggc attgtccctt tegtcttcgc aaaggagtac aacgtgcacc 480  
 139 ctgacattct cagcaccgca gtcatttttg gcatgctcat cgccttgccg atcacgctcg 540  
 140 tctactacat cctgctcggc ctgtgaccga cccgtgggtg atggcaatgg catgccccgc 600  
 141 attgctgtaa ctgtaaagac cgctgctgcc actttccgtt caagggaggc aagtgaggag 660  
 142 actgtctgct acgacatttg cttggcgctt caaaaatgag tggcttggtt ctctctctct 720  
 143 tctatctatt ttttattttt tctctagaag taggtgtgag gattgtatgg atggaaagt 780  
 144 tgggaggtgg acaagtcgcg gtagctaggt aggcagacaa tggtaggca aaacggacca 840  
 145 aaaggaggtg caagtaacaa agcttgaagg gaacaggaga tccagtttaa gcacgtcacg 900  
 146 ggatgggttg gatatttcaa cgggttcagg gtattttggt tggctgcgct gaccgatgta 960  
 147 aaatcagcgc gccattgtga caggagatcg atcttgcttg agataaacag ctcacctccg 1020  
 148 gagtttgatg gcttgagata agggctcaac tcaaaataga cagaaatata taccgtattt 1080  
 149 gtcactga 1088

151 &lt;210&gt; SEQ ID NO: 4

152 &lt;211&gt; LENGTH: 187

153 &lt;212&gt; TYPE: PRT

154 &lt;213&gt; ORGANISM: Zea mays

156 &lt;400&gt; SEQUENCE: 4

157 Asp Gly Lys Ala Ala Ala Gly Gly Asp Pro Ser Thr Val Ala Ala  
 158 1 5 10 15  
 160 Pro Thr Ala Met Pro Pro Thr Ser Val Met Thr Arg Leu Ile Leu Ile  
 161 20 25 30  
 163 Met Val Trp Arg Gln Leu Ile Arg Asn Pro Asn Thr Tyr Ser Ser Leu  
 164 35 40 45  
 166 Ile Gly Val Ile Trp Ser Leu Val Cys Phe Arg Trp Asn Phe Gln Met  
 167 50 55 60  
 169 Pro Ala Ile Val Leu Gln Ser Ile Ser Ile Leu Ser Asp Ala Gly Leu  
 170 65 70 75 80  
 172 Gly Met Ala Met Phe Ser Leu Gly Leu Phe Met Ala Leu Gln Pro Arg  
 173 85 90 95  
 175 Ile Ile Ala Cys Gly Asn Lys Val Ala Thr Phe Ala Met Ala Val Arg  
 176 100 105 110  
 178 Phe Leu Thr Gly Pro Ala Val Met Ala Ala Ala Ser Phe Ala Val Gly  
 179 115 120 125  
 181 Leu Arg Gly Thr Leu Leu His Val Ala Ile Val Gln Ala Ala Leu Pro  
 182 130 135 140  
 184 Gln Gly Ile Val Pro Phe Val Phe Ala Lys Glu Tyr Asn Val His Pro  
 185 145 150 155 160

1011314294...1011314294

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/030,884

DATE: 06/21/2002

TIME: 11:44:56

Input Set : A:\BB1355 USPCT Corrected Seq List.txt

Output Set: N:\CRF3\06212002\J030884.raw

```

187 Asp Ile Leu Ser Thr Ala Val Ile Phe Gly Met Leu Ile Ala Leu Pro
188                               165                170                175
190 Ile Thr Leu Val Tyr Tyr Ile Leu Leu Gly Leu
191                               180                185
193 <210> SEQ ID NO: 5
194 <211> LENGTH: 253
195 <212> TYPE: DNA
196 <213> ORGANISM: Zea mays
198 <220> FEATURE:
199 <221> NAME/KEY: unsure
200 <222> LOCATION: (150)
201 <223> OTHER INFORMATION: n=a,c,g or t
203 <220> FEATURE:
204 <221> NAME/KEY: unsure
205 <222> LOCATION: (164)
206 <223> OTHER INFORMATION: n=a,c,g or t
208 <220> FEATURE:
209 <221> NAME/KEY: unsure
210 <222> LOCATION: (194)
211 <223> OTHER INFORMATION: n=a,c,g or t
213 <220> FEATURE:
214 <221> NAME/KEY: unsure
215 <222> LOCATION: (229)
216 <223> OTHER INFORMATION: n=a,c,g or t
218 <220> FEATURE:
219 <221> NAME/KEY: unsure
220 <222> LOCATION: (237)
221 <223> OTHER INFORMATION: n=a,c,g or t
223 <220> FEATURE:
224 <221> NAME/KEY: unsure
225 <222> LOCATION: (240)
226 <223> OTHER INFORMATION: n=a,c,g or t
228 <400> SEQUENCE: 5
229 gccccacccc actcatcaca ctctcccacc gcacctcgcc gccgcggggc accgcgccat 60
230 aaagtgcggt cccggcctgc acggacgtcg aggagcagct cgcaagtgtt tcttggtgcg 120
W--> 231 tcgatcggca agatgatcac cggcacggan cttctaccac gtcntgacgg ccatgggtgcc 180
W--> 232 gttgtacgtt gccntgatcc tggcgtacgg atccgtcagg tggtaggcgna tcttcangcn 240
233 gggaccagtg ctc 253
235 <210> SEQ ID NO: 6
236 <211> LENGTH: 31
237 <212> TYPE: PRT
238 <213> ORGANISM: Zea mays
240 <220> FEATURE:
241 <221> NAME/KEY: UNSURE
242 <222> LOCATION: (3)
243 <223> OTHER INFORMATION: Xaa = ANY AMINO ACID
245 <220> FEATURE:
246 <221> NAME/KEY: UNSURE
247 <222> LOCATION: (8)

```

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/030,884

DATE: 06/21/2002

TIME: 11:44:56

Input Set : A:\BB1355 USPCT Corrected Seq List.txt

Output Set: N:\CRF3\06212002\J030884.raw

248 <223> OTHER INFORMATION: Xaa = ANY AMINO ACID  
 250 <220> FEATURE:  
 251 <221> NAME/KEY: UNSURE  
 252 <222> LOCATION: (18)  
 253 <223> OTHER INFORMATION: Xaa = ANY AMINO ACID  
 255 <400> SEQUENCE: 6  
 W--> 256 Ala Arg Xaa Phe Tyr His Val Xaa Thr Ala Met Val Pro Leu Tyr Val  
 257 1 5 10 15  
 W--> 259 Ala Xaa Ile Leu Ala Tyr Gly Ser Val Arg Trp Trp Arg Ile Phe  
 260 20 25 30  
 262 <210> SEQ ID NO: 7  
 263 <211> LENGTH: 624  
 264 <212> TYPE: DNA  
 265 <213> ORGANISM: Zea mays  
 267 <220> FEATURE:  
 268 <221> NAME/KEY: unsure  
 269 <222> LOCATION: (48)..(49)  
 270 <223> OTHER INFORMATION: n=a,c,g or t  
 272 <220> FEATURE:  
 273 <221> NAME/KEY: unsure  
 274 <222> LOCATION: (51)..(52)  
 275 <223> OTHER INFORMATION: n=a,c,g or t  
 277 <220> FEATURE:  
 278 <221> NAME/KEY: unsure  
 279 <222> LOCATION: (99)  
 280 <223> OTHER INFORMATION: n=a,c,g or t  
 282 <220> FEATURE:  
 283 <221> NAME/KEY: unsure  
 284 <222> LOCATION: (102)..(103)  
 285 <223> OTHER INFORMATION: n=a,c,g or t  
 287 <220> FEATURE:  
 288 <221> NAME/KEY: unsure  
 289 <222> LOCATION: (107)..(108)  
 290 <223> OTHER INFORMATION: n=a,c,g or t  
 292 <220> FEATURE:  
 293 <221> NAME/KEY: unsure  
 294 <222> LOCATION: (112)  
 295 <223> OTHER INFORMATION: n=a,c,g or t  
 297 <220> FEATURE:  
 298 <221> NAME/KEY: unsure  
 299 <222> LOCATION: (114)  
 300 <223> OTHER INFORMATION: n=a,c,g or t  
 302 <220> FEATURE:  
 303 <221> NAME/KEY: unsure  
 304 <222> LOCATION: (116)  
 305 <223> OTHER INFORMATION: n=a,c,g or t  
 307 <220> FEATURE:  
 308 <221> NAME/KEY: unsure  
 309 <222> LOCATION: (118)

RAW SEQUENCE LISTING ERROR SUMMARY  
PATENT APPLICATION: US/10/030,884

DATE: 06/21/2002  
TIME: 11:44:57

Input Set : A:\BB1355 USPCT Corrected Seq List.txt  
Output Set: N:\CRF3\06212002\J030884.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; N Pos. 413,466,526,535,549,560,601,602,603,628  
Seq#:3; N Pos. 110  
Seq#:5; N Pos. 150,164,194,229,237,240  
Seq#:6; Xaa Pos. 3,8,18  
Seq#:7; N Pos. 48,49,51,52,99,102,103,107,108,112,114,116,118,129,137,389  
Seq#:7; N Pos. 444,456,490,555,622  
Seq#:8; Xaa Pos. 46,50,61  
Seq#:11; N Pos. 126,192,205,237,242,244,255,258,263,265,287,430,449,455,488  
Seq#:11; N Pos. 490  
Seq#:12; Xaa Pos. 10,14,25,27,31,32,33,34,89,91,96,98,109,110  
Seq#:15; N Pos. 42,374,412,415,431,443,463,475,482,511,514,519,521,530,535  
Seq#:15; N Pos. 543  
Seq#:16; Xaa Pos. 108,109  
Seq#:23; N Pos. 530  
Seq#:24; Xaa Pos. 33,78  
Seq#:28; Xaa Pos. 38  
Seq#:31; N Pos. 237,250,347  
Seq#:32; Xaa Pos. 25,32,64  
Seq#:35; N Pos. 22,46,58,61,91,98,101,122,177,201,297,300,301,317,333,336  
Seq#:35; N Pos. 347,360,367,389,406,435,441  
Seq#:36; Xaa Pos. 10,12,13,20,38,69,78,79,80,85  
Seq#:39; N Pos. 366,380,390,418,421,434




1001300884, 11025003

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:  
EMIL M. OROZCO, JR.



CASE NO.: BB1355 APPLICATION NO.: 10/030,884

CONFIRMATION NO.: 6028 GROUP ART UNIT: UNKNOWN

EXAMINER: UNKNOWN I.A.FILING DATE: 05/03/2000

FOR: AUXIN TRANSPORT PROTEINS

**PRELIMINARY AMENDMENT AND RESPONSE TO NOTIFICATION OF MISSING  
REQUIREMENTS UNDER 35 U.S.C. 371**

Commissioner of Patents  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

Sir:

This is a Preliminary Amendment to the Sequence Listing pursuant to 37 C.F.R. 1.825(a). This also serves as the response to the NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 dated March 22, 2002.

Please enter the following:

**IN THE SPECIFICATION:**

Please replace the originally filed Sequence Listing with the enclosed substitute Sequence Listing.

The substitute Sequence Listing now contains the following amendments:

At <110>, the inventor is now listed as the applicant.

At <140>, the current U.S. application number has been inserted.

In SEQ ID NOs:1, 3, 5, 7, 11, 15, 23, 31, 35, and 39, <223> has been added (reciting "n=a, c, g, or t") to all originally listed Feature sections where <221> recited "unsure".

In SEQ ID NOs:6, 8, 12, 16, 24, 28, 32, and 36, <223> has been added (reciting "Xaa = ANY AMINO ACID") to all originally listed Feature sections where <221> recited "unsure".

**REMARKS**

The substitute Sequence Listing enclosed herewith has been voluntarily amended to facilitate its administrative processing, and not for reasons related to patentability.

Application No.: 10/030,884  
Docket No.: BB1355

Page 2

I hereby state that the amendments included in the substitute Sequence Listing are supported in the application, as filed, at least in the original Sequence Listing, for the amendments to SEQ ID NOs: 1, 3, 5, 6, 7, 8, 11, 12, 15, 16, 23, 24, 28, 31, 32, 35, 36, and 39. The amendments to <110> and <140> in the Sequence Listing reflect U.S. filing information. Thus, the substitute Sequence Listing does not include new matter.

A copy of the substitute Sequence Listing in computer readable form, along with the required Statement under 37 C.F.R. 1.821(g) and 1.825(b), are filed simultaneously herewith and serve as the response to the NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 (copy enclosed).

Please charge any necessary fees or credits to Deposit Account 04-1928 (E. I. du Pont de Nemours and Company).

In view of the foregoing, allowance of the above-referenced application is respectfully requested.

Respectfully submitted,



J. KENNETH JOUNG  
Attorney For Applicants  
Registration No. 41,881  
Telephone: 302-992-4929  
Facsimile: 302-892-1026

Dated: 22 May 2002

Enclosures: copy of NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371  
substitute Sequence Listing

TITLE

## AUXIN TRANSPORT PROTEINS

This application claims the benefit of U.S. Provisional Application No. 60/133,040, filed May 7, 1999.

5

FIELD OF THE INVENTION

This invention is in the field of plant molecular biology. More specifically, this invention pertains to nucleic acid fragments encoding auxin transport proteins in plants and seeds.

BACKGROUND OF THE INVENTION

10

Auxins are a major class of plant hormones that influence diverse aspects of plant behavior and development including vascular tissue differentiation, apical development, tropic responses, and organ (e.g., flower, leaf) development. The term "auxin" refers to a diverse group of natural and synthetic chemical substances that are able to stimulate elongation growth in coleoptiles and many stems. Indole-3-acetic acid (IAA) is the principal auxin in higher plants, though other molecules such as 4-chloroindole-3-acetic acid and phenylacetic acid have been shown to have auxin activity. Synthetic auxins include 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) and 2,4-dichlorophenoxyacetic acid (2,4-D); both are commonly used as herbicides.

15

Distribution of auxins in concentration gradients within plant organs enables auxins to convey to cells their relative location, allowing the plants to respond accordingly to a given stimulus. A classic example that illustrates auxin action is the differential growth and curvature of etiolated coleoptiles exposed to light. It is believed that the phototropic stimulus results in a lateral redistribution of auxin in the coleoptile such that the shaded side has a higher auxin concentration than the illuminated side. With more auxin stimulating cell elongation on the shaded side, the end-result is the apparent bending of the coleoptile towards the light source.

20

25

The foregoing description underscores the importance of polar transport in auxin function. Not surprisingly, a number of genetic and physiological studies have focused on the polar auxin transport system operating in plant cells. *Arabidopsis* mutants with impaired auxin transport capabilities exhibit varying phenotypes: *pin1* mutants develop naked, pin-like inflorescences with few normal flowers (Gälweiler, L. et al., (1998) *Science* 282:2226-2230), while defects in *pin2* (also called *eir1* and *agr1*) are restricted to the root, altering growth and gravitropic response (Luschnig, C. et al., (1998) *Genes Dev.* 12:2175-2187). Proteins encoded by *AUX1*, *PIN1* and *PIN2* genes which have been identified to be important for auxin transport and are putative membrane proteins that have significant homology with a number of bacterial membrane transporters (Luschnig, C. et al. *supra*; Gälweiler L. et al., (1998) *Science* 282:2226-2230; Bennett, M. J. et al., (1996)

30

35

*Science* 273:948-950; WO 99/63092-A1; U.S. Application No. 60/087,789; EP 0 814 161 A1), consistent with a role for these proteins in auxin transport.

Since auxin affects several aspects of plant development, and polar transport is a vital component of auxin function, it is envisioned that proteins involved in auxin polar transport may serve as potential targets for new herbicide discovery and design. Blocking of normal function of these auxin transport proteins can cause severe plant growth defects; this is supported by the phenotype of mutants where a particular auxin transport protein has been rendered nonfunctional, particularly the *Arabidopsis* pin1 mutants. In addition, since some of these auxin transport proteins have been shown to be root-specific and impact root development to a significant degree, manipulation of auxin transport proteins may be a powerful strategy for developing more robust root systems in plants, which in turn may enhance food production, especially in arid climates.

#### SUMMARY OF THE INVENTION

The present invention concerns an isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) a first nucleotide sequence encoding a polypeptide of at least 30 amino acids having at least 85% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:6; (b) a second nucleotide sequence encoding a polypeptide of at least 50 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:16, 28, 36, and 40; (c) a third nucleotide sequence encoding a polypeptide of at least 50 amino acids having at least 85% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:12; (d) a fourth nucleotide sequence encoding a polypeptide of at least 50 amino acids having at least 90% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:8 and 24; (e) a fifth nucleotide sequence encoding a polypeptide of at least 50 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:18 and 32; (f) a sixth nucleotide sequence encoding a polypeptide of at least 90 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:42; (g) a seventh nucleotide sequence encoding a polypeptide of at least 95 amino acids that has at least 95% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:46; (h) an eighth nucleotide sequence encoding a polypeptide of at least 100 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NO:20; (i) a ninth nucleotide sequence encoding a polypeptide of at least 100 amino acids having at least 90% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:2; (j) a tenth nucleotide sequence encoding a polypeptide of at least 150 amino acids having at least 95%

identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:4; (k) an eleventh nucleotide sequence encoding a polypeptide of at least 300 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:38; (l) a twelfth nucleotide sequence encoding a polypeptide of at least 350 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:10; (m) a thirteenth nucleotide sequence encoding a polypeptide of at least 400 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:22, 26 and 30; (n) a fourteenth nucleotide sequence encoding a polypeptide of at least 500 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:34; (o) a fifteenth nucleotide sequence encoding a polypeptide of at least 200 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:14; (p) a sixteenth nucleotide sequence encoding a polypeptide of at least 250 amino acids having at least 90% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:48; and (q) a seventeenth nucleotide sequence comprising the complement of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), or (p).

In a second embodiment, it is preferred that the isolated polynucleotide of the claimed invention comprises a first nucleotide sequence which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 45, and 47 that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 46, and 48.

In a third embodiment, this invention concerns an isolated polynucleotide comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 45, and 47 and the complement of such nucleotide sequences.

In a fourth embodiment, this invention relates to a chimeric gene comprising an isolated polynucleotide of the present invention operably linked to at least one suitable regulatory sequence.

In a fifth embodiment, the present invention concerns a host cell comprising a chimeric gene of the present invention or an isolated polynucleotide of the present invention. The host cell may be eukaryotic, such as a yeast or a plant cell, or prokaryotic, such as a bacterial cell. The present invention also relates to a virus, preferably a baculovirus, comprising an isolated polynucleotide of the present invention or a chimeric gene of the present invention.

In a sixth embodiment, the invention also relates to a process for producing a host cell comprising a chimeric gene of the present invention or an isolated polynucleotide of the present invention, the process comprising either transforming or transfecting a compatible host cell with a chimeric gene or isolated polynucleotide of the present invention.

- 5 In a seventh embodiment, the invention concerns an auxin transport polypeptide selected from the group consisting of: (a) a polypeptide of at least 30 amino acids having at least 85% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:6; (b) a polypeptide of at least 50 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:16, 28, 36, and 40; (c) a polypeptide of at least 50 amino acids having at least 85% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:12; (d) a polypeptide of at least 50 amino acids having at least 90% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:8 and 24; (e) a polypeptide of at least 50 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:18 and 32; (f) a polypeptide of at least 90 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:42; (g) a polypeptide of at least 95 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:46; (h) a polypeptide of at least 100 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NO:20; (i) a polypeptide of at least 100 amino acids having at least 90% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:2; (j) a polypeptide of at least 150 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:4; (k) a polypeptide of at least 300 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:38; (l) a polypeptide of at least 350 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:10; (m) a polypeptide of at least 400 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:22, 26 and 30; (n) a polypeptide of at least 500 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:34; (o) a polypeptide of at least 200 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:14; and (p) a polypeptide of at least 250 amino acids having at least 90% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:48.

In an eighth embodiment, the invention relates to a method of selecting an isolated polynucleotide that affects the level of expression of an auxin transport polypeptide or enzyme activity in a host cell, preferably a plant cell, the method comprising the steps of: (a) constructing an isolated polynucleotide of the present invention or a chimeric gene of the present invention; (b) introducing the isolated polynucleotide or the chimeric gene into a host cell; (c) measuring the level of the auxin transport polypeptide or enzyme activity in the host cell containing the isolated polynucleotide; and (d) comparing the level of the auxin transport polypeptide or enzyme activity in the host cell containing the isolated polynucleotide with the level of the auxin transport polypeptide or enzyme activity in the host cell that does not contain the isolated polynucleotide.

In a ninth embodiment, the invention concerns a method of obtaining a nucleic acid fragment encoding a substantial portion of an auxin transport polypeptide, preferably a plant auxin transport polypeptide, comprising the steps of: synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 45, and 47 and the complement of such nucleotide sequences; and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the oligonucleotide primer. The amplified nucleic acid fragment preferably will encode a substantial portion of an auxin transport polypeptide amino acid sequence.

In a tenth embodiment, this invention relates to a method of obtaining a nucleic acid fragment encoding all or a substantial portion of the amino acid sequence encoding an auxin transport polypeptide comprising the steps of: probing a cDNA or genomic library with an isolated polynucleotide of the present invention; identifying a DNA clone that hybridizes with an isolated polynucleotide of the present invention; isolating the identified DNA clone; and sequencing the cDNA or genomic fragment that comprises the isolated DNA clone.

In an eleventh embodiment, this invention concerns a composition, such as a hybridization mixture, comprising an isolated polynucleotide or isolated polypeptide of the present invention.

In a twelfth embodiment, this invention concerns a method for positive selection of a transformed cell comprising: (a) transforming a host cell with the chimeric gene of the present invention or a construct of the present invention; and (b) growing the transformed host cell, preferably a plant cell, such as a monocot or a dicot, under conditions which allow expression of the auxin transport polypeptide polynucleotide in an amount sufficient to complement a null mutant to provide a positive selection means.

A further embodiment of the instant invention is a method for evaluating at least one compound for its ability to inhibit the activity of an auxin transport protein, the method comprising the steps of: (a) transforming a host cell with a chimeric gene comprising a

nucleic acid fragment encoding an auxin transport polypeptide, operably linked to at least one suitable regulatory sequence; (b) growing the transformed host cell under conditions that are suitable for expression of the chimeric gene wherein expression of the chimeric gene results in production of the encoded auxin transport protein in the transformed host cell;

5 (c) optionally purifying the auxin transport polypeptide expressed by the transformed host cell; (d) treating the auxin transport polypeptide with a compound to be tested; and (e) comparing the activity of the auxin transport polypeptide that has been treated with a test compound to the activity of an untreated auxin transport polypeptide, thereby selecting compounds with potential for inhibitory activity.

10 In a further embodiment, the instant invention concerns a method of modulating expression of an auxin transport protein in a plant, comprising the steps of: (a) transforming a plant cell with a nucleic acid fragment encoding the auxin transport protein operably linked in sense or antisense orientation to a promoter; and (b) growing the plant cell under plant growing conditions to produce a regenerated plant capable of expressing the nucleic acid for

15 a time sufficient to modulate expression of the nucleic acid fragment in the plant compared to a corresponding non-transformed plant, thereby resulting in at least one of the following: a more robust root system, an altered root angle, or redirected root growth.

#### BRIEF DESCRIPTION OF THE DRAWING AND SEQUENCE LISTINGS

20 The invention can be more fully understood from the following detailed description, the accompanying drawing and Sequence Listing which form a part of this application.

Figure 1 depicts the amino acid sequence alignment between the auxin transport protein encoded by the nucleotide sequences derived from the corn clone p0119.cmtn124r (SEQ ID NO:14), soybean clone sfl1.pk131.g9 (SEQ ID NO:30), soybean clone

25 src3c.pk026.o11 (SEQ ID NO:34), and wheat clone wdk1c.pk008.g12 (SEQ ID NO:38), the auxin transport protein EIR1 from *Arabidopsis thaliana* (NCBI GenBank Identifier (GI) No. 3377507; SEQ ID NO:43), and the auxin transport protein AtPIN1 from *Arabidopsis thaliana* (NCBI GenBank Identifier (GI) No. 4151319; SEQ ID NO:44). Amino acids which are conserved among all and at least two sequences with an amino acid at that position are

30 indicated with an asterisk (\*). Dashes are used by the program to maximize alignment of the sequences.

Table 1 lists the polypeptides that are described herein, the designation of the cDNA clones that comprise the nucleic acid fragments encoding polypeptides representing all or a substantial portion of these polypeptides, and the corresponding identifier (SEQ ID NO:) as used in the attached Sequence Listing. Table 1 also identifies the cDNA clones as

35 individual ESTs ("EST"), sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), contigs assembled from two or more ESTs ("Contig"), contigs assembled from an FIS and one or more ESTs ("Contig\*"), or sequences encoding at a



minimum the mature protein derived from an EST, FIS, a contig, or an FIS and PCR ("CGS"). Nucleotide SEQ ID NOs:5, 7, 11, 17, 23, 27, 31, 35, and 41 correspond to nucleotide SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, and 17, respectively, presented in U.S. Provisional Application No. 60/133,040, filed May 7, 1999. Amino acid SEQ ID NOs:6, 8, 12, 18, 24, 28, 32, 36, and 42 correspond to amino acid SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, and 18, respectively, presented in U.S. Provisional Application No. 60/133,040, filed May 7, 1999. The sequence descriptions and Sequence Listing attached hereto comply with the rules governing nucleotide and/or amino acid sequence disclosures in patent applications as set forth in 37 C.F.R. §1.821-1.825.

TABLE 1

## Auxin Transport Proteins

Protein (Plant Source)	Clone Designation	Status	SEQ ID NO:	
			(Nucleotide)	(Amino Acid)
Auxin Transport Protein (Corn)	ceb1.pk0082.a5	EST	1	2
Auxin Transport Protein (Corn)	Contig of: cr1.pk0022.a4 cr1n.pk0033.e3 csi1n.pk0045.a5 csi1n.pk0050.d5 p0005.cbmej72r p0041.crtba02r	Contig	3	4
Auxin Transport Protein (Corn)	p0016.ctsag12r	EST	5	6
Auxin Transport Protein (Corn)	Contig of: p0097.cqrai63r p0094.csssh17r	Contig	7	8
Auxin Transport Protein (Corn)	p0094.csssh17r	FIS	9	10
Auxin Transport Protein (Corn)	p0119.cmtnl24r	EST	11	12
Auxin Transport Protein (Corn)	cil1c.pk001.b7	FIS	47	48
Auxin Transport Protein (Corn)	p0119.cmtnl24r	CGS	13	14
Auxin Transport Protein (Rice)	rr1.pk0019.c4	EST	15	16
Auxin Transport Protein (Rice)	rsl1n.pk003.n3	EST	17	18
Auxin Transport Protein (Rice)	rsl1n.pk003.n3	FIS	19	20
Auxin Transport Protein (Soybean)	scr1c.pk003.g7	FIS	21	22

Protein (Plant Source)	Clone Designation	Status	SEQ ID NO:	
			(Nucleotide)	(Amino Acid)
Auxin Transport Protein (Soybean)	sdp4c.pk003.h2	EST	23	24
Auxin Transport Protein (Soybean)	sdp4c.pk003.h2	FIS	25	26
Auxin Transport Protein (Soybean)	sfl1.pk131.g9	EST	27	28
Auxin Transport Protein (Soybean)	sfl1.pk131.g9(FIS)	CGS	29	30
Auxin Transport Protein (Soybean)	src3c.pk026.o11	EST	31	32
Auxin Transport Protein (Soybean)	src3c.pk026.o11(FIS)	CGS	33	34
Auxin Transport Protein (Wheat)	wdk1c.pk008.g12	EST	35	36
Auxin Transport Protein (Wheat)	wdk1c.pk008.g12(FIS)	CGS	37	38
Auxin Transport Protein (Wheat)	wdr1f.pk001.g9	EST	39	40
Auxin Transport Protein (Wheat)	wle1n.pk0109.h1	EST	41	42
Auxin Transport Protein (Wheat)	wle1n.pk0109.h1	FIS	45	46

5 The Sequence Listing contains the one letter code for nucleotide sequence characters and the three letter codes for amino acids as defined in conformity with the IUPAC-IUBMB standards described in *Nucleic Acids Res.* 13:3021-3030 (1985) and in the *Biochemical J.* 219 (No. 2):345-373 (1984) which are herein incorporated by reference. The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.

#### 10 DETAILED DESCRIPTION OF THE INVENTION

10 In the context of this disclosure, a number of terms shall be utilized. The terms "polynucleotide", "polynucleotide sequence", "nucleic acid sequence", and "nucleic acid fragment"/"isolated nucleic acid fragment" are used interchangeably herein. These terms encompass nucleotide sequences and the like. A polynucleotide may be a polymer of RNA or DNA that is single- or double-stranded, that optionally contains synthetic, non-natural or  
15 altered nucleotide bases. A polynucleotide in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA, synthetic DNA, or mixtures thereof. An isolated polynucleotide of the present invention may include at least one of 60 contiguous nucleotides, preferably at least one of 40 contiguous nucleotides, most preferably

one of at least 30 contiguous nucleotides derived from SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 45, 47 or the complement of such sequences.

The term "isolated polynucleotide" refers to a polynucleotide that is substantially free from other nucleic acid sequences, such as and not limited to other chromosomal and extrachromosomal DNA and RNA. Isolated polynucleotides may be purified from a host cell in which they naturally occur. Conventional nucleic acid purification methods known to skilled artisans may be used to obtain isolated polynucleotides. The term also embraces recombinant polynucleotides and chemically synthesized polynucleotides.

The term "recombinant" means, for example, that a nucleic acid sequence is made by an artificial combination of two otherwise separated segments of sequence, e.g., by chemical synthesis or by the manipulation of isolated nucleic acids by genetic engineering techniques.

As used herein, "contig" refers to a nucleotide sequence that is assembled from two or more constituent nucleotide sequences that share common or overlapping regions of sequence homology. For example, the nucleotide sequences of two or more nucleic acid fragments can be compared and aligned in order to identify common or overlapping sequences. Where common or overlapping sequences exist between two or more nucleic acid fragments, the sequences (and thus their corresponding nucleic acid fragments) can be assembled into a single contiguous nucleotide sequence.

As used herein, "substantially similar" refers to nucleic acid fragments wherein changes in one or more nucleotide bases results in substitution of one or more amino acids, but do not affect the functional properties of the polypeptide encoded by the nucleotide sequence. "Substantially similar" also refers to nucleic acid fragments wherein changes in one or more nucleotide bases does not affect the ability of the nucleic acid fragment to mediate alteration of gene expression by gene silencing through for example antisense or co-suppression technology. "Substantially similar" also refers to modifications of the nucleic acid fragments of the instant invention such as deletion or insertion of one or more nucleotides that do not substantially affect the functional properties of the resulting transcript vis-à-vis the ability to mediate gene silencing or alteration of the functional properties of the resulting protein molecule. It is therefore understood that the invention encompasses more than the specific exemplary nucleotide or amino acid sequences and includes functional equivalents thereof. The terms "substantially similar" and "corresponding substantially" are used interchangeably herein.

Substantially similar nucleic acid fragments may be selected by screening nucleic acid fragments representing subfragments or modifications of the nucleic acid fragments of the instant invention, wherein one or more nucleotides are substituted, deleted and/or inserted, for their ability to affect the level of the polypeptide encoded by the unmodified nucleic acid fragment in a plant or plant cell. For example, a substantially similar nucleic acid fragment

representing at least one of 30 contiguous nucleotides derived from the instant nucleic acid fragment can be constructed and introduced into a plant or plant cell. The level of the polypeptide encoded by the unmodified nucleic acid fragment present in a plant or plant cell exposed to the substantially similar nucleic acid fragment can then be compared to the level of the polypeptide in a plant or plant cell that is not exposed to the substantially similar nucleic acid fragment.

For example, it is well known in the art that antisense suppression and co-suppression of gene expression may be accomplished using nucleic acid fragments representing less than the entire coding region of a gene, and by using nucleic acid fragments that do not share 100% sequence identity with the gene to be suppressed. Moreover, alterations in a nucleic acid fragment which result in the production of a chemically equivalent amino acid at a given site, but do not effect the functional properties of the encoded polypeptide, are well known in the art. Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a functionally equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the polypeptide molecule would also not be expected to alter the activity of the polypeptide. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products. Consequently, an isolated polynucleotide comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 45, and 47 and the complement of such nucleotide sequences may be used in methods of selecting an isolated polynucleotide that affects the expression of an auxin transport polypeptide in a host cell. A method of selecting an isolated polynucleotide that affects the level of expression of a polypeptide in a virus or in a host cell (eukaryotic, such as plant or yeast, prokaryotic such as bacterial) may comprise the steps of: constructing an isolated polynucleotide of the present invention or a chimeric gene of the present invention; introducing the isolated polynucleotide or the chimeric gene into a host cell; measuring the level of a polypeptide or enzyme activity in the host cell containing the isolated polynucleotide; and comparing the level of a polypeptide or enzyme activity in the host cell containing the isolated polynucleotide with the level of a polypeptide or enzyme activity in a host cell that does not contain the isolated polynucleotide.

Moreover, substantially similar nucleic acid fragments may also be characterized by their ability to hybridize. Estimates of such homology are provided by either DNA-DNA or

DNA-RNA hybridization under conditions of stringency as is well understood by those skilled in the art (Hames and Higgins, Eds. (1985) *Nucleic Acid Hybridisation*, IRL Press, Oxford, U.K.). Stringency conditions can be adjusted to screen for moderately similar fragments, such as homologous sequences from distantly related organisms, to highly similar fragments, such as genes that duplicate functional enzymes from closely related organisms. Post-hybridization washes determine stringency conditions. One set of preferred conditions uses a series of washes starting with 6X SSC, 0.5% SDS at room temperature for 15 min, then repeated with 2X SSC, 0.5% SDS at 45°C for 30 min, and then repeated twice with 0.2X SSC, 0.5% SDS at 50°C for 30 min. A more preferred set of stringent conditions uses higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2X SSC, 0.5% SDS was increased to 60°C. Another preferred set of highly stringent conditions uses two final washes in 0.1X SSC, 0.1% SDS at 65°C.

Substantially similar nucleic acid fragments of the instant invention may also be characterized by the percent identity of the amino acid sequences that they encode to the amino acid sequences disclosed herein, as determined by algorithms commonly employed by those skilled in this art. Suitable nucleic acid fragments (isolated polynucleotides of the present invention) encode polypeptides that are at least about 70% identical, preferably at least about 80% identical to the amino acid sequences reported herein. Preferred nucleic acid fragments encode amino acid sequences that are about 85% identical to the amino acid sequences reported herein. More preferred nucleic acid fragments encode amino acid sequences that are at least about 90% identical to the amino acid sequences reported herein. Most preferred are nucleic acid fragments that encode amino acid sequences that are at least about 95% identical to the amino acid sequences reported herein. Suitable nucleic acid fragments not only have the above identities but typically encode a polypeptide having at least 30 or 50 amino acids, preferably at least 90 or 100 amino acids, more preferably at least 150 amino acids, still more preferably at least 200 amino acids, and most preferably at least 250, 300, 350, 400 or 500 amino acids. Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS* 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5.

A "substantial portion" of an amino acid or nucleotide sequence comprises an amino acid or a nucleotide sequence that is sufficient to afford putative identification of the protein or gene that the amino acid or nucleotide sequence comprises. Amino acid and nucleotide sequences can be evaluated either manually by one skilled in the art, or by using computer-

based sequence comparison and identification tools that employ algorithms such as BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also [www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)). In general, a sequence of ten or more contiguous amino acids or thirty or more contiguous nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene. Moreover, with respect to nucleotide sequences, gene-specific oligonucleotide probes comprising 30 or more contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., *in situ* hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12 or more nucleotides may be used as amplification primers in PCR in order to obtain a particular nucleic acid fragment comprising the primers. Accordingly, a "substantial portion" of a nucleotide sequence comprises a nucleotide sequence that will afford specific identification and/or isolation of a nucleic acid fragment comprising the sequence. The instant specification teaches amino acid and nucleotide sequences encoding polypeptides that comprise one or more particular plant proteins. The skilled artisan, having the benefit of the sequences as reported herein, may now use all or a substantial portion of the disclosed sequences for purposes known to those skilled in this art. Accordingly, the instant invention comprises the complete sequences as reported in the accompanying Sequence Listing, as well as substantial portions of those sequences as defined above.

"Codon degeneracy" refers to divergence in the genetic code permitting variation of the nucleotide sequence without effecting the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleic acid fragment comprising a nucleotide sequence that encodes all or a substantial portion of the amino acid sequences set forth herein. The skilled artisan is well aware of the "codon-bias" exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a nucleic acid fragment for improved expression in a host cell, it is desirable to design the nucleic acid fragment such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

"Synthetic nucleic acid fragments" can be assembled from oligonucleotide building blocks that are chemically synthesized using procedures known to those skilled in the art. These building blocks are ligated and annealed to form larger nucleic acid fragments which may then be enzymatically assembled to construct the entire desired nucleic acid fragment. "Chemically synthesized", as related to a nucleic acid fragment, means that the component nucleotides were assembled *in vitro*. Manual chemical synthesis of nucleic acid fragments may be accomplished using well established procedures, or automated chemical synthesis can be performed using one of a number of commercially available machines. Accordingly, the nucleic acid fragments can be tailored for optimal gene expression based on optimization of the nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan

appreciates the likelihood of successful gene expression if codon usage is biased towards those codons favored by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell where sequence information is available.

“Gene” refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. “Native gene” refers to a gene as found in nature with its own regulatory sequences. “Chimeric gene” refers any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature.

Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature.

“Endogenous gene” refers to a native gene in its natural location in the genome of an organism. A “foreign gene” refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A “transgene” is a gene that has been introduced into the genome by a transformation procedure.

“Coding sequence” refers to a nucleotide sequence that codes for a specific amino acid sequence. “Regulatory sequences” refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, and polyadenylation recognition sequences.

“Promoter” refers to a nucleotide sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. The promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. Accordingly, an “enhancer” is a nucleotide sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter. Promoters may be derived in their entirety from a native gene, or may be composed of different elements derived from different promoters found in nature, or may even comprise synthetic nucleotide segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters which cause a nucleic acid fragment to be expressed in most cell types at most times are commonly referred to as “constitutive promoters”. New promoters of various types useful in plant cells are constantly being discovered; numerous examples may be found in the compilation by Okamuro and Goldberg (1989) *Biochemistry of Plants* 15:1-82. It is further recognized that since in most cases the exact boundaries of regulatory sequences

have not been completely defined, nucleic acid fragments of different lengths may have identical promoter activity.

“Translation leader sequence” refers to a nucleotide sequence located between the promoter sequence of a gene and the coding sequence. The translation leader sequence is present in the fully processed mRNA upstream of the translation start sequence. The translation leader sequence may affect processing of the primary transcript to mRNA, mRNA stability or translation efficiency. Examples of translation leader sequences have been described (Turner and Foster (1995) *Mol. Biotechnol.* 3:225-236).

“3' Non-coding sequences” refers to nucleotide sequences located downstream of a coding sequence and includes polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is exemplified by Ingelbrecht et al. (1989) *Plant Cell* 1:671-680.

“RNA transcript” refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from posttranscriptional processing of the primary transcript and is referred to as the mature RNA. “Messenger RNA (mRNA)” refers to the RNA that is without introns and that can be translated into polypeptides by the cell. “cDNA” refers to DNA that is complementary to and derived from an mRNA template. The cDNA can be single-stranded or converted to double stranded form using, for example, the Klenow fragment of DNA polymerase I. “Sense RNA” refers to an RNA transcript that includes the mRNA and can be translated into a polypeptide by the cell. “Antisense RNA” refers to an RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene (see U.S. Patent No. 5,107,065, incorporated herein by reference). The complementarity of an antisense RNA may be with any part of the specific nucleotide sequence, i.e., at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence. “Functional RNA” refers to sense RNA, antisense RNA, ribozyme RNA, or other RNA that may not be translated but yet has an effect on cellular processes.

The term “operably linked” refers to the association of two or more nucleic acid fragments so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.



The term "expression", as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragment of the invention. "Expression" may also refer to translation of mRNA into a polypeptide. "Antisense inhibition" refers to the production of antisense RNA transcripts capable of suppressing the expression of the target protein. "Overexpression" refers to the production of a gene product in transgenic organisms that exceeds levels of production in normal or non-transformed organisms. "Co-suppression" refers to the production of sense RNA transcripts capable of suppressing the expression of identical or substantially similar foreign or endogenous genes (U.S. Patent No. 5,231,020, incorporated herein by reference).

A "protein" or "polypeptide" is a chain of amino acids arranged in a specific order determined by the coding sequence in a polynucleotide encoding the polypeptide. In the context of this disclosure, a number of terms shall be utilized. The terms "protein" and "polypeptide" are used interchangeably herein. Each protein or polypeptide has a unique function.

"Altered levels" or "altered expression" refers to the production of gene product(s) in transgenic organisms in amounts or proportions that differ from that of normal or non-transformed organisms.

"Null mutant" refers to a host cell which either lacks the expression of a certain polypeptide or expresses a polypeptide which is inactive or does not have any detectable expected enzymatic function.

"Mature protein" refers to a post-translationally processed polypeptide; i.e., one from which any pre- or propeptides present in the primary translation product have been removed. "Precursor protein" refers to the primary product of translation of mRNA; i.e., with pre- and propeptides still present. Pre- and propeptides may be but are not limited to intracellular localization signals.

A "chloroplast transit peptide" is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the chloroplast or other plastid types present in the cell in which the protein is made. "Chloroplast transit sequence" refers to a nucleotide sequence that encodes a chloroplast transit peptide. A "signal peptide" is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the secretory system (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53). If the protein is to be directed to a vacuole, a vacuolar targeting signal (*supra*) can further be added, or if to the endoplasmic reticulum, an endoplasmic reticulum retention signal (*supra*) may be added. If the protein is to be directed to the nucleus, any signal peptide present should be removed and instead a nuclear localization signal included (Raikhel (1992) *Plant Phys.* 100:1627-1632).

"Transformation" refers to the transfer of a nucleic acid fragment into the genome of a host organism, resulting in genetically stable inheritance. Host organisms containing the

transformed nucleic acid fragments are referred to as "transgenic" organisms. Examples of methods of plant transformation include *Agrobacterium*-mediated transformation (De Blaere et al. (1987) *Meth. Enzymol.* 143:277) and particle-accelerated or "gene gun" transformation technology (Klein et al. (1987) *Nature (London)* 327:70-73; U.S. Patent No. 4,945,050, incorporated herein by reference). Thus, isolated polynucleotides of the present invention can be incorporated into recombinant constructs, typically DNA constructs, capable of introduction into and replication in a host cell. Such a construct can be a vector that includes a replication system and sequences that are capable of transcription and translation of a polypeptide-encoding sequence in a given host cell. A number of vectors suitable for stable transfection of plant cells or for the establishment of transgenic plants have been described in, e.g., Pouwels et al., *Cloning Vectors: A Laboratory Manual*, 1985, supp. 1987; Weissbach and Weissbach, *Methods for Plant Molecular Biology*, Academic Press, 1989; and Flevin et al., *Plant Molecular Biology Manual*, Kluwer Academic Publishers, 1990. Typically, plant expression vectors include, for example, one or more cloned plant genes under the transcriptional control of 5' and 3' regulatory sequences and a dominant selectable marker. Such plant expression vectors also can contain a promoter regulatory region (e.g., a regulatory region controlling inducible or constitutive, environmentally- or developmentally-regulated, or cell- or tissue-specific expression), a transcription initiation start site, a ribosome binding site, an RNA processing signal, a transcription termination site, and/or a polyadenylation signal.

Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook et al. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter "Maniatis").

"PCR" or "polymerase chain reaction" is a technique used for the amplification of specific DNA segments (U.S. Patent Nos. 4,683,195 and 4,800,159).

The present invention concerns an isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) a first nucleotide sequence encoding a polypeptide of at least 30 amino acids having at least 85% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:6; (b) a second nucleotide sequence encoding a polypeptide of at least 50 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:16, 28, 36, and 40; (c) a third nucleotide sequence encoding a polypeptide of at least 50 amino acids having at least 85% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:12; (d) a fourth nucleotide sequence encoding a polypeptide of at least 50 amino acids having at least 90% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:8 and 24; (e) a fifth nucleotide sequence encoding

a polypeptide of at least 50 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:18 and 32; (f) a sixth nucleotide sequence encoding a polypeptide of at least 90 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:42; (g) a seventh nucleotide sequence encoding a polypeptide of at least 95 amino acids that has at least 95% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:46; (h) an eighth nucleotide sequence encoding a polypeptide of at least 100 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NO:20; (i) a ninth nucleotide sequence encoding a polypeptide of at least 100 amino acids having at least 90% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:2; (j) a tenth nucleotide sequence encoding a polypeptide of at least 150 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:4; (k) an eleventh nucleotide sequence encoding a polypeptide of at least 300 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:38; (l) a twelfth nucleotide sequence encoding a polypeptide of at least 350 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:10; (m) a thirteenth nucleotide sequence encoding a polypeptide of at least 400 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:22, 26 and 30; (n) a fourteenth nucleotide sequence encoding a polypeptide of at least 500 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:34; (o) a fifteenth nucleotide sequence encoding a polypeptide of at least 200 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:14; (p) a sixteenth nucleotide sequence encoding a polypeptide of at least 250 amino acids having at least 90% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:48; and (q) a seventeenth nucleotide sequence comprising the complement of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o) or (p).

Preferably, the first nucleotide sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 45, and 47 that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 46, and 48.

Nucleic acid fragments encoding at least a substantial portion of several auxin transport proteins have been isolated and identified by comparison of random plant cDNA

sequences to public databases containing nucleotide and protein sequences using the BLAST algorithms well known to those skilled in the art. The nucleic acid fragments of the instant invention may be used to isolate cDNAs and genes encoding homologous proteins from the same or other plant species. Isolation of homologous genes using sequence-dependent protocols is well known in the art. Examples of sequence-dependent protocols include, but are not limited to, methods of nucleic acid hybridization, and methods of DNA and RNA amplification as exemplified by various uses of nucleic acid amplification technologies (e.g., polymerase chain reaction, ligase chain reaction).

For example, genes encoding other auxin transport polypeptides, either as cDNAs or genomic DNAs, could be isolated directly by using all or a substantial portion of the instant nucleic acid fragments as DNA hybridization probes to screen libraries from any desired plant employing methodology well known to those skilled in the art. Specific oligonucleotide probes based upon the instant nucleic acid sequences can be designed and synthesized by methods known in the art (Maniatis). Moreover, the entire sequence(s) can be used directly to synthesize DNA probes by methods known to the skilled artisan such as random primer DNA labeling, nick translation, end-labeling techniques, or RNA probes using available *in vitro* transcription systems. In addition, specific primers can be designed and used to amplify a part or all of the instant sequences. The resulting amplification products can be labeled directly during amplification reactions or labeled after amplification reactions, and used as probes to isolate full length cDNA or genomic fragments under conditions of appropriate stringency.

In addition, two short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols to amplify longer nucleic acid fragments encoding homologous genes from DNA or RNA. The polymerase chain reaction may also be performed on a library of cloned nucleic acid fragments wherein the sequence of one primer is derived from the instant nucleic acid fragments, and the sequence of the other primer takes advantage of the presence of the polyadenylic acid tracts to the 3' end of the mRNA precursor encoding plant genes. Alternatively, the second primer sequence may be based upon sequences derived from the cloning vector. For example, the skilled artisan can follow the RACE protocol (Frohman et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:8998-9002) to generate cDNAs by using PCR to amplify copies of the region between a single point in the transcript and the 3' or 5' end. Primers oriented in the 3' and 5' directions can be designed from the instant sequences. Using commercially available 3' RACE or 5' RACE systems (BRL), specific 3' or 5' cDNA fragments can be isolated (Ohara et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:5673-5677; Loh et al. (1989) *Science* 243:217-220). Products generated by the 3' and 5' RACE procedures can be combined to generate full-length cDNAs (Frohman and Martin (1989) *Techniques* 1:165). Consequently, a polynucleotide comprising a nucleotide sequence of at least one of 60 (preferably one of at least 40, most preferably one

of at least 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 45, and 47 and the complement of such nucleotide sequences may be used in such methods to obtain a nucleic acid fragment encoding a substantial portion of an amino acid sequence of a polypeptide.

The present invention relates to a method of obtaining a nucleic acid fragment encoding a substantial portion of an auxin transport polypeptide, preferably a substantial portion of a plant auxin transport polypeptide, comprising the steps of: synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 45, and 47 and the complement of such nucleotide sequences; and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the oligonucleotide primer. The amplified nucleic acid fragment preferably will encode a substantial portion of an auxin transport polypeptide.

Availability of the instant nucleotide and deduced amino acid sequences facilitates immunological screening of cDNA expression libraries. Synthetic peptides representing substantial portions of the instant amino acid sequences may be synthesized. These peptides can be used to immunize animals to produce polyclonal or monoclonal antibodies with specificity for peptides or proteins comprising the amino acid sequences. These antibodies can be then be used to screen cDNA expression libraries to isolate full-length cDNA clones of interest (Lerner (1984) *Adv. Immunol.* 36:1-34; Maniatis).

In another embodiment, this invention concerns viruses and host cells comprising either the chimeric genes of the invention as described herein or an isolated polynucleotide of the invention as described herein. Examples of host cells which can be used to practice the invention include, but are not limited to, yeast, bacteria, and plants.

As was noted above, the nucleic acid fragments of the instant invention may be used to create transgenic plants in which the disclosed polypeptides are present at higher or lower levels than normal or in cell types or developmental stages in which they are not normally found. This would have the effect of altering the level of auxin efflux in those cells. In addition, since some of these auxin transport proteins may be root-specific and impact root development to a significant degree, these auxin transport proteins may lead to novel strategies for developing transgenic plants with more robust root systems, which may enhance food production, especially in arid climates. The nucleic acid fragments of the instant invention may also be used to regulate root angle, and thus modify plant susceptibility to root lodging, root angle being a determinant of lodging susceptibility. Modified root gravitropic responses (as mediated by manipulation of the nucleic acid fragments of the instant invention) would also be useful for redirecting root growth (by

inhibiting gravitropism in short durations) for soil remediation projects and alleviate soil erosion problems. Roots may also be made to grow deeper beyond the top layers of the soil, reducing root tip damage caused by insect feeding and possibly generating a root system that extends downward rather than laterally into neighboring root zones, thus minimizing competition for nutrients among different root systems, making planting at higher densities a possibility. The auxin transport proteins disclosed herein may also be engineered to transport other compounds into and/or out of the plant, for example, such as into storage compartments or into media for harvesting.

Overexpression of the proteins of the instant invention may be accomplished by first constructing a chimeric gene in which the coding region is operably linked to a promoter capable of directing expression of a gene in the desired tissues at the desired stage of development. The chimeric gene may comprise promoter sequences and translation leader sequences derived from the same genes. 3' Non-coding sequences encoding transcription termination signals may also be provided. The instant chimeric gene may also comprise one or more introns in order to facilitate gene expression.

Plasmid vectors comprising the instant isolated polynucleotide (or chimeric gene) may be constructed. The choice of plasmid vector is dependent upon the method that will be used to transform host plants. The skilled artisan is well aware of the genetic elements that must be present on the plasmid vector in order to successfully transform, select and propagate host cells containing the chimeric gene. The skilled artisan will also recognize that different independent transformation events will result in different levels and patterns of expression (Jones et al. (1985) *EMBO J.* 4:2411-2418; De Almeida et al. (1989) *Mol. Gen. Genetics* 218:78-86), and thus that multiple events must be screened in order to obtain lines displaying the desired expression level and pattern. Such screening may be accomplished by Southern analysis of DNA, Northern analysis of mRNA expression, Western analysis of protein expression, or phenotypic analysis.

For some applications it may be useful to direct the instant polypeptides to different cellular compartments, or to facilitate secretion from the cell. It is thus envisioned that the chimeric gene described above may be further supplemented by directing the coding sequence to encode the instant polypeptides with appropriate intracellular targeting sequences such as transit sequences (Keegstra (1989) *Cell* 56:247-253), signal sequences or sequences encoding endoplasmic reticulum localization (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53), or nuclear localization signals (Raikhel (1992) *Plant Phys.* 100:1627-1632) with or without removing targeting sequences that are already present. While the references cited give examples of each of these, the list is not exhaustive and more targeting signals of use may be discovered in the future.

It may also be desirable to reduce or eliminate expression of genes encoding the instant polypeptides in plants for some applications. In order to accomplish this, a chimeric

gene designed for co-suppression of the instant polypeptide can be constructed by linking a gene or gene fragment encoding that polypeptide to plant promoter sequences.

Alternatively, a chimeric gene designed to express antisense RNA for all or part of the instant nucleic acid fragment can be constructed by linking the gene or gene fragment in reverse orientation to plant promoter sequences. Either the co-suppression or antisense chimeric genes could be introduced into plants via transformation wherein expression of the corresponding endogenous genes are reduced or eliminated.

Molecular genetic solutions to the generation of plants with altered gene expression have a decided advantage over more traditional plant breeding approaches. Changes in plant phenotypes can be produced by specifically inhibiting expression of one or more genes by antisense inhibition or cosuppression (U.S. Patent Nos. 5,190,931, 5,107,065 and 5,283,323). An antisense or cosuppression construct would act as a dominant negative regulator of gene activity. While conventional mutations can yield negative regulation of gene activity these effects are most likely recessive. The dominant negative regulation available with a transgenic approach may be advantageous from a breeding perspective. In addition, the ability to restrict the expression of a specific phenotype to the reproductive tissues of the plant by the use of tissue specific promoters may confer agronomic advantages relative to conventional mutations which may have an effect in all tissues in which a mutant gene is ordinarily expressed.

The person skilled in the art will know that special considerations are associated with the use of antisense or cosuppression technologies in order to reduce expression of particular genes. For example, the proper level of expression of sense or antisense genes may require the use of different chimeric genes utilizing different regulatory elements known to the skilled artisan. Once transgenic plants are obtained by one of the methods described above, it will be necessary to screen individual transgenics for those that most effectively display the desired phenotype. Accordingly, the skilled artisan will develop methods for screening large numbers of transformants. The nature of these screens will generally be chosen on practical grounds. For example, one can screen by looking for changes in gene expression by using antibodies specific for the protein encoded by the gene being suppressed, or one could establish assays that specifically measure enzyme activity. A preferred method will be one which allows large numbers of samples to be processed rapidly, since it will be expected that a large number of transformants will be negative for the desired phenotype.

In another embodiment, the present invention concerns an auxin transport polypeptide selected from the group consisting of: (a) a polypeptide of at least 30 amino acids having at least 85% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:6; (b) a polypeptide of at least 50 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:16, 28, 36, and 40; (c) a polypeptide of at

- least 50 amino acids having at least 85% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:12; (d) a polypeptide of at least 50 amino acids having at least 90% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:8 and 24; (e) a
- 5 polypeptide of at least 50 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:18 and 32; (f) a polypeptide of at least 90 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:42; (g) a polypeptide of at least 95 amino acids having at least 95% identity based on
- 10 the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:46; (h) a polypeptide of at least 100 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NO:20; (i) a polypeptide of at least 100 amino acids having at least 90% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:2;
- 15 (j) a polypeptide of at least 150 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:4; (k) a polypeptide of at least 300 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:38; (l) a polypeptide of at least 350 amino acids having at least 95% identity based on the Clustal method of alignment when
- 20 compared to a polypeptide of SEQ ID NO:10; (m) a polypeptide of at least 400 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:22, 26 and 30; (n) a polypeptide of at least 500 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:34; (o) a polypeptide
- 25 of at least 200 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:14; (p) a polypeptide of at least 250 amino acids having at least 90% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:48.

The instant polypeptides (or portions thereof) may be produced in heterologous host

30 cells, particularly in the cells of microbial hosts, and can be used to prepare antibodies to the proteins by methods well known to those skilled in the art. The antibodies are useful for detecting the polypeptides of the instant invention *in situ* in cells or *in vitro* in cell extracts. Preferred heterologous host cells for production of the instant polypeptides are microbial hosts. Microbial expression systems and expression vectors containing regulatory sequences

35 that direct high level expression of foreign proteins are well known to those skilled in the art. Any of these could be used to construct a chimeric gene for production of the instant polypeptides. This chimeric gene could then be introduced into appropriate microorganisms via transformation to provide high level expression of the encoded auxin transport protein.



An example of a vector for high level expression of the instant polypeptides in a bacterial host is provided (Example 6).

Additionally, the instant auxin transport proteins can be used as a target to facilitate design and/or identification of inhibitors of these proteins that may be useful as herbicides.

5 This is desirable because the auxin transport proteins described herein are essential components of the polar transport system involved in auxin redistribution and hence auxin function. Accordingly, inhibition of the activity of one or more of the enzymes described herein could lead to inhibition of plant growth. Thus, the instant auxin transport proteins could be appropriate for new herbicide discovery and design.

10 The present invention further provides a method for modulating (i.e., increasing or decreasing) the concentration or composition of the polypeptides of the present invention in a plant or part thereof. Modulation of the polypeptides can be effected by increasing or decreasing the concentration and/or the composition of the polypeptides in a plant. The method comprises transforming a plant cell with a construct comprising a nucleic acid  
15 fragment of the present invention to obtain a transformed plant cell, growing the transformed plant cell under plant forming conditions, and expressing the nucleic acid fragment in the plant for a time sufficient to modulate concentration and/or composition of the polypeptides in the plant or plant part.

In some embodiments, the content and/or composition of polypeptides of the present  
20 invention in a plant may be modulated by altering, *in vivo* or *in vitro*, the promoter of a non-isolated gene of the present invention to up- or down-regulate gene expression. In some embodiments, the coding regions of native genes of the present invention can be altered via substitution, addition, insertion, or deletion to decrease activity of the encoded enzyme. See, e.g., Kmiec, U.S. Patent No. 5,565,350; Zarling *et al.*, PCT/US93/03868.

25 In some embodiments, an isolated nucleic acid fragment (e.g., a vector) comprising a promoter sequence is transfected into a plant cell. Subsequently, a plant cell comprising the isolated nucleic acid is selected for by means known to those of skill in the art such as, but not limited to, Southern blot, DNA sequencing, or PCR analysis using primers specific to the promoter and to the nucleic acid and detecting amplicons produced therefrom. A plant or  
30 plant part altered or modified by the foregoing embodiments is grown under plant forming conditions for a time sufficient to modulate the concentration and/or composition of polypeptides of the present invention in the plant. Plant forming conditions are well known in the art.

In general, concentration of the polypeptides is increased or decreased by at least 5%,  
35 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% relative to a native control plant, plant part, or cell lacking the aforementioned transgene. Modulation in the present invention may occur during and/or subsequent to growth of the plant to the desired stage of development.

Modulating nucleic acid expression temporally and/or in particular tissues can be controlled by employing the appropriate promoter operably linked to a nucleic acid fragment of the present invention in, for example, sense or antisense orientation as discussed in greater detail above. Induction of expression of a nucleic acid fragment of the present invention can also be controlled by exogenous administration of an effective amount of inducing compound. Inducible promoters and inducing compounds that activate expression from these promoters are well known in the art.

Examples of inducible promoters are the Adh1 promoter which is inducible by hypoxia or cold stress, the Hsp70 promoter which is inducible by heat stress, and the PPKK promoter which is inducible by light. Also useful are promoters which are chemically inducible.

Examples of promoters under developmental control include promoters that initiate transcription preferentially in certain tissues such as leaves, roots, fruit, seeds, or flowers. An exemplary promoter is the anther specific promoter 5126 (U.S. Patent Nos. 5,689,049 and 5,689,051). Examples of seed-preferred promoters include, but are not limited to, 27 kD gamma zein promoter and waxy promoter (Boronat et al. (1986) *Plant Sci.* 47:95-102; Reina et al. (1990) *Nucleic Acids Res.* 18(21):6426; Kloesgen et al. (1986) *Mol. Gen. Genet.* 203:237-244). Promoters that are expressed in the embryo, pericarp, and endosperm are disclosed in US applications Serial Nos. 60/097,233 filed August 20, 1998 and 60/098,230 filed August 28, 1998. The disclosures of each of these are incorporated herein by reference in their entirety.

Either heterologous or non-heterologous (i.e., endogenous) promoters can be employed to direct expression of the nucleic acids of the present invention. These promoters can also be used, for example, in chimeric genes to drive expression of antisense nucleic acids to reduce, increase, or alter concentration and/or composition of the proteins of the present invention in a desired tissue.

All or a substantial portion of the polynucleotides of the instant invention may also be used as probes for genetically and physically mapping the genes that they are a part of, and used as markers for traits linked to those genes. Such information may be useful in plant breeding in order to develop lines with desired phenotypes. For example, the instant nucleic acid fragments may be used as restriction fragment length polymorphism (RFLP) markers. Southern blots (Maniatis) of restriction-digested plant genomic DNA may be probed with the nucleic acid fragments of the instant invention. The resulting banding patterns may then be subjected to genetic analyses using computer programs such as MapMaker (Lander et al. (1987) *Genomics* 1:174-181) in order to construct a genetic map. In addition, the nucleic acid fragments of the instant invention may be used to probe Southern blots containing restriction endonuclease-treated genomic DNAs of a set of individuals representing parent and progeny of a defined genetic cross. Segregation of the DNA polymorphisms is noted

and used to calculate the position of the instant nucleic acid sequence in the genetic map previously obtained using this population (Botstein et al. (1980) *Am. J. Hum. Genet.* 32:314-331).

The production and use of plant gene-derived probes for use in genetic mapping is described in Bernatzky and Tanksley (1986) *Plant Mol. Biol. Reporter* 4:37-41. Numerous publications describe genetic mapping of specific cDNA clones using the methodology outlined above or variations thereof. For example, F2 intercross populations, backcross populations, randomly mated populations, near isogenic lines, and other sets of individuals may be used for mapping. Such methodologies are well known to those skilled in the art.

Nucleic acid probes derived from the instant nucleic acid sequences may also be used for physical mapping (i.e., placement of sequences on physical maps; see Hoheisel et al. In: *Nonmammalian Genomic Analysis: A Practical Guide*, Academic press 1996, pp. 319-346, and references cited therein).

In another embodiment, nucleic acid probes derived from the instant nucleic acid sequences may be used in direct fluorescence *in situ* hybridization (FISH) mapping (Trask (1991) *Trends Genet.* 7:149-154). Although current methods of FISH mapping favor use of large clones (several to several hundred KB; see Laan et al. (1995) *Genome Res.* 5:13-20), improvements in sensitivity may allow performance of FISH mapping using shorter probes.

A variety of nucleic acid amplification-based methods of genetic and physical mapping may be carried out using the instant nucleic acid sequences. Examples include allele-specific amplification (Kazazian (1989) *J. Lab. Clin. Med.* 11:95-96), polymorphism of PCR-amplified fragments (CAPS; Sheffield et al. (1993) *Genomics* 16:325-332), allele-specific ligation (Landegren et al. (1988) *Science* 241:1077-1080), nucleotide extension reactions (Sokolov (1990) *Nucleic Acid Res.* 18:3671), Radiation Hybrid Mapping (Walter et al. (1997) *Nat. Genet.* 7:22-28) and Happy Mapping (Dear and Cook (1989) *Nucleic Acid Res.* 17:6795-6807). For these methods, the sequence of a nucleic acid fragment is used to design and produce primer pairs for use in the amplification reaction or in primer extension reactions. The design of such primers is well known to those skilled in the art. In methods employing PCR-based genetic mapping, it may be necessary to identify DNA sequence differences between the parents of the mapping cross in the region corresponding to the instant nucleic acid sequence. This, however, is generally not necessary for mapping methods.

Loss of function mutant phenotypes may be identified for the instant cDNA clones either by targeted gene disruption protocols or by identifying specific mutants for these genes contained in a maize population carrying mutations in all possible genes (Ballinger and Benzer (1989) *Proc. Natl. Acad. Sci USA* 86:9402-9406; Koes et al. (1995) *Proc. Natl. Acad. Sci USA* 92:8149-8153; Bensen et al. (1995) *Plant Cell* 7:75-84). The latter approach may be accomplished in two ways. First, short segments of the instant nucleic acid

fragments may be used in polymerase chain reaction protocols in conjunction with a mutation tag sequence primer on DNAs prepared from a population of plants in which Mutator transposons or some other mutation-causing DNA element has been introduced (see Bensen, *supra*). The amplification of a specific DNA fragment with these primers indicates the insertion of the mutation tag element in or near the plant gene encoding the instant polypeptide. Alternatively, the instant nucleic acid fragment may be used as a hybridization probe against PCR amplification products generated from the mutation population using the mutation tag sequence primer in conjunction with an arbitrary genomic site primer, such as that for a restriction enzyme site-anchored synthetic adaptor. With either method, a plant containing a mutation in the endogenous gene encoding the instant polypeptide can be identified and obtained. This mutant plant can then be used to determine or confirm the natural function of the instant polypeptides disclosed herein.

#### EXAMPLES

The present invention is further defined in the following Examples, in which parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, various modifications of the invention in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

The disclosure of each reference set forth herein is incorporated herein by reference in its entirety.

#### EXAMPLE 1

##### Composition of cDNA Libraries; Isolation and Sequencing of cDNA Clones

cDNA libraries representing mRNAs from various corn (*Zea mays*), rice (*Oryza sativa*), soybean (*Glycine max*), and wheat (*Triticum aestivum*) tissues were prepared. The characteristics of the libraries are described below. Corn developmental stages are explained in the publication "How a Corn Plant Develops" from the Iowa State University Coop. Ext. Service Special Report No. 48 reprinted June 1993.

**TABLE 2**  
cDNA Libraries from Corn, Rice, Soybean, and Wheat

Library	Tissue	Clone
ceb1	Corn Embryo 10 to 11 Days After Pollination	ceb1.pk0082.a5
cil1c	Corn (EB90) Pooled Immature Leaf Tissue at V4, V6 and V8	cil1c.pk001.b7
cr1	Corn Root From 7 Day Old Seedlings	cr1.pk0022.a4
cr1n	Corn Root From 7 Day Old Seedlings*	cr1n.pk0033.e3
csi1n	Corn Silk*	csi1n.pk0045.a5 csi1n.pk0050.d5
p0005	Corn Immature Ear	p0005.cbmej72r
p0016	Corn Tassel Shoot, Pooled, 0.1-1.4 cm	p0016.ctsag12r
p0041	Corn Root Tip Smaller Than 5 mm in Length, Four Days After Imbibition	p0041.crtba02r
p0094	Corn Leaf Collars for the Ear Leaf (EL), screened 1 and the Next Leaf Above and Below the EL; Growth Conditions: Field; Control or Untreated Tissues	p0094.cssh17r
p0097	Corn V9 Whorl Section (7 cm) From Plant Infected Four Times With European Corn Borer	p0097.cqrai63r
p0119	Corn V12-Stage Ear Shoot With Husk, Night Harvested*	p0119.cmtnl24r
rr1	Rice Root of Two Week Old Developing Seedling	rr1.pk0019.c4
rsl1n	Rice 15-Day-Old Seedling*	rsl1n.pk003.n3
scr1c	Soybean Embryogenic Suspension Culture Subjected to 4 Vacuum Cycles and Collected 12 Hrs Later	scr1c.pk003.g7
sdp4c	Soybean Developing Pod (10-12 mm)	sdp4c.pk003.h2
sfl1	Soybean Immature Flower	sfl1.pk131.g9
src3c	Soybean 8 Day Old Root Infected With Cyst Nematode	src3c.pk026.o11
wdk1c	Wheat Developing Kernel, 3 Days After Anthesis	wdk1c.pk008.g12
wdr1f	Wheat Developing Root (Full Length)	wdr1f.pk001.g9
wle1n	Wheat Leaf From 7 Day Old Etiolated Seedling*	wle1n.pk0109.h1

\*These libraries were normalized essentially as described in U.S. Patent No. 5,482,845, incorporated herein by reference.

5

cDNA libraries may be prepared by any one of many methods available. For example, the cDNAs may be introduced into plasmid vectors by first preparing the cDNA libraries in Uni-ZAP™ XR vectors according to the manufacturer's protocol (Stratagene Cloning Systems, La Jolla, CA). The Uni-ZAP™ XR libraries are converted into plasmid libraries according to the protocol provided by Stratagene. Upon conversion, cDNA inserts will be contained in the plasmid vector pBluescript. In addition, the cDNAs may be introduced directly into precut Bluescript II SK(+) vectors (Stratagene) using T4 DNA

10

ligase (New England Biolabs), followed by transfection into DH10B cells according to the manufacturer's protocol (GIBCO BRL Products). Once the cDNA inserts are in plasmid vectors, plasmid DNAs are prepared from randomly picked bacterial colonies containing recombinant pBluescript plasmids, or the insert cDNA sequences are amplified via  
5 polymerase chain reaction using primers specific for vector sequences flanking the inserted cDNA sequences. Amplified insert DNAs or plasmid DNAs are sequenced in dye-primer sequencing reactions to generate partial cDNA sequences (expressed sequence tags or "ESTs"; see Adams et al., (1991) *Science* 252:1651-1656). The resulting ESTs are analyzed using a Perkin Elmer Model 377 fluorescent sequencer.

## 10 EXAMPLE 2

### Identification of cDNA Clones

cDNA clones encoding auxin transport protein were identified by conducting BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also [www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)) searches for similarity to sequences contained in the  
15 BLAST "nr" database (comprising all non-redundant GenBank CDS translations, sequences derived from the 3-dimensional structure Brookhaven Protein Data Bank, the last major release of the SWISS-PROT protein sequence database, EMBL, and DDBJ databases). The cDNA sequences obtained in Example 1 were analyzed for similarity to all publicly available DNA sequences contained in the "nr" database using the BLASTN algorithm  
20 provided by the National Center for Biotechnology Information (NCBI). The DNA sequences were translated in all reading frames and compared for similarity to all publicly available protein sequences contained in the "nr" database using the BLASTX algorithm (Gish and States (1993) *Nat. Genet.* 3:266-272) provided by the NCBI. For convenience, the P-value (probability) of observing a match of a cDNA sequence to a sequence contained  
25 in the searched databases merely by chance as calculated by BLAST are reported herein as "pLog" values, which represent the negative of the logarithm of the reported P-value. Accordingly, the greater the pLog value, the greater the likelihood that the cDNA sequence and the BLAST "hit" represent homologous proteins.

## EXAMPLE 3

### Characterization of cDNA Clones Encoding Auxin Transport Protein

30 The BLASTX search using the EST sequences from clones p0016.ctsag12r, p0119.cmtnl24r and wle1n.pk0109.h1, and the contig assembled from EST sequences from clones p0097.cqrai63r and p0094.cssh17r revealed similarity of the proteins encoded by the cDNAs to the auxin transport protein encoded by REH1 (Rice EIR1 Homolog) from rice  
35 (NCBI Gene Identifier No. 3377509). The BLAST results for each of these ESTs are shown in Table 3:

**TABLE 3**

BLAST Results for Clones Encoding Polypeptides Homologous to REH1 Protein

Clone	BLAST pLog Score 3377509
p0016.ctsag12r	10.5
Contig of: p0097.cqrai63r p0094.csssh17r	40.7
p0119.cmtnl24r	34.4
wle1n.pk0109.h1	52.0

5 The BLASTX search using the EST sequences from clones rsl1n.pk003.n3, src3c.pk026.o11 and wdk1c.pk008.g12 revealed similarity of the proteins encoded by the cDNAs to the auxin transport protein encoded by EIR1 from *Arabidopsis thaliana* (NCBI Gene Identifier No. 3377507). The BLAST results for each of these ESTs are shown in Table 4:

10

**TABLE 4**

BLAST Results for Clones Encoding Polypeptides Homologous to EIR1 Protein

Clone	BLAST pLog Score 3377507
rsl1n.pk003.n3	38.2
src3c.pk026.o11	39.2
wdk1c.pk008.g12	41.0

15 The BLASTX search using the EST sequences from clone sfl1.pk131.g9 revealed similarity of the protein encoded by the cDNA to the auxin transport protein encoded by PIN1 from *Arabidopsis thaliana* (NCBI Gene Identifier No. 4151319) with a pLog value of 30.2. The BLASTX search using the EST sequences from clone sdp4c.pk003.h2 revealed similarity of the protein encoded by the cDNA to a putative auxin transport protein encoded by a gene from *Arabidopsis thaliana* (NCBI Gene Identifier No. 3785972) with a pLog value of 37.7.

20 The sequence of a substantial portion of the cDNA insert from clone p0016.ctsag12r is shown in SEQ ID NO:5; the deduced amino acid sequence of this portion of the cDNA is shown in SEQ ID NO:6. The sequence of a contig assembled from a portion of the cDNA insert from clones p0097.cqrai63r and p0094.csssh17r is shown in SEQ ID NO:7; the deduced amino acid sequence of this contig is shown in SEQ ID NO:8. The sequence of a substantial portion of the cDNA insert from clone p0119.cmtnl24r is shown in SEQ ID NO:11; the deduced amino acid sequence of this portion of the cDNA is shown in SEQ ID NO:12. The sequence of a substantial portion of the cDNA insert from clone rsl1n.pk003.n3

is shown in SEQ ID NO:17; the deduced amino acid sequence of this portion of the cDNA is shown in SEQ ID NO:18. The sequence of a substantial portion of the cDNA insert from clone sdp4c.pk003.h2 is shown in SEQ ID NO:23; the deduced amino acid sequence of this portion of the cDNA is shown in SEQ ID NO:24. The sequence of a substantial portion of the cDNA insert from clone sfl1.pk131.g9 is shown in SEQ ID NO:27; the deduced amino acid sequence of this portion of the cDNA is shown in SEQ ID NO:28. The sequence of a substantial portion of the cDNA insert from clone src3c.pk026.o11 is shown in SEQ ID NO:31; the deduced amino acid sequence of this portion of the cDNA is shown in SEQ ID NO:32. The sequence of a substantial portion of the cDNA insert from clone wdk1c.pk008.g12 is shown in SEQ ID NO:35; the deduced amino acid sequence of this portion of the cDNA is shown in SEQ ID NO:36. The sequence of a substantial portion of the cDNA insert from wle1n.pk0109.h1 is shown in SEQ ID NO:41; the deduced amino acid sequence of this cDNA is shown in SEQ ID NO:42. BLAST scores and probabilities indicate that the instant nucleic acid fragments encode portions of auxin transport proteins.

The BLASTX search using the EST sequences from clones listed in Table 5 revealed similarity of the polypeptides encoded by the cDNAs to auxin transport proteins from rice (NCBI GenBank Identifier (GI) Nos. 3377509 and 7489524) and Arabidopsis (NCBI GenBank Identifier (GI) Nos. 5902405, 5817301, 4151319, 3377507, and 3785972). Shown in Table 5 are the BLAST results for individual ESTs ("EST"), the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), contigs assembled from two or more ESTs ("Contig"), contigs assembled from an FIS and one or more ESTs ("Contig\*"), or sequences encoding the entire protein derived from an FIS, a contig, or an FIS and PCR ("CGS"):

**TABLE 5**  
BLAST Results for Sequences Encoding Polypeptides Homologous  
to Auxin Transport Protein

Clone	Status	BLAST Results	
		NCBI GenBank Identifier (GI) No.	pLog Score
ceb1.pk0082.a5	EST	3377509	79.10
Contig of:	Contig	3377509	91.70
cr1.pk0022.a4			
cr1n.pk0033.e3			
csi1n.pk0045.a5			
csi1n.pk0050.d5			
p0005.cbmej72r			
p0041.crtba02r			
p0094.cssh17r	FIS	3377509	>254.00
p0119.cmtnl24r (FIS)	CGS	7489524	180.00
cil1.pk001.b7	FIS	7489524	135.00
rr1.pk0019.c4	EST	5902405	33.30



Clone	Status	BLAST Results	
		NCBI GenBank Identifier (GI) No.	pLog Score
rsl1n.pk003.n3	FIS	5817301	155.00
scr1c.pk003.g7	FIS	4151319	170.00
sdp4c.pk003.h2	FIS	5817301	>254.00
sfl1.pk131.g9(FIS)	CGS	4151319	>254.00
src3c.pk026.o11(FIS)	CGS	3377507	>254.00
wdk1c.pk008.g12(FIS)	CGS	3377507	>254.00
wdr1f.pk001.g9	EST	3785972	27.30
wle1n.pko109.hl	FIS	3377509	48.00

Figure 1 presents an alignment of the amino acid sequences set forth in SEQ ID NOs:14, 30, 34, and 38, the auxin transport protein EIR1 sequence from *Arabidopsis thaliana* (NCBI GenBank Identifier (GI) No. 3377507; SEQ ID NO:43), and the auxin transport protein AtPIN1 sequence from *Arabidopsis thaliana* (NCBI GenBank Identifier (GI) No. 4151319; SEQ ID NO:44). The data in Table 6 represents a calculation of the percent identity of the amino acid sequences set forth in SEQ ID NOs:14, 30, 34, and 38, the auxin transport protein EIR1 sequence from *Arabidopsis thaliana* (NCBI GenBank Identifier (GI) No. 3377507; SEQ ID NO:43), and the auxin transport protein AtPIN1 from *Arabidopsis thaliana* (NCBI GenBank Identifier (GI) No. 4151319; SEQ ID NO:44).

TABLE 6

Percent Identity of Amino Acid Sequences Deduced From the Nucleotide Sequences of cDNA Clones Encoding Polypeptides Homologous to Auxin Transport Protein

SEQ ID NO.	Percent Identity to	
	SEQ ID NO:43	SEQ ID NO:44
14	51.5	55.3
30	57.9	72.3
34	75.1	59.6
38	59.7	52.1

Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. Sequence alignments, BLAST scores and

probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones encode all or a substantial portion of an auxin transport protein.

#### EXAMPLE 4

##### Expression of Chimeric Genes in Monocot Cells

5 A chimeric gene comprising a cDNA encoding the instant polypeptide in sense orientation with respect to the maize 27 kD zein promoter that is located 5' to the cDNA fragment, and the 10 kD zein 3' end that is located 3' to the cDNA fragment, can be constructed. The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites  
10 (NcoI or SmaI) can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the digested vector pML103 as described below. Amplification is then performed in a standard PCR. The amplified DNA is then digested with restriction enzymes NcoI and SmaI and fractionated on an agarose gel. The appropriate band can be isolated from the gel and combined with a 4.9 kb NcoI-SmaI fragment of the  
15 plasmid pML103. Plasmid pML103 has been deposited under the terms of the Budapest Treaty at ATCC (American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209), and bears accession number ATCC 97366. The DNA segment from pML103 contains a 1.05 kb Sall-NcoI promoter fragment of the maize 27 kD zein gene and a 0.96 kb SmaI-Sall fragment from the 3' end of the maize 10 kD zein gene in the vector  
20 pGem9Zf(+) (Promega). Vector and insert DNA can be ligated at 15°C overnight, essentially as described (Maniatis). The ligated DNA may then be used to transform *E. coli* XL1-Blue (Epicurian Coli XL-1 Blue™; Stratagene). Bacterial transformants can be screened by restriction enzyme digestion of plasmid DNA and limited nucleotide sequence analysis using the dideoxy chain termination method (Sequenase™ DNA Sequencing Kit;  
25 U.S. Biochemical). The resulting plasmid construct would comprise a chimeric gene encoding, in the 5' to 3' direction, the maize 27 kD zein promoter, a cDNA fragment encoding the instant polypeptide, and the 10 kD zein 3' region.

The chimeric gene described above can then be introduced into corn cells by the following procedure. Immature corn embryos can be dissected from developing caryopses  
30 derived from crosses of the inbred corn lines H99 and LH132. The embryos are isolated 10 to 11 days after pollination when they are 1.0 to 1.5 mm long. The embryos are then placed with the axis-side facing down and in contact with agarose-solidified N6 medium (Chu et al. (1975) *Sci. Sin. Peking* 18:659-668). The embryos are kept in the dark at 27°C. Friable embryogenic callus consisting of undifferentiated masses of cells with somatic  
35 proembryoids and embryoids borne on suspensor structures proliferates from the scutellum of these immature embryos. The embryogenic callus isolated from the primary explant can be cultured on N6 medium and sub-cultured on this medium every 2 to 3 weeks.

The plasmid, p35S/Ac (obtained from Dr. Peter Eckes, Hoechst Ag, Frankfurt, Germany) may be used in transformation experiments in order to provide for a selectable marker. This plasmid contains the *Pat* gene (see European Patent Publication 0 242 236) which encodes phosphinothricin acetyl transferase (PAT). The enzyme PAT confers resistance to herbicidal glutamine synthetase inhibitors such as phosphinothricin. The *pat* gene in p35S/Ac is under the control of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*.

The particle bombardment method (Klein et al. (1987) *Nature* 327:70-73) may be used to transfer genes to the callus culture cells. According to this method, gold particles (1  $\mu$ m in diameter) are coated with DNA using the following technique. Ten  $\mu$ g of plasmid DNAs are added to 50  $\mu$ L of a suspension of gold particles (60 mg per mL). Calcium chloride (50  $\mu$ L of a 2.5 M solution) and spermidine free base (20  $\mu$ L of a 1.0 M solution) are added to the particles. The suspension is vortexed during the addition of these solutions. After 10 minutes, the tubes are briefly centrifuged (5 sec at 15,000 rpm) and the supernatant removed. The particles are resuspended in 200  $\mu$ L of absolute ethanol, centrifuged again and the supernatant removed. The ethanol rinse is performed again and the particles resuspended in a final volume of 30  $\mu$ L of ethanol. An aliquot (5  $\mu$ L) of the DNA-coated gold particles can be placed in the center of a Kapton<sup>TM</sup> flying disc (Bio-Rad Labs). The particles are then accelerated into the corn tissue with a Biolistic<sup>TM</sup> PDS-1000/He (Bio-Rad Instruments, Hercules CA), using a helium pressure of 1000 psi, a gap distance of 0.5 cm and a flying distance of 1.0 cm.

For bombardment, the embryogenic tissue is placed on filter paper over agarose-solidified N6 medium. The tissue is arranged as a thin lawn and covered a circular area of about 5 cm in diameter. The petri dish containing the tissue can be placed in the chamber of the PDS-1000/He approximately 8 cm from the stopping screen. The air in the chamber is then evacuated to a vacuum of 28 inches of Hg. The macrocarrier is accelerated with a helium shock wave using a rupture membrane that bursts when the He pressure in the shock tube reaches 1000 psi.

Seven days after bombardment the tissue can be transferred to N6 medium that contains glufosinate (2 mg per liter) and lacks casein or proline. The tissue continues to grow slowly on this medium. After an additional 2 weeks the tissue can be transferred to fresh N6 medium containing glufosinate. After 6 weeks, areas of about 1 cm in diameter of actively growing callus can be identified on some of the plates containing the glufosinate-supplemented medium. These calli may continue to grow when sub-cultured on the selective medium.

Plants can be regenerated from the transgenic callus by first transferring clusters of tissue to N6 medium supplemented with 0.2 mg per liter of 2,4-D. After two weeks the

tissue can be transferred to regeneration medium (Fromm et al. (1990) *Bio/Technology* 8:833-839).

### EXAMPLE 5

#### Expression of Chimeric Genes in Dicot Cells

5 A seed-specific construct composed of the promoter and transcription terminator from the gene encoding the  $\beta$  subunit of the seed storage protein phaseolin from the bean *Phaseolus vulgaris* (Doyle et al. (1986) *J. Biol. Chem.* 261:9228-9238) can be used for expression of the instant polypeptides in transformed soybean. The phaseolin construct includes about 500 nucleotides upstream (5') from the translation initiation codon and about  
10 1650 nucleotides downstream (3') from the translation stop codon of phaseolin. Between the 5' and 3' regions are the unique restriction endonuclease sites Nco I (which includes the ATG translation initiation codon), Sma I, Kpn I and Xba I. The entire construct is flanked by Hind III sites.

The cDNA fragment of this gene may be generated by polymerase chain reaction  
15 (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the expression vector. Amplification is then performed as described above, and the isolated fragment is inserted into a pUC18 vector carrying the seed construct.

Soybean embryos may then be transformed with the expression vector comprising  
20 sequences encoding the instant polypeptides. To induce somatic embryos, cotyledons, 3-5 mm in length dissected from surface sterilized, immature seeds of the soybean cultivar A2872, can be cultured in the light or dark at 26°C on an appropriate agar medium for 6-10 weeks. Somatic embryos which produce secondary embryos are then excised and placed into a suitable liquid medium. After repeated selection for clusters of somatic  
25 embryos which multiplied as early, globular staged embryos, the suspensions are maintained as described below.

Soybean embryogenic suspension cultures can be maintained in 35 mL liquid media on a rotary shaker, 150 rpm, at 26°C with florescent lights on a 16:8 hour day/night schedule. Cultures are subcultured every two weeks by inoculating approximately 35 mg of tissue into  
30 35 mL of liquid medium.

Soybean embryogenic suspension cultures may then be transformed by the method of particle gun bombardment (Klein et al. (1987) *Nature* (London) 327:70-73, U.S. Patent No. 4,945,050). A DuPont Biolistic™ PDS1000/HE instrument (helium retrofit) can be used for these transformations.

35 A selectable marker gene which can be used to facilitate soybean transformation is a chimeric gene composed of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812), the hygromycin phosphotransferase gene from plasmid pJR225 (from *E. coli*; Gritz et al. (1983) *Gene* 25:179-188) and the 3' region of the nopaline synthase

gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*. The seed construct comprising the phaseolin 5' region, the fragment encoding the instant polypeptide and the phaseolin 3' region can be isolated as a restriction fragment. This fragment can then be inserted into a unique restriction site of the vector carrying the marker gene.

5 To 50  $\mu$ L of a 60 mg/mL 1  $\mu$ m gold particle suspension is added (in order): 5  $\mu$ L DNA (1  $\mu$ g/ $\mu$ L), 20  $\mu$ L spermidine (0.1 M), and 50  $\mu$ L  $\text{CaCl}_2$  (2.5 M). The particle preparation is then agitated for three minutes, spun in a microfuge for 10 seconds and the supernatant removed. The DNA-coated particles are then washed once in 400  $\mu$ L 70% ethanol and resuspended in 40  $\mu$ L of anhydrous ethanol. The DNA/particle suspension can  
10 be sonicated three times for one second each. Five  $\mu$ L of the DNA-coated gold particles are then loaded on each macro carrier disk.

Approximately 300-400 mg of a two-week-old suspension culture is placed in an empty 60x15 mm petri dish and the residual liquid removed from the tissue with a pipette. For each transformation experiment, approximately 5-10 plates of tissue are normally  
15 bombarded. Membrane rupture pressure is set at 1100 psi and the chamber is evacuated to a vacuum of 28 inches mercury. The tissue is placed approximately 3.5 inches away from the retaining screen and bombarded three times. Following bombardment, the tissue can be divided in half and placed back into liquid and cultured as described above.

Five to seven days post bombardment, the liquid media may be exchanged with fresh  
20 media, and eleven to twelve days post bombardment with fresh media containing 50 mg/mL hygromycin. This selective media can be refreshed weekly. Seven to eight weeks post bombardment, green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated green tissue is removed and inoculated into individual flasks to generate new, clonally propagated, transformed embryogenic suspension  
25 cultures. Each new line may be treated as an independent transformation event. These suspensions can then be subcultured and maintained as clusters of immature embryos or regenerated into whole plants by maturation and germination of individual somatic embryos.

#### EXAMPLE 6

##### Expression of Chimeric Genes in Microbial Cells

30 The cDNAs encoding the instant polypeptides can be inserted into the T7 *E. coli* expression vector pBT430. This vector is a derivative of pET-3a (Rosenberg et al. (1987) *Gene* 56:125-135) which employs the bacteriophage T7 RNA polymerase/T7 promoter system. Plasmid pBT430 was constructed by first destroying the EcoR I and Hind III sites in pET-3a at their original positions. An oligonucleotide adaptor containing EcoR I and  
35 Hind III sites was inserted at the BamH I site of pET-3a. This created pET-3aM with additional unique cloning sites for insertion of genes into the expression vector. Then, the Nde I site at the position of translation initiation was converted to an Nco I site using

oligonucleotide-directed mutagenesis. The DNA sequence of pET-3aM in this region, 5'-CATATGG, was converted to 5'-CCCATGG in pBT430.

Plasmid DNA containing a cDNA may be appropriately digested to release a nucleic acid fragment encoding the protein. This fragment may then be purified on a 1% NuSieve GTG™ low melting agarose gel (FMC). Buffer and agarose contain 10 µg/mL ethidium bromide for visualization of the DNA fragment. The fragment can then be purified from the agarose gel by digestion with GELase™ (Epicentre Technologies) according to the manufacturer's instructions, ethanol precipitated, dried and resuspended in 20 µL of water. Appropriate oligonucleotide adapters may be ligated to the fragment using T4 DNA ligase (New England Biolabs, Beverly, MA). The fragment containing the ligated adapters can be purified from the excess adapters using low melting agarose as described above. The vector pBT430 is digested, dephosphorylated with alkaline phosphatase (NEB) and deproteinized with phenol/chloroform as described above. The prepared vector pBT430 and fragment can then be ligated at 16°C for 15 hours followed by transformation into DH5 electrocompetent cells (GIBCO BRL). Transformants can be selected on agar plates containing LB media and 100 µg/mL ampicillin. Transformants containing the gene encoding the instant polypeptide are then screened for the correct orientation with respect to the T7 promoter by restriction enzyme analysis.

For high level expression, a plasmid clone with the cDNA insert in the correct orientation relative to the T7 promoter can be transformed into *E. coli* strain BL21(DE3) (Studier et al. (1986) *J. Mol. Biol.* 189:113-130). Cultures are grown in LB medium containing ampicillin (100 mg/L) at 25°C. At an optical density at 600 nm of approximately 1, IPTG (isopropylthio-β-galactoside, the inducer) can be added to a final concentration of 0.4 mM and incubation can be continued for 3 h at 25°. Cells are then harvested by centrifugation and re-suspended in 50 µL of 50 mM Tris-HCl at pH 8.0 containing 0.1 mM DTT and 0.2 mM phenyl methylsulfonyl fluoride. A small amount of 1 mm glass beads can be added and the mixture sonicated 3 times for about 5 seconds each time with a microprobe sonicator. The mixture is centrifuged and the protein concentration of the supernatant determined. One µg of protein from the soluble fraction of the culture can be separated by SDS-polyacrylamide gel electrophoresis. Gels can be observed for protein bands migrating at the expected molecular weight.

#### EXAMPLE 7

##### Evaluating Compounds for Their Ability to Inhibit the Activity of Auxin Transport Proteins

The polypeptides described herein may be produced using any number of methods known to those skilled in the art. Such methods include, but are not limited to, expression in bacteria as described in Example 6, or expression in eukaryotic cell culture, *in planta*, and using viral expression systems in suitably infected organisms or cell lines. The instant

polypeptides may be expressed either as mature forms of the proteins as observed *in vivo* or as fusion proteins by covalent attachment to a variety of enzymes, proteins or affinity tags. Common fusion protein partners include glutathione S-transferase ("GST"), thioredoxin ("Trx"), maltose binding protein, and C- and/or N-terminal hexahistidine polypeptide ("His<sub>6</sub>"). The fusion proteins may be engineered with a protease recognition site at the fusion point so that fusion partners can be separated by protease digestion to yield intact mature enzyme. Examples of such proteases include thrombin, enterokinase and factor Xa. However, any protease can be used which specifically cleaves the peptide connecting the fusion protein and the enzyme.

Purification of the instant polypeptides, if desired, may utilize any number of separation technologies familiar to those skilled in the art of protein purification. Examples of such methods include, but are not limited to, homogenization, filtration, centrifugation, heat denaturation, ammonium sulfate precipitation, desalting, pH precipitation, ion exchange chromatography, hydrophobic interaction chromatography and affinity chromatography, wherein the affinity ligand represents a substrate, substrate analog or inhibitor. When the instant polypeptides are expressed as fusion proteins, the purification protocol may include the use of an affinity resin which is specific for the fusion protein tag attached to the expressed enzyme or an affinity resin containing ligands which are specific for the enzyme. For example, the instant polypeptides may be expressed as a fusion protein coupled to the C-terminus of thioredoxin. In addition, a (His)<sub>6</sub> peptide may be engineered into the N-terminus of the fused thioredoxin moiety to afford additional opportunities for affinity purification. Other suitable affinity resins could be synthesized by linking the appropriate ligands to any suitable resin such as Sepharose-4B. In an alternate embodiment, a thioredoxin fusion protein may be eluted using dithiothreitol; however, elution may be accomplished using other reagents which interact to displace the thioredoxin from the resin. These reagents include  $\beta$ -mercaptoethanol or other reduced thiol. The eluted fusion protein may be subjected to further purification by traditional means as stated above, if desired. Proteolytic cleavage of the thioredoxin fusion protein and the enzyme may be accomplished after the fusion protein is purified or while the protein is still bound to the ThioBond™ affinity resin or other resin.

Crude, partially purified or purified enzyme, either alone or as a fusion protein, may be utilized in assays for the evaluation of compounds for their ability to inhibit enzymatic activation of the auxin transport proteins disclosed herein. Assays may be conducted under well known experimental conditions which permit optimal enzymatic activity. For example, assays for auxin transport proteins are presented by Chen, R. et al., (1998) *Proc. Natl. Acad. Sci. USA* 95:15112-15117.

CLAIMS

What is claimed is:

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- 5 (a) a first nucleotide sequence encoding a polypeptide of at least 30 amino acids that has at least 85% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:6;
- (b) a second nucleotide sequence encoding a polypeptide of at least 50 amino acids that has at least 80% identity based on the Clustal method of  
10 alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:16, 28, 36, and 40;
- (c) a third nucleotide sequence encoding a polypeptide of at least 50 amino acids that has at least 85% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:12;
- 15 (d) a fourth nucleotide sequence encoding a polypeptide of at least 50 amino acids that has at least 90% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:8 and 24;
- 20 (e) a fifth nucleotide sequence encoding a polypeptide of at least 50 amino acids that has at least 95% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:18 and 32;
- 25 (f) a sixth nucleotide sequence encoding a polypeptide of at least 90 amino acids that has at least 95% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:42;
- (g) a seventh nucleotide sequence encoding a polypeptide of at least 95 amino acids that has at least 95% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:46;
- 30 (h) an eighth nucleotide sequence encoding a polypeptide of at least 100 amino acids that has at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NO:20;
- (i) a ninth nucleotide sequence encoding a polypeptide of at least 100 amino acids that has at least 90% identity based on the Clustal method of  
35 alignment when compared to a polypeptide of SEQ ID NO:2;
- (j) a tenth nucleotide sequence encoding a polypeptide of at least 150 amino acids that has at least 95% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:4;



- 5 (k) an eleventh nucleotide sequence encoding a polypeptide of at least 300 amino acids that has at least 80% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:38;
- (l) a twelfth nucleotide sequence encoding a polypeptide of at least 350 amino acids that has at least 95% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:10;
- 10 (m) a thirteenth nucleotide sequence encoding a polypeptide of at least 400 amino acids that has at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:22, 26 and 30;
- (n) a fourteenth nucleotide sequence encoding a polypeptide of at least 500 amino acids that has at least 80% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:34;
- 15 (o) a fifteenth nucleotide sequence encoding a polypeptide of at least 200 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:14;
- (p) a sixteenth nucleotide sequence encoding a polypeptide of at least 250 amino acids having at least 90% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:48; and
- 20 (q) a seventeenth nucleotide sequence comprising a complement of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o) or (p).

2. The isolated polynucleotide of Claim 1, wherein the first nucleotide sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 45, and 47 that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 46, and 48.

25

3. The isolated polynucleotide of Claim 1 wherein the nucleotide sequences are DNA.

30 4. The isolated polynucleotide of Claim 1 wherein the nucleotide sequences are RNA.

5. A chimeric gene comprising the isolated polynucleotide of Claim 1 operably linked to at least one suitable regulatory sequence.

6. A host cell comprising the chimeric gene of Claim 5.

7. A host cell comprising the isolated polynucleotide of Claim 1.

35 8. The host cell of Claim 7 wherein the host cell is selected from the group consisting of yeast, bacteria, and plant.

9. A virus comprising the isolated polynucleotide of Claim 1.

10. A polypeptide selected from the group consisting of:

- 5
- (a) a polypeptide of at least 30 amino acids that has at least 85% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:6;
- (b) a polypeptide of at least 50 amino acids that has at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:16, 28, 36, and 40;
- 10
- (c) a polypeptide of at least 50 amino acids that has at least 85% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:12;
- (d) a polypeptide of at least 50 amino acids that has at least 90% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:8 and 24;
- 15
- (e) a polypeptide of at least 50 amino acids that has at least 95% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:18 and 32;
- (f) a polypeptide of at least 90 amino acids that has at least 95% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:42;
- 20
- (g) a polypeptide of at least 95 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:46;
- (h) a polypeptide of at least 100 amino acids that has at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NO:20;
- 25
- (i) a polypeptide of at least 100 amino acids that has at least 90% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:2;
- (j) a polypeptide of at least 150 amino acids that has at least 95% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:4;
- 30
- (k) a polypeptide of at least 300 amino acids that has at least 80% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:38;
- 35
- (l) a polypeptide of at least 350 amino acids that has at least 95% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:10;

- (m) a polypeptide of at least 400 amino acids that has at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:22, 26 and 30;
- 5 (n) a polypeptide of at least 500 amino acids that has at least 80% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:34;
- (o) a polypeptide of at least 200 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:14; and
- 10 (p) a polypeptide of at least 250 amino acids having at least 90% identity based on the Clustal method of alignment when compared to a polypeptide of SEQ ID NO:48.

11. A method of selecting an isolated polynucleotide that affects the level of expression of a polypeptide in a plant cell, the method comprising the steps of:

- 15 (a) constructing the isolated polynucleotide comprising a nucleotide sequence of at least one of 30 contiguous nucleotides derived from the isolated polynucleotide of Claim 1;
- (b) introducing the isolated polynucleotide into the plant cell;
- (c) measuring the level of the polypeptide in the plant cell containing the polynucleotide; and
- 20 (d) comparing the level of the polypeptide in the plant cell containing the isolated polynucleotide with the level of the polypeptide in a plant cell that does not contain the isolated polynucleotide.

12. The method of Claim 11 wherein the isolated polynucleotide consists of the nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 45, and 47 that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 46, and 48.

13. A method of selecting an isolated polynucleotide that affects the level of expression of a polypeptide in a plant cell, the method comprising the steps of:

- 30 (a) constructing the isolated polynucleotide of Claim 1;
- (b) introducing the isolated polynucleotide into the plant cell;
- (c) measuring the level of the polypeptide in the plant cell containing the polynucleotide; and
- 35 (d) comparing the level of the polypeptide in the plant cell containing the isolated polynucleotide with the level of the polypeptide in a plant cell that does not contain the polynucleotide.

14. A method of obtaining a nucleic acid fragment encoding a polypeptide comprising the steps of:

- 5 (a) synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 30 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 45, and 47 and a complement of such nucleotide sequences; and
- (b) amplifying the nucleic acid sequence using the oligonucleotide primer.

10 15. A method of obtaining a nucleic acid fragment encoding a polypeptide comprising the steps of:

- 15 (a) probing a cDNA or genomic library with an isolated polynucleotide comprising at least one of 30 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 45, and 47 and a complement of such nucleotide sequences;
- (b) identifying a DNA clone that hybridizes with the isolated polynucleotide;
- (c) isolating the identified DNA clone; and
- (d) sequencing a cDNA or genomic fragment that comprises the isolated DNA clone.

20 16. A method for evaluating at least one compound for its ability to inhibit the activity of a protein, the method comprising the steps of:

- 25 (a) transforming a host cell with a chimeric gene comprising a nucleic acid fragment encoding the polypeptide, operably linked to at least one suitable regulatory sequence;
- (b) growing the transformed host cell under conditions that are suitable for expression of the chimeric gene wherein expression of the chimeric gene results in production of the auxin transport protein encoded by the operably linked nucleic acid fragment in the transformed host cell;
- 30 (c) optionally purifying the auxin transport polypeptide expressed by the transformed host cell;
- (d) treating the auxin transport polypeptide with a compound to be tested; and
- (e) comparing the activity of the auxin transport polypeptide that has been treated with the test compound to the activity of an untreated auxin transport polypeptide,

35 thereby selecting compounds with potential for inhibitory activity.

17. A composition comprising the isolated polynucleotide of Claim 1.

18. A composition comprising the isolated polypeptide of Claim 10.

19. The isolated polynucleotide of Claim 1 comprising a nucleotide sequence having at least one of 30 contiguous nucleotides.
20. A method for positive selection of a transformed cell comprising:
- 5 (a) transforming a host cell with the chimeric gene of Claim 5; and
- (b) growing the transformed host cell under conditions which allow expression of a polynucleotide in an amount sufficient to complement a null mutant to provide a positive selection means.
21. The method of Claim 20 wherein the host cell is a plant.
22. The method of Claim 21 wherein the plant cell is a monocot.
- 10 23. The method of Claim 21 wherein the plant cell is a dicot.
24. A method of modulating expression of a polypeptide for modulating root development in a plant, comprising the steps of:
- (a) stably transforming a plant cell with an auxin transport protein polynucleotide operably linked to a promoter, wherein the polynucleotide is
- 15 in sense or antisense orientation; and
- (b) growing the plant cell under plant growing conditions to produce a regenerated plant capable of expressing the polynucleotide for a time sufficient to modulate root development in the plant.

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 15/29, 15/82, 5/10, C12Q 1/68,</b> <b>C07K 14/415</b>		<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/68389</b> <b>(43) International Publication Date:</b> 16 November 2000 (16.11.00)
<b>(21) International Application Number:</b> PCT/US00/12061 <b>(22) International Filing Date:</b> 3 May 2000 (03.05.00) <b>(30) Priority Data:</b> 60/133,040 7 May 1999 (07.05.99) US <b>(71) Applicants (for all designated States except US):</b> E. I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US). PIONEER HI-BRED INTERNATIONAL, INC. [US/US]; 7100 N.W. 62nd Avenue, Johnston, IA 50131 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> OROZCO, Emil, M., Jr. [US/US]; 2 Dutton Farm Lane, West Grove, PA 19390 (US). WENG, Zude [CN/US]; Apartment 1B, 9122 Lincoln Drive, Des Plaines, IL 60016 (US). BRUCE, Wesley, B. [US/US]; 4625 96th Street, Des Moines, IA 50322 (US). CAHOON, Rebecca, E. [US/US]; 2331 West 18th Street, Wilmington, DE 19806 (US). TAO, Yong [CN/US]; 101-8 Thorn lane, Newark, DE 19711 (US). <b>(74) Agent:</b> GEIGER, Kathleen, W.; E.I. du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>	

**(54) Title:** AUXIN TRANSPORT PROTEINS

```
*** * * * *
SEQ ID NO:14  MITALDLYHVLTAVVPLYVAMTILAYGSRVWRWRIFTPQCSCGINREVALFAVPLLSFHFIS
SEQ ID NO:30  MITLTDFYHVMTAMVPLYVAMILAYGSVKWKKIFSPDQCSCGINREVALFAVPLLSFHFIA
SEQ ID NO:34  MITGKDIYDVFAAIVPLYVAMILAYGSRVWRWRIFTPQCSCGINREVALFAVPLLSFHFIS
SEQ ID NO:38  MITGKDIYDVLAADVPLYVAMFAMAYGSRVWRWGIFTPQCSCGINREVALFAVPLLSFHFIS
SEQ ID NO:43  MITGKDMYDVLAAMVPLYVAMILAYGSRVWRWGIFTPQCSCGINREVALFAVPLLSFHFIS
SEQ ID NO:44  MITAADFYHVMTAMVPLYVAMILAYGSVKWKKIFTPQCSCGINREVALFAVPLLSFHFIA
1 60

* * * * *
SEQ ID NO:14  TNDPFAMNLRFLAADTLQKVAVLALLALASRGLSSPRALG-----LDWSITLFSLS
SEQ ID NO:30  SNNPYEMNLRFLAADTLQKIIILVLLAVW----SNITKRG-----CLEWAITLFSLS
SEQ ID NO:34  SNDPYAMNYHFIAADCLQKVVLGALFLWNT----FTKHG-----SLDWTITLFSLS
SEQ ID NO:38  TNDPYAMDYRFLAADSLQKVLILAALAVWHNVLSRYRCRGGEAGEASSLDWTITLFSLS
SEQ ID NO:43  SNDPYAMNYHFIAADSLQKVVLILAALFLWQA----FSRRG-----SLEWMITLFSLS
SEQ ID NO:44  ANNPYAMNLRFLAADSLQKVIVLSLLFLW----CKLSRNG-----SLDWTITLFSLS
61 120

*****
SEQ ID NO:14  TLPNTLVMGIPLLRGMYGASSAGTLMVQVVVLCIIWYTLMLFLFEYRAARALVLDQFPD
SEQ ID NO:30  TLPNTLVMGIPLLKGMYGDFS--GSLMVQIVVLCIIWYTLMLFLFEFRGARMLEIQFPP
SEQ ID NO:34  TLPNTLVMGIPLLKAMYGDFS--GSLMVQIVVLCIIWYTLMLFLFEYRGAKLLITEQFPP
SEQ ID NO:38  TLPNTLVMGIPLLRAMYGDFS--GSLMVQIVVLCIIWYTLMLFLFEYRGAKALISEQFPP
SEQ ID NO:43  TLPNTLVMGIPLLRAMYGDFS--GSLMVQIVVLCIIWYTLMLFLFEFRGAKLLISEQFPP
SEQ ID NO:44  TLPNTLVMGIPLLKGMYGDFS--GSLMVQIVVLCIIWYTLMLFLFEYRGAKLLISEQFPP
321 780
```

**(57) Abstract**

This invention relates to an isolated nucleic acid fragment encoding an auxin transport protein. The invention also relates to the construction of a chimeric gene encoding all or a substantial portion of the auxin transport protein, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the auxin transport protein in a transformed host cell. The present invention also relates to methods using the auxin transport protein in modulating root development, and in discovering compounds with potential herbicidal activity.

\*\*\*\*  
 TLPNTLVMGIPLLRCMYGASSAGTLMVQVVVLQCIWYTLMLFLFEYRAARALVLDQFPD  
 TLPNTLVMGIPLLKMGYDFS-GSLMVQIVVLQCIWYTLMLFLFEFRGARM LISEQFP-  
 TLPNTLVMGIPLLKAMYDFS-GSLMVQIVVLQSVIWYTLMLFMFEYRGAKLLITEQFP-  
 TLPNTLVMGIPLLRAMYDFS-GSLMVQIVVLQSVIWYTLMLFLFEYRGAKALISEQFP  
 TLPNTLVMGIPLLRAMYDFS-GNLMVQIVVLQSVIWYTLMLFLFEFRGAKLLISEQFP-  
 TLPNTLVMGIPLLKMGYNFS-GDLMVQIVVLQCIWYILMLFLFEYRGAKLLISEQFP-  
 121 180

SEQ ID NO:14  
SEQ ID NO:30  
SEQ ID NO:34  
SEQ ID NO:38  
SEQ ID NO:43  
SEQ ID NO:44





## FIGURE 1 CONTINUED

```

*      *      *      *      *
-----EKGACGGGGGGHSPQQA-----VAVPAKRKDLHM
-FHYHA-----AGGTGHPAPNPGMFSPSNGSKSVAANANAKRPNGQAQLKPEDGNRDLHM
LFN-----GGLVSSNYPPNP-MFSGSTSAAGGPKKDSGGG-----GAVAPNKKELHM
-FK-----GGEAAAPYAPNP-GMM-----MPAPRKKELGGSNSNS-----DKELHM
LYN-----NNSVPS-YPPNP-MFTGSTSGASGVKKKESGGGGGGVGVGGQNKEMNM
RFHYQSGSGGGGAHYAPNPGMFSPNTGGGGTAAGNAPVVGK--RQDGNGRDLHM
361

```

```

***** *      *
LVWSSASPVSE-----RAAVHVFAGGA----DHADVLAQAQAYDEY---GRDDY
FVWSSASPVSDV-----FGA-----HEYGGG--HDQKEVKLNVS PGKVEN
FVWSSASPVSEGNLRHAVNRAASTDFGTVDPSKAVPHETVASKAVHELIIENMSPGRRGS
FVWSSASPVSEANLRNAVNHAASTDFAAAPPAATPRDGATPRGVS SVTPVMKKDASS
FVWSSASPVSEANAKNAMTRGSSTDVSTDPKVSIPPHDNLATKAMQNLIENMSPGRKGH
FVWSSASPVSDV-----FGGGGNHHADYSTATNDHQKDVKISVPQNSND
421

```

```

*** *****
SSRTKNGSGG-ADKGGPTLS-KLGSNSTAQLYPKD----DGEGRAAAVAMP PASVMTRLI
NHRDT--QEDYLEKDEFSGNR---EMDREMNQLEGEKVGDGK---PKTMPPASVMTRLI
GERPEMDEG-----AKIPASGSPYTCQKKVDMEDGNAN-KNQOMPPASVMTRLI
GAVEVEIEDGMKSPATGLGAKFPVSGSPYVAPRKKGADVPGLEEAHPMP PASVMTRLI
VEMDQDGNNG-----GK-----SPYMGKKGSDVEDGGPGRKQMP PASVMTRLI
NQ-----YVEREEFSFGNK---DDDSKVLATDGGNNISNKTTOAKVMPPTSVMTRLI
481

```

SEQ ID NO:14  
SEQ ID NO:30  
SEQ ID NO:34  
SEQ ID NO:38  
SEQ ID NO:43  
SEQ ID NO:44

SEQ ID NO:14  
SEQ ID NO:30  
SEQ ID NO:34  
SEQ ID NO:38  
SEQ ID NO:43  
SEQ ID NO:44

SEQ ID NO:14  
SEQ ID NO:30  
SEQ ID NO:34  
SEQ ID NO:38  
SEQ ID NO:43  
SEQ ID NO:44



## DECLARATION and POWER OF ATTORNEY

My residence, post office address and citizenship are as stated below next to my name.

## AUXIN TRANSPORT PROTEINS

■ was filed on **03 MAY 2000** as U.S. Application No. \_\_\_\_\_ α PCT International Application No. **PCT/US00/12061** and was amended on \_\_\_\_\_ (if applicable)

I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in 37 CFR § 1.56.

Application No.	Country	Filing Date	Priority Claimed (Yes/No)
-----------------	---------	-------------	---------------------------

**U.S. Provisional Application No.**  
**60/133,040**

**U.S. Filing Date**  
MAY 07, 1999

Application No.	Filing Date	Status (patented, pending or abandoned)
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		
61		
62		
63		
64		
65		
66		
67		
68		
69		
70		
71		
72		
73		
74		
75		
76		
77		
78		
79		
80		
81		
82		
83		
84		
85		
86		
87		
88		
89		
90		
91		
92		
93		
94		
95		
96		
97		
98		
99		
100		

Name: KATHLEEN W. GEIGER




Registration No 35,880

KATHLEEN W. GEIGER

**E. I. du Pont de Nemours and Company and  
Pioneer Hi-Bred International, Inc.  
Legal - Patents  
Wilmington, DE 19898, U.S.A.**

**Tel. No.**  
(302) 302-992-3749  
**Fax No.**  
(302) 302-773-0164

INVENTOR(S)

<b>Full Name of Inventor</b>	<b>Last Name</b> <b>OROZCO, JR.</b>	<b>First Name</b> <b>EMIL</b>	<b>Middle Name</b> <b>M.</b>	
	Signature (please sign full name) 		Date <u>June 15, 2000</u>	
<b>Residence &amp; Citizenship</b>	<b>City</b> <b>WEST GROVE</b> PA	<b>State or Foreign Country</b> <b>PENNSYLVANIA</b>		<b>Country of Citizenship</b> <b>U.S.A.</b>
<b>Post Office Address</b>	<b>Post Office Address</b> <b>2 DUTTON FARM LANE</b>		<b>State or Country</b> <b>PENNSYLVANIA</b>	<b>Zip Code</b> <b>19390</b>
<b>Full Name of Inventor</b>	<b>Last Name</b> <b>WENG</b>	<b>First Name</b> <b>ZUDE</b>	<b>Middle Name</b>	
	Signature (please sign full name) 		Date <u>6/21/2000</u>	
<b>Residence &amp; Citizenship</b>	<b>City</b> <b>DES PLAINES</b> IL	<b>State or Foreign Country</b> <b>ILLINOIS</b>		<b>Country of Citizenship</b> <b>CN</b>
<b>Post Office Address</b>	<b>Post Office Address</b> <b>9122 LINCOLN DRIVE, APART 1B</b>		<b>State or Country</b> <b>ILLINOIS</b>	<b>Zip Code</b> <b>60016</b>
<b>Full Name of Inventor</b>	<b>Last Name</b> <b>BRUCE</b>	<b>First Name</b> <b>WESLEY</b>	<b>Middle Name</b> <b>B.</b>	
	Signature (please sign full name) 		Date <u>6/30/2000</u>	
<b>Residence &amp; Citizenship</b>	<b>City</b> <b>DES MOINES</b> IA	<b>State or Foreign Country</b> <b>IOWA</b>		<b>Country of Citizenship</b> <b>U.S.A.</b>
<b>Post Office Address</b>	<b>Post Office Address</b> <b>4625 96TH STREET</b>		<b>State or Country</b> <b>IOWA</b>	<b>Zip Code</b> <b>50322</b>

■ Additional Inventors are being named on separately numbered sheets attached hereto.

## DECLARATION AND POWER OF ATTORNEY - Page 2

Docket No.: **BB1355PCT**

Full Name of Inventor	Last Name <b>CAHOON</b>	First Name <b>REBECCA</b>	Middle Name <b>E.</b>
	Signature (please sign full name): <i>Rebecca E. Cahoon</i>		Date: <i>June 15, 2000</i>
Residence & Citizenship	City <b>WILMINGTON</b> DE	State or Foreign Country <b>DELAWARE</b>	Country of Citizenship <b>U.S.A.</b>
Post Office Address	Post Office Address <b>2331 WEST 18TH STREET</b>	City <b>WILMINGTON</b>	State or Country <b>DELAWARE</b>
			Zip Code <b>19806</b>
Full Name of Inventor	Last Name <b>TAO</b>	First Name <b>YONG</b>	Middle Name
	Signature (please sign full name): <i>Yong TAO</i>		Date: <i>June 16, 2000</i>
Residence & Citizenship	City <b>NEWARK</b> DE	State or Foreign Country <b>DELAWARE</b>	Country of Citizenship <b>CN</b>
Post Office Address	Post Office Address <b>101-8 THORN LANE</b>	City <b>NEWARK</b>	State or Country <b>DELAWARE</b>
			Zip Code <b>19711</b>

WO 00/68389

PCT/US00/12061

SEQUENCE LISTING

<110> E. I. du Pont de Nemours and Company  
Pioneer Hi-Bred International, Inc.

<120> Auxin Transport Proteins

<130> BB1355

<140>  
<141>

<150> 60/133,040  
<151> 1999-05-07

<160> 48

<170> Microsoft Office 97

<210> 1  
<211> 629  
<212> DNA  
<213> Zea mays

<220>  
<221> unsure  
<222> (413)

<220>  
<221> unsure  
<222> (466)

<220>  
<221> unsure  
<222> (526)

<220>  
<221> unsure  
<222> (535)

<220>  
<221> unsure  
<222> (549)

<220>  
<221> unsure  
<222> (560)

<220>  
<221> unsure  
<222> (601)..(602)..(603)

<220>  
<221> unsure  
<222> (628)

<400> 1  
gctaaaattg ctaatatattc tccaaaggaa acaagatata taatgtttat cttcagacag 60  
catgaagcaa gataagatat atatatatcg attcttcgac cgcagtcagc atgtttgaca 120  
gatcgcaatg cctcactcac tgaatcactg aatagatcgc tgctgctcga gctatctttc 180





<210> 5  
 <211> 253  
 <212> DNA  
 <213> Zea mays

<220>  
 <221> unsure  
 <222> (150)

<220>  
 <221> unsure  
 <222> (164)

<220>  
 <221> unsure  
 <222> (194)

<220>  
 <221> unsure  
 <222> (229)

<220>  
 <221> unsure  
 <222> (237)

<220>  
 <221> unsure  
 <222> (240)

<400> 5  
 gccccacccc actcatcaca ctctcccacc gcacctcgcc gccgcggggc accgcgccat 60  
 aaagtgcgtt cccggcctgc acggacgtcg aggagcagct cgcaagtgtt tcttggtgcg 120  
 tcgatcggca agatgatcac cggcacggan cttctaccac gtcntgacgg ccatgggtgcc 180  
 gttgtacgtt gcctgatcc tggcgtacgg atccgtcagg tgggtggcna tcttcangcn 240  
 gggaccagtg ctc 253

<210> 6  
 <211> 31  
 <212> PRT  
 <213> Zea mays

<220>  
 <221> UNSURE  
 <222> (3)

<220>  
 <221> UNSURE  
 <222> (8)

<220>  
 <221> UNSURE  
 <222> (18)

<400> 6  
 Ala Arg Xaa Phe Tyr His Val Xaa Thr Ala Met Val Pro Leu Tyr Val  
 1 5 10 15  
 Ala Xaa Ile Leu Ala Tyr Gly Ser Val Arg Trp Trp Arg Ile Phe  
 20 25 30



<210> 7  
<211> 624  
<212> DNA  
<213> Zea mays

<220>  
<221> unsure  
<222> (48)..(49)

<220>  
<221> unsure  
<222> (51)..(52)

<220>  
<221> unsure  
<222> (99)

<220>  
<221> unsure  
<222> (102)..(103)

<220>  
<221> unsure  
<222> (107)..(108)

<220>  
<221> unsure  
<222> (112)

<220>  
<221> unsure  
<222> (114)

<220>  
<221> unsure  
<222> (116)

<220>  
<221> unsure  
<222> (118)

<220>  
<221> unsure  
<222> (129)

<220>  
<221> unsure  
<222> (137)

<220>  
<221> unsure  
<222> (389)

<220>  
<221> unsure  
<222> (444)

<220>  
<221> unsure  
<222> (456)

<220>  
 <221> unsure  
 <222> (490)

<220>  
 <221> unsure  
 <222> (555)

<220>  
 <221> unsure  
 <222> (622)

<400> 7  
 ggatgggtcca aggagagctt ggggctcgct gccacctcgc gcgccagnnc nnaaataaat 60  
 cactcccacg cacacccacc accgcgccga gcacctccnc cnncccnnc tncncncnc 120  
 caccctccnc actagcncta tctagctgag tgaactgaac agcccactgg ctgctcttag 180  
 ctaagctcag ctgtaaagct aaggttcgga gtagctagcg tgggtggccgg agagtgtagc 240  
 gagcggcggtt cagctcaccg ggggctgctg ggtgagttag ggaaccagcg tcgtgagagc 300  
 gctccaagat gattacgggg acggacttct accacgtcat gacggccgtg gtgccgctgt 360  
 acgtggcgat gatcctggcc tacgggtcng tgcggtggtg gcgcattctt tcgccggaac 420  
 aatgctccgg gatcaaccgc ttctntggcg tcttcncggt gccgctgctg tccttccact 480  
 tcatctccan caacaacct acaccatgaa cctgcgcttc atcgccgccg aaacctggca 540  
 aaactcatgg tgctnggcag gctcaccgcg tgggaaccact caacgccggg ggaacctgga 600  
 aattgaacat caagctcttc tnct 624

<210> 8  
 <211> 78  
 <212> PRT  
 <213> Zea mays

<220>  
 <221> UNSURE  
 <222> (46)

<220>  
 <221> UNSURE  
 <222> (50)

<220>  
 <221> UNSURE  
 <222> (61)

<400> 8  
 Met Ile Thr Gly Thr Asp Phe Tyr His Val Met Thr Ala Val Val Pro  
 1 5 10 15  
 Leu Tyr Val Ala Met Ile Leu Ala Tyr Gly Ser Val Arg Trp Trp Arg  
 20 25 30  
 Ile Phe Ser Pro Glu Gln Cys Ser Gly Ile Asn Arg Phe Xaa Ala Leu  
 35 40 45  
 Phe Xaa Val Pro Leu Leu Ser Phe His Phe Ile Ser Xaa Gln Gln Pro  
 50 55 60  
 Tyr Thr Met Asn Leu Arg Phe Ile Ala Ala Glu Thr Trp Gln  
 65 70 75

<210> 9  
 <211> 1426  
 <212> DNA  
 <213> Zea mays

<400> 9  
 ccacgcgtcc gggatggtcc aaggagagct tggggctcgc tgccacctcg cgcgccagcg 60  
 cctaaataaa tcaactccac gcacacccac caccgcgcgc agcacctcct ccttcccttc 120  
 cttctctctc ccaccctcct cactagctct atctagctga gtgaactgaa cagcccactg 180  
 gctcgtctta gctaagctca gctgtaaagc taagggttcgg agtagctagc gtgggtggccg 240  
 gagagtgtag cgagcggcgt tcagctcacc gggggctgct ggggtgagtga gggaaccagc 300  
 gtcgtgagag cgctccaaga tgattacggg gacggacttc taccacgtca tgacggccgt 360  
 ggtgccgctg tacgtggcga tgatcctggc ctacgggtcg gtgcggtggt ggcgcattct 420  
 ctgcgcggac cagtgtccg ggatcaaccg cttcgtggcg ctcttcgcgg tgccgctgct 480  
 gtccttccac ttcatctcca ccaacaaccc ctacaccatg aacctgcgct tcatcgccgc 540  
 cgacacgctg cagaagctca tgggtgctggc catgctcacc gcgtggagcc acctcagccg 600  
 ccggggcagc ctggagtga ccatcacgct cttctccctc tccacgctgc ccaacacgct 660  
 cgtcatgggc atccccctgc tcaagggcat gtacggcgac ttctccggca gcctcatggt 720  
 gcagatcgct gtgctccagt gcatcatctg gtacacgctc atgctcttca tttctgagta 780  
 ccggcggcgc cggatgctca tcaccgagca gttcccgac aacgcggggg ccatcgctc 840  
 categtcgtc gacccggacg tgggtctcct cgacggccgc agggacgcca tcgagacgga 900  
 ggccgaggtc aaggaggacg gcaggataca cgtcaccgtg cgccgctcca acgcctcgcg 960  
 ctccgacatc tactcgcgcc gctccatggg cttctccagc accacgccgc gccccagcaa 1020  
 cctgaccaac gccgagatct actcgctgca gtcgtcgcgc aaccggaccc cgcggggctc 1080  
 cagcttcaac cacaacgaat tctactccat ggtcggccgc agctccaact tcggcgcgcg 1140  
 cgacgcgttc ggcacccgca ccggcgccac gccgcgccg tccaactacg aggacgacgc 1200  
 gtccaagccc aagtaccctc tcccgtggt gaatgcgacg tccggggcgg gggcggtc 1260  
 ctaccccgcg ccgaacccgg ccgtggccgc ggcgcccaag ggccgagga aggcggcgac 1320  
 gaacgggcag gccaaaggcg aggacctcca catgttcgtc tggagctcca gcgcgtcgcc 1380  
 cgtgtcggac gtcttcggcg gtggcgcccc ggactacaac gaggcc 1426

<210> 10  
 <211> 369  
 <212> PRT  
 <213> Zea mays

<400> 10  
 Met Ile Thr Gly Thr Asp Phe Tyr His Val Met Thr Ala Val Val Pro  
 1 5 10 15  
 Leu Tyr Val Ala Met Ile Leu Ala Tyr Gly Ser Val Arg Trp Trp Arg  
 20 25 30  
 Ile Phe Ser Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Leu  
 35 40 45  
 Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Thr Asn Asn Pro  
 50 55 60  
 Tyr Thr Met Asn Leu Arg Phe Ile Ala Ala Asp Thr Leu Gln Lys Leu  
 65 70 75 80  
 Met Val Leu Ala Met Leu Thr Ala Trp Ser His Leu Ser Arg Arg Gly  
 85 90 95  
 Ser Leu Glu Trp Thr Ile Thr Leu Phe Ser Leu Ser Thr Leu Pro Asn  
 100 105 110  
 Thr Leu Val Met Gly Ile Pro Leu Lys Gly Met Tyr Gly Asp Phe  
 115 120 125

Ser Gly Ser Leu Met Val Gln Ile Val Val Leu Gln Cys Ile Ile Trp  
 130 135 140  
 Tyr Thr Leu Met Leu Phe Met Phe Glu Tyr Arg Gly Ala Arg Met Leu  
 145 150 155 160  
 Ile Thr Glu Gln Phe Pro Asp Asn Ala Gly Ala Ile Ala Ser Ile Val  
 165 170 175  
 Val Asp Pro Asp Val Val Ser Leu Asp Gly Arg Arg Asp Ala Ile Glu  
 180 185 190  
 Thr Glu Ala Glu Val Lys Glu Asp Gly Arg Ile His Val Thr Val Arg  
 195 200 205  
 Arg Ser Asn Ala Ser Arg Ser Asp Ile Tyr Ser Arg Arg Ser Met Gly  
 210 215 220  
 Phe Ser Ser Thr Thr Pro Arg Pro Ser Asn Leu Thr Asn Ala Glu Ile  
 225 230 235 240  
 Tyr Ser Leu Gln Ser Ser Arg Asn Pro Thr Pro Arg Gly Ser Ser Phe  
 245 250 255  
 Asn His Asn Asp Phe Tyr Ser Met Val Gly Arg Ser Ser Asn Phe Gly  
 260 265 270  
 Ala Ala Asp Ala Phe Gly Ile Arg Thr Gly Ala Thr Pro Arg Pro Ser  
 275 280 285  
 Asn Tyr Glu Asp Asp Ala Ser Lys Pro Lys Tyr Pro Leu Pro Val Val  
 290 295 300  
 Asn Ala Thr Ser Gly Ala Gly Ala Ala His Tyr Pro Ala Pro Asn Pro  
 305 310 315 320  
 Ala Val Ala Ala Ala Pro Lys Gly Ala Arg Lys Ala Ala Thr Asn Gly  
 325 330 335  
 Gln Ala Lys Gly Glu Asp Leu His Met Phe Val Trp Ser Ser Ser Ala  
 340 345 350  
 Ser Pro Val Ser Asp Val Phe Gly Gly Gly Ala Pro Asp Tyr Asn Glu  
 355 360 365

Ala

<210> 11  
 <211> 504  
 <212> DNA  
 <213> Zea mays

<220>  
 <221> unsure  
 <222> (126)

<220>  
<221> unsure  
<222> (192)

<220>  
<221> unsure  
<222> (205)

<220>  
<221> unsure  
<222> (237)

<220>  
<221> unsure  
<222> (242)

<220>  
<221> unsure  
<222> (244)

<220>  
<221> unsure  
<222> (255)

<220>  
<221> unsure  
<222> (258)

<220>  
<221> unsure  
<222> (263)

<220>  
<221> unsure  
<222> (265)

<220>  
<221> unsure  
<222> (287)

<220>  
<221> unsure  
<222> (430)

<220>  
<221> unsure  
<222> (449)

<220>  
<221> unsure  
<222> (455)

<220>  
<221> unsure  
<222> (488)

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (490)

&lt;400&gt; 11

```

tttttttgagc cctacaacca ctctcttttt cattgctcca cactaccatc tcattctctcc 60
gccatttttac accactccct tctcgtttga acccaacaaa ttggcactgc tcgtcgccga 120
cccctnctcc ctccccgcgt cccccgacaa gccatccgcg gccatgatca ccgcgctgga 180
cctctaccac gngctgacgg ctggnggtgc cgctgtacgt ggccatgacg ctggcgcnacg 240
gntnctgccc ctggnggngc atntncaacg cggaaccagt ctccggnatc aaccgcttcg 300
tggcgctctt cgcggtgccg ctctctctct tccacttcat ctccaccaac gacccttcg 360
ccatgaacct gcgcttcttg gccgtcgaca cgctgcagaa ggtggccgct ctgcgctgc 420
tggcgctggn ctcccgcggc ctctctctcnc cgagngcgct cagggctcga ctggagcatc 480
aagctctnnc cctctctcac gctc                                     504

```

&lt;210&gt; 12

&lt;211&gt; 114

&lt;212&gt; PRT

&lt;213&gt; Zea mays

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (10)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (14)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (25)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (27)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (31)..(32)..(33)..(34)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (89)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (91)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (96)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (98)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (109)..(110)

&lt;400&gt; 12

Met Ile Thr Ala Leu Asp Leu Tyr His Xaa Leu Thr Ala Xaa Val Pro  
 1 5 10 15

Leu Tyr Val Ala Met Thr Leu Ala Xaa Gly Xaa Val Arg Trp Xaa Xaa  
 20 25 30

Xaa Xaa Thr Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Leu  
 35 40 45

Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Thr Asn Asp Pro  
 50 55 60

Phe Ala Met Asn Leu Arg Phe Leu Ala Val Asp Thr Leu Gln Lys Val  
 65 70 75 80

Ala Val Leu Ala Leu Leu Ala Leu Xaa Ser Xaa Ala Ala Ser Ser Xaa  
 85 90 95

Arg Xaa Arg Ser Gly Leu Asp Trp Ser Ile Lys Leu Xaa Xaa Leu Ser  
 100 105 110

Thr Leu

&lt;210&gt; 13

&lt;211&gt; 2769

&lt;212&gt; DNA

&lt;213&gt; Zea mays

&lt;400&gt; 13

ccacgcgtcc gctgagccct acaaccactc tcttcttcat tgctccacac taccatctca 60  
 tctctccgcc attttacacc actcccttct cgttgcaacc caacaaattg gcactgctcg 120  
 tcgcgcgacc ctctccctc ccgcggtccc ccgacaagcc atccgcggcc atgatcaccg 180  
 cgctggacct ctaccacgtg ctgacggcgg tgggtccgct gtacgtggcc atgacgctgg 240  
 cgtacggctc cgtccgctgg tggcgcatct tcacgcggga ccagtgtcc gggatcaacc 300  
 gcttcgtggc gctcttgcgc gtgccgtccc tctcttcca cttcatctcc accaacgacc 360  
 ccttcgccat gaacctgcgc ttcttgccgc ccgacacgct gcagaagggtg gccgtcctcg 420  
 cgctgctggc gctggcctcc cgcggcctct cctccccgcg cgcgctcggg ctcgactgga 480  
 gcatcaecgt cttctccctc tccacgctcc ccaacacgct cgtcatgggc atcccgctgc 540  
 tgcgaggcat gtacggcgcg tgcgcggcgg gcacgctcat ggtccaggtc gtcgtcctcc 600  
 agtgcacat ctggtacacg ctcatgctct tctcttccga gtaccgcgcc gcgcgcgcgc 660  
 tcgtcctcga ccagttcccc gacggcgccg ccgcgtccat cgtctccttc cgcgtcgact 720  
 ccgacgtcgt ctgcgtcgcc aggggggacg tcgagctcga ggccgagccc gacggcgctcg 780  
 ccggcgccgg cgcggtctcc tcccgcggcg gggacgcggg gcgggtgcgc gtcaccgtgc 840  
 gcaagtccac cagctcgcgc tccgaggcgg cgtgctcgca ctgcgactcc cagaccatgc 900  
 agccccgtgt gtccaacctc tccggcgtgg agatctactc gctgcagtcg tcgcgcgaacc 960  
 ccaccccgcg cgggtccagc ttcaaccacg ccgacttctt caacatcgtc ggcgcgcgccg 1020  
 ccaaggggagg cggaggagcg gcgggggacg aggagaaggg cgcattgcgc ggcggcgccg 1080  
 gaggacactc gccgcagcgg caggccgtcg ccgtgccggc caagagggaag gacctgcaca 1140  
 tgctcgtctg gagctccagc gcctcgcggg tgtccgagcg cgcgcgcgtg cactcttcg 1200  
 gcgcggcgcg cgtgacctat gccgacgtcc tcgccaaagg agcccaggcc tacgacgagt 1260  
 acggggcgga cgactacagc agcaggacga agaacgggag cggcggcgcg gacaagggcg 1320  
 ggccgacgct gtcgaagctg ggtccaactc cgacggcgga gctgtacccc aaggacgacg 1380

WO 00/68389

PCT/US00/12061

```

gcgaggggag ggccggcgcg gtggcgatgc cgcggcgag cgtgatgacg cggctcatcc 1440
tcatcatggt gtggaggaaag ctgatccgga accccaacac ctactccagc ctcacggcg 1500
tcgtctgggc cctggctctcc tacaggtggg gcatcgagat gccagcgatc atcgcccggt 1560
cgatttcgat cctgtcggac gcggtctcgc ggatggccat gttcagccta ggcctgttca 1620
tggcgctgca gccgaggatc atcgcgatgc ggaacaagct ggcggccatc gcgatggcg 1680
tccggttcgt cgcaggcccc gcggtcatgg ccgcccctc catcgccgtc ggtctgcgcg 1740
gcgtcctcct ccacatcgcc atcgccagg ctgctctgcc tcaggggatc gtgccgttcg 1800
tgttcgccaa ggagtacggc gttcatcccg acatcctgag cacagcgtat ggtccaataa 1860
catcgcatgg ttcatcact tgccatagtt aacgggaaaa aaaagcagaa gcaatcgatg 1920
acgacgcact gaattcacta tgattcatta ctaatgatgg tgtgttcag cagtgcagtc 1980
aaagaaccac taataagcac tgatctagga cagcatcagc atgattgatt gcttgttttc 2040
tcctgacaat ctgcatttct tactacacag tgtgccttca ctcacccatc cagatgatca 2100
tacaacacta ctgatgcac tttttttttg attctgctgc agcgtgatct tcgggatgct 2160
catcgctctg cccatcaccc tggcttacta catcttgctg gggctgtgag cctctctcgc 2220
tcgcttcttc agcgtgcgga aggcgccatg ctgtggtgta tcggccccac atgaaatttc 2280
tgatgagcat tagcgattac tattagctta gcgaagaatg atgagatggg tcggccctgt 2340
cgggactggg ggagtcagac cagaccccc tcgaacaaaa gtttcttttg gcttctgtcc 2400
gtcagaaaca aaagtgttg cttttggcat gcgcactcga agcacagcag cagcagcagc 2460
atcatccatg agatgatact cctctcgaat cctagagcta gcgaaggcaa taataagata 2520
ccacaaggca atggaatcaa caaaagcttc atgcgacgcg ctatcatatc aaggaaacaa 2580
tgcagaatac aacggagtct agtgcgcaat ggcttcttct cttttttttt cttgcgaaaa 2640
gggtttctag actgattaaa ggattccaaa tagcatctct ggattcgatt tctttcgcag 2700
acaaattttc tggctttttt agaaaaatcc tctcgttgaa aaaaaaaaaa aaaaaaaaaa 2760
aaaaaaaaag

```

<210> 14  
 <211> 573  
 <212> PRT  
 <213> Zea mays

<400> 14  
 Met Ile Thr Ala Leu Asp Leu Tyr His Val Leu Thr Ala Val Val Pro  
 1 5 10 15  
 Leu Tyr Val Ala Met Thr Leu Ala Tyr Gly Ser Val Arg Trp Trp Arg  
 20 25 30  
 Ile Phe Thr Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Leu  
 35 40 45  
 Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Thr Asn Asp Pro  
 50 55 60  
 Phe Ala Met Asn Leu Arg Phe Leu Ala Ala Asp Thr Leu Gln Lys Val  
 65 70 75 80  
 Ala Val Leu Ala Leu Leu Ala Leu Ala Ser Arg Gly Leu Ser Ser Pro  
 85 90 95  
 Arg Ala Leu Gly Leu Asp Trp Ser Ile Thr Leu Phe Ser Leu Ser Thr  
 100 105 110  
 Leu Pro Asn Thr Leu Val Met Gly Ile Pro Leu Leu Arg Gly Met Tyr  
 115 120 125  
 Gly Ala Ser Ser Ala Gly Thr Leu Met Val Gln Val Val Val Leu Gln  
 130 135 140  
 Cys Ile Ile Trp Tyr Thr Leu Met Leu Phe Leu Phe Glu Tyr Arg Ala  
 145 150 155 160



WO 00/68389

PCT/US00/12061

Ala	Arg	Ala	Leu	Val	Leu	Asp	Gln	Phe	Pro	Asp	Gly	Ala	Ala	Ala	Ser	165	170	175
Ile	Val	Ser	Phe	Arg	Val	Asp	Ser	Asp	Val	Val	Ser	Leu	Ala	Arg	Gly	180	185	190
Asp	Val	Glu	Leu	Glu	Ala	Glu	Pro	Asp	Gly	Val	Ala	Gly	Ala	Gly	Ala	195	200	205
Val	Ser	Ser	Arg	Gly	Gly	Asp	Ala	Gly	Arg	Val	Arg	Val	Thr	Val	Arg	210	215	220
Lys	Ser	Thr	Ser	Ser	Arg	Ser	Glu	Ala	Ala	Cys	Ser	His	Ser	His	Ser	225	230	235
Gln	Thr	Met	Gln	Pro	Arg	Val	Ser	Asn	Leu	Ser	Gly	Val	Glu	Ile	Tyr	245	250	255
Ser	Leu	Gln	Ser	Ser	Arg	Asn	Pro	Thr	Pro	Arg	Gly	Ser	Ser	Phe	Asn	260	265	270
His	Ala	Asp	Phe	Phe	Asn	Ile	Val	Gly	Ala	Ala	Ala	Lys	Gly	Gly	Gly	275	280	285
Gly	Ala	Ala	Gly	Asp	Glu	Glu	Lys	Gly	Ala	Cys	Gly	Gly	Gly	Gly	Gly	290	295	300
Gly	His	Ser	Pro	Gln	Pro	Gln	Ala	Val	Ala	Val	Pro	Ala	Lys	Arg	Lys	305	310	315
Asp	Leu	His	Met	Leu	Val	Trp	Ser	Ser	Ser	Ala	Ser	Pro	Val	Ser	Glu	325	330	335
Arg	Ala	Ala	Val	His	Val	Phe	Gly	Ala	Gly	Gly	Ala	Asp	His	Ala	Asp	340	345	350
Val	Leu	Ala	Lys	Gly	Ala	Gln	Ala	Tyr	Asp	Glu	Tyr	Gly	Arg	Asp	Asp	355	360	365
Tyr	Ser	Ser	Arg	Thr	Lys	Asn	Gly	Ser	Gly	Gly	Ala	Asp	Lys	Gly	Gly	370	375	380
Pro	Thr	Leu	Ser	Lys	Leu	Gly	Ser	Asn	Ser	Thr	Ala	Gln	Leu	Tyr	Pro	385	390	395
Lys	Asp	Asp	Gly	Glu	Gly	Arg	Ala	Ala	Ala	Val	Ala	Met	Pro	Pro	Ala	405	410	415
Ser	Val	Met	Thr	Arg	Leu	Ile	Leu	Ile	Met	Val	Trp	Arg	Lys	Leu	Ile	420	425	430
Arg	Asn	Pro	Asn	Thr	Tyr	Ser	Ser	Leu	Ile	Gly	Val	Val	Trp	Ser	Leu	435	440	445
Val	Ser	Tyr	Arg	Trp	Gly	Ile	Glu	Met	Pro	Ala	Ile	Ile	Ala	Arg	Ser	450	455	460
Ile	Ser	Ile	Leu	Ser	Asp	Ala	Gly	Leu	Gly	Met	Ala	Met	Phe	Ser	Leu	465	470	475

```
<220>
<221>   unsure
<222>   (482)
```

WO 00/68389

PCT/US00/12061

<220>  
<221> unsure  
<222> (511)

<220>  
<221> unsure  
<222> (514)

<220>  
<221> unsure  
<222> (519)

<220>  
<221> unsure  
<222> (521)

<220>  
<221> unsure  
<222> (530)

<220>  
<221> unsure  
<222> (535)

<220>  
<221> unsure  
<222> (543)

<400> 15  
gagcgacgtc gagatgaacg ggcgcgtcgt cgcggcgccg gngcggcggc ggcggcggtcc 60  
ggctaccgtt ctgggcgacg gcgaggacgg tggggctgaa gctggcgagg aacccgaacg 120  
tgtacgccag cgttctcggc gtcgtgtggg cgtgcatcgc gtacaggtgg cacctgagct 180  
tgccgggggat cgtgacgggg tcgctgcagg tgatgtccag gactggcacg gggatgtcca 240  
tgttcagcat ggggttggtc atggggcagc aggagagggg gatagcgtgc ggggcggggc 300  
tgacggcgct ggggatggcg ctgcgggttc tcgccgggtc gctcgccacg ctgctcggcg 360  
ccgcgcgcct cggnctccgc ggcgacgtcc tgcacctcgc catcatacag gncgnactgc 420  
tcaatcgatt nttcttcgtt ttncaaagga gtatggctta ttncgatgac tcagnacggc 480  
gntatattcg gacattatcc tgtgcgatct ntnaatang nggtttgggn ttgtnaaatc 540  
atn 543

<210> 16  
<211> 110  
<212> PRT  
<213> Oryza sativa

<220>  
<221> UNSURE  
<222> (108)..(109)

<400> 16  
Val Gly Leu Lys Leu Ala Arg Asn Pro Asn Val Tyr Ala Ser Val Leu  
1 5 10 15  
Gly Val Val Trp Ala Cys Ile Ala Tyr Arg Trp His Leu Ser Leu Pro  
20 25 30  
Gly Ile Val Thr Gly Ser Leu Gln Val Met Ser Arg Thr Gly Thr Gly  
35 40 45

WO 00/68389

PCT/US00/12061

Met Ser Met Phe Ser Met Gly Leu Phe Met Gly Gln Gln Glu Arg Val  
 50 55 60  
 Ile Ala Cys Gly Ala Gly Leu Thr Ala Leu Gly Met Ala Leu Arg Phe  
 65 70 75 80  
 Val Ala Gly Pro Leu Ala Thr Leu Val Gly Ala Ala Ala Leu Gly Leu  
 85 90 95  
 Arg Gly Asp Val Leu His Leu Ala Ile Ile Gln Xaa Xaa Leu  
 100 105 110

<210> 17  
 <211> 330  
 <212> DNA  
 <213> Oryza sativa

<400> 17  
 ctccactcgg ccgctcctgc atgtataact agctagttct agctcgctca ggcaactcgat 60  
 ccaccgccgg gcgcgttgga ttgagatagg ctgaggagat gatatccggg cactgacttct 120  
 acacggtgat ggcgccggtg gtgccgctgt acgtggcgat gttcctggcg tacgggtcgg 180  
 tgcggtggtg ggcatcttc acgccggacc agtgcctcgg catcaaccgc ttcgtcgcca 240  
 tcttcgccgt gccgctcctg tccttccact tcatctccac caacgaccgc tacgccatga 300  
 acctccgctt cctggcggcg ggacacgctg 330

<210> 18  
 <211> 74  
 <212> PRT  
 <213> Oryza sativa

<400> 18  
 Met Ile Ser Gly His Asp Phe Tyr Thr Val Met Ala Ala Val Val Pro  
 1 5 10 15  
 Leu Tyr Val Ala Met Phe Leu Ala Tyr Gly Ser Val Arg Trp Trp Gly  
 20 25 30  
 Ile Phe Thr Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Ile  
 35 40 45  
 Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Thr Asn Asp Pro  
 50 55 60  
 Tyr Ala Met Asn Leu Arg Phe Leu Ala Ala  
 65 70

<210> 19  
 <211> 2162  
 <212> DNA  
 <213> Oryza sativa

<400> 19  
 ctccactcgg ccgctcctgc atgtataact agctagttct agctcgctca ggcaactcgat 60  
 ccaccgccgg gcgcgttgga ttgagatagg ctgaggagat gatatccggg cactgacttct 120  
 acacggtgat ggcgccggtg gtgccgctgt acgtggcgat gttcctggcg tacgggtcgg 180  
 tgcggtggtg ggcatcttc acgccggacc agtgcctcgg catcaaccgc ttcgtcgcca 240  
 tcttcgccgt gccgctcctg tccttccact tcatctccac caacgaccgc tacgccatga 300  
 acctccgctt cctggcggcg gacacgctgc agaagctgct cgctcctggcg gggctcgccg 360  
 cgtggtcggc cctcccctcg cggaccggcg cgccgcggtt ggactggtcc atcacgctct 420  
 tctccctctc cactgctgcc aacacgctcg tcatggggat cccgctgctg atcgccatgt 480

```

acggggccata ctccggctcg ctcatgggtcc agatcgctcgt gctccagtgc atcatctggt 540
acacgctgat gctcttcttc ttcgagttcc gcgcccgcgcg gatgctgatc gccgaccagt 600
tcccggacac ggccggcgtcc atcgtgtccc tgcacgtcga cccggacgtg gtgtcgctgg 660
agggcgggcca cgcggagacg gaggccgagg tggcggcggga cgggcggctg cacgtcaccg 720
tgcgccggtc ctccggtgtcg cggcgggtcgc tgcgtgtcac gccgcggccg tcgaacctga 780
cgggagcggga gatctactcg cttagctcgt cgcggaaccc aaccccgcgg ggctccaact 840
tcaaccacgc cgacttcttc gccatgggtcg gcggcggggc accgcccccg acgcccgtg 900
cggtgccgcgg ctccgagcttc ggccgctccg agctttactc gctgcaatcg tcggggggcc 960
caaccccgag gcagtccaac ttcgacgagc actcggcacg gccgccgaaa ccaccggcaa 1020
cgaccacggg ggcactcaac cacgatgcca aggagctcca catgttcgtg tggagctcga 1080
gcgcgtctcc cgtctcagaa gtcagcggcc tgcctgtgtt cagtggcggc ggccggcggc 1140
gcgctctcga cgtccggcgc aaggaaatcc acatgggtcat ccccgccgac ctgccgcaga 1200
acaacggctc agggcaaagag cacgaggagt acggcgcagt ggcatgggt ggccggcggc 1260
gcggagagaa cttcagcttc ggaggcggca agacggtgga cggcggcggg gcagtagacg 1320
aggtagcggc cttgcctgac gggctgacga agatgggtc gagctcgacg gcggagctgc 1380
acccgaaggt cgtccgacgtc gacggaccga acgcccggcg cggcggcggc ggccgggggc 1440
agtaccaaat gccgcggcg agcgtgatga cacgcctcat cctcataatg gtgtggcgca 1500
agctcatccg caacccccaa acttactcca gcctcctcgg cctcgccctg tccctcgctg 1560
ccttcgggat tgttcatggc gctgcagccc agcatcatcg cgtgtggcaa atcagccgcc 1620
gtcgtctcca tggccgtccg ctctctcgcg ggccctgcgg tcatggccgc cgcgtcaate 1680
gccatcgga cccgcgggac gctcctgacg gtcgccattg ttcaggcggc ttaccacaa 1740
gggattgtgc cttttgtttt tgcaaaagaa tacaatgtcc acccgcccat cctgacaca 1800
gcggtaattt ttggcatgct aatagctctt ccaatcacat tgctgtacta catccttctt 1860
ggactatgat caagaaagct tatggacgct ctcacataaa acggaagaaa tgggggcaaa 1920
gagagagaaa aaaaagcgat cctgtccatc tcaaacagcg tatgcttata tgtatagcct 1980
gttgctcgac attgcccatg atgacaagac aacgaagttg ttacagagct atatatctct 2040
gcgacatttg tacaagagat aacgacagaa tgtactcaaa tataaccgat attagatatg 2100
tgttctgtta aagatctcaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2160
aa

```

<210> 20  
 <211> 589  
 <212> PRT  
 <213> Oryza sativa

<400> 20  
 Met Ile Ser Gly His Asp Phe Tyr Thr Val Met Ala Ala Val Val Pro  
 1 5 10 15  
 Leu Tyr Val Ala Met Phe Leu Ala Tyr Gly Ser Val Arg Trp Trp Gly  
 20 25 30  
 Ile Phe Thr Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Ile  
 35 40 45  
 Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Thr Asn Asp Pro  
 50 55 60  
 Tyr Ala Met Asn Leu Arg Phe Leu Ala Ala Asp Thr Leu Gln Lys Leu  
 65 70 75 80  
 Leu Val Leu Ala Gly Leu Ala Ala Trp Ser Arg Leu Pro Ser Arg Thr  
 85 90 95  
 Gly Ala Pro Arg Leu Asp Trp Ser Ile Thr Leu Phe Ser Leu Ser Thr  
 100 105 110  
 Leu Pro Asn Thr Leu Val Met Gly Ile Pro Leu Leu Ile Ala Met Tyr  
 115 120 125

Gly Pro Tyr Ser Gly Ser Leu Met Val Gln Ile Val Val Leu Gln Cys  
 130 135 140  
 Ile Ile Trp Tyr Thr Leu Met Leu Phe Leu Phe Glu Phe Arg Ala Ala  
 145 150 155 160  
 Arg Met Leu Ile Ala Asp Gln Phe Pro Asp Thr Ala Ala Ser Ile Val  
 165 170 175  
 Ser Leu His Val Asp Pro Asp Val Val Ser Leu Glu Gly Gly His Ala  
 180 185 190  
 Glu Thr Glu Ala Glu Val Ala Ala Asp Gly Arg Leu His Val Thr Val  
 195 200 205  
 Arg Arg Ser Ser Val Ser Arg Arg Ser Leu Leu Val Thr Pro Arg Pro  
 210 215 220  
 Ser Asn Leu Thr Gly Ala Glu Ile Tyr Ser Leu Ser Ser Ser Arg Asn  
 225 230 235 240  
 Pro Thr Pro Arg Gly Ser Asn Phe Asn His Ala Asp Phe Phe Ala Met  
 245 250 255  
 Val Gly Gly Gly Pro Pro Pro Pro Thr Pro Ala Ala Val Arg Gly Ser  
 260 265 270  
 Ser Phe Gly Ala Ser Glu Leu Tyr Ser Leu Gln Ser Ser Arg Gly Pro  
 275 280 285  
 Thr Pro Arg Gln Ser Asn Phe Asp Glu His Ser Ala Arg Pro Pro Lys  
 290 295 300  
 Pro Pro Ala Thr Thr Thr Gly Ala Leu Asn His Asp Ala Lys Glu Leu  
 305 310 315 320  
 His Met Phe Val Trp Ser Ser Ser Ala Ser Pro Val Ser Glu Val Ser  
 325 330 335  
 Gly Leu Pro Val Phe Ser Gly Gly Gly Gly Gly Ala Leu Asp Val  
 340 345 350  
 Gly Ala Lys Glu Ile His Met Val Ile Pro Ala Asp Leu Pro Gln Asn  
 355 360 365  
 Asn Gly Ser Gly Lys Glu His Glu Glu Tyr Gly Ala Val Ala Leu Gly  
 370 375 380  
 Gly Gly Gly Gly Gly Glu Asn Phe Ser Phe Gly Gly Gly Lys Thr Val  
 385 390 395 400  
 Asp Gly Ala Glu Ala Val Asp Glu Glu Ala Ala Leu Pro Asp Gly Leu  
 405 410 415  
 Thr Lys Met Gly Ser Ser Ser Thr Ala Glu Leu His Pro Lys Val Val  
 420 425 430  
 Asp Val Asp Gly Pro Asn Ala Gly Gly Gly Ala Ala Gly Ala Gly Gln  
 435 440 445

Tyr Gln Met Pro Pro Ala Ser Val Met Thr Arg Leu Ile Leu Ile Met  
 450 455 460  
 Val Trp Arg Lys Leu Ile Arg Asn Pro Asn Thr Tyr Ser Ser Leu Leu  
 465 470 475 480  
 Gly Leu Ala Trp Ser Leu Val Ala Phe Arg Leu Phe Met Ala Leu Gln  
 485 490 495  
 Pro Ser Ile Ile Ala Cys Gly Lys Ser Ala Ala Val Val Ser Met Ala  
 500 505 510  
 Val Arg Phe Leu Ala Gly Pro Ala Val Met Ala Ala Ala Ser Ile Ala  
 515 520 525  
 Ile Gly Leu Arg Gly Thr Leu Leu His Val Ala Ile Val Gln Ala Ala  
 530 535 540  
 Leu Pro Gln Gly Ile Val Pro Phe Val Phe Ala Lys Glu Tyr Asn Val  
 545 550 555 560  
 His Pro Ala Ile Leu Ser Thr Ala Val Ile Phe Gly Met Leu Ile Ala  
 565 570 575  
 Leu Pro Ile Thr Leu Leu Tyr Tyr Ile Leu Leu Gly Leu  
 580 585

<210> 21  
 <211> 1618  
 <212> DNA  
 <213> Glycine max

<400> 21  
 gcacgaggat ctctgagcag ttcccagaca ctgccggtac cattgtctcc atccatgtcg 60  
 actctgatgt catgtctctt gacggacgac agcaccctct ggaaaccgat gcccaaatca 120  
 aagaggacgg caagctccac gtcactgtca gaaaatccaa cgcttccaga tccgacatct 180  
 tttctagaag gtcccagggc ttctcttcca ccaccctcg cccttccaat ctcaccaatg 240  
 ctgagattta ctctcttcag tctctctgaa accctactcc acgtggctcc agtttcaacc 300  
 acaccgattt ctactccatg atggtctgtg gtgtaattc taacttttgt gccaacgatg 360  
 tttatggcct ttctgcttcc agaggaccaa ctcccagacc ttccaattac gacgaggatg 420  
 cttctaataa taacaatggg aagccgaggt accactaccc tgctgtctgga acaggaacag 480  
 gaacaggaac aggaacggga acgggaacag ggcactaccc tgctcctaac cctggcatgt 540  
 tctctcccac tgcttctaaa aacgtcgcca agaagccaga cgatccaaat aaggaccttc 600  
 atatgttcgt ttggagtcca agtgcttccc cggtttcgga tgtgttttgt ggtggacatg 660  
 aatatgatca taaagaactc aagttaactg tatctccagg aaaagtggag ggtaatatta 720  
 atagagacac tcaagaggag taccagccag agaaagatga atttagtttt ggaaacagag 780  
 ggattgagga tgagcatgaa ggtgagaaag ttggaaacgg aaatccaaaa acaatgcctc 840  
 cagcaagtgt aatgacgagg cttattttga tcatggtgtg gaggaaactt atcagaaacc 900  
 ccaacaccta ctccagccta atcggcctaa cttgggtcact catttcattc aggtggaacg 960  
 taaaaatgcc agccataatt gccaaagtcta ttctgatatt gtcagatgca gggcttggga 1020  
 tggccatgtt tagtcttggt ctgttcattg ctttgcaacc gaggatcata gcatgtggaa 1080  
 attccacagc agctttttct atggccgtga gattccttac aggtccagct gtcattggcag 1140  
 ctgcttccat tgctgttgga ctcaaaggcg ttctcttgca cgttgctatt gttcaggcag 1200  
 ctcttccctc aggaattgtc ccatttgtct ttgccaaagg atacaatgta catcctgata 1260  
 ttctcagtac ggggtgttatt tttgggatgt tgattgcatt gccattacg ctctgtgtact 1320  
 acatcttgct ggggttatga gtgaatgaga agatggagga tatgaagatt acatgtggca 1380  
 tggcatgcat gcaatctcgt ttgagactcc ttagagcacg acaacaaatg ttcaatgaaa 1440  
 tacaaaagca tcaccataat tgaataggag gaatcgatca acggatgagt tttcattttt 1500  
 cttcttcttt tttttttaat gaattgtcct tgctcagtga aaatgtaaaa tcatgtttgt 1560  
 agctaattta taaaatggct atctcgttaa atttcaaatt aaaaaaaaaa aaaaaaaaaa 1618

WO 00/68389

PCT/US00/12061

<210> 22  
<211> 443  
<212> PRT  
<213> Glycine max

<400> 22  
Ile Ser Glu Gln Phe Pro Asp Thr Ala Gly Thr Ile Val Ser Ile His  
1 5 10 15  
Val Asp Ser Asp Val Met Ser Leu Asp Gly Arg Gln His Pro Leu Glu  
20 25 30  
Thr Asp Ala Gln Ile Lys Glu Asp Gly Lys Leu His Val Thr Val Arg  
35 40 45  
Lys Ser Asn Ala Ser Arg Ser Asp Ile Phe Ser Arg Arg Ser Gln Gly  
50 55 60  
Phe Ser Ser Thr Thr Pro Arg Pro Ser Asn Leu Thr Asn Ala Glu Ile  
65 70 75 80  
Tyr Ser Leu Gln Ser Ser Arg Asn Pro Thr Pro Arg Gly Ser Ser Phe  
85 90 95  
Asn His Thr Asp Phe Tyr Ser Met Met Ala Ala Gly Arg Asn Ser Asn  
100 105 110  
Phe Gly Ala Asn Asp Val Tyr Gly Leu Ser Ala Ser Arg Gly Pro Thr  
115 120 125  
Pro Arg Pro Ser Asn Tyr Asp Glu Asp Ala Ser Asn Asn Asn Asn Gly  
130 135 140  
Lys Pro Arg Tyr His Tyr Pro Ala Ala Gly Thr Gly Thr Gly Thr Gly  
145 150 155 160  
Thr Gly Thr Gly Thr Gly Thr Gly His Tyr Pro Ala Pro Asn Pro Gly  
165 170 175  
Met Phe Ser Pro Thr Ala Ser Lys Asn Val Ala Lys Lys Pro Asp Asp  
180 185 190  
Pro Asn Lys Asp Leu His Met Phe Val Trp Ser Ser Ser Ala Ser Pro  
195 200 205  
Val Ser Asp Val Phe Gly Gly Gly His Glu Tyr Asp His Lys Glu Leu  
210 215 220  
Lys Leu Thr Val Ser Pro Gly Lys Val Glu Gly Asn Ile Asn Arg Asp  
225 230 235 240  
Thr Gln Glu Glu Tyr Gln Pro Glu Lys Asp Glu Phe Ser Phe Gly Asn  
245 250 255  
Arg Gly Ile Glu Asp Glu His Glu Gly Glu Lys Val Gly Asn Gly Asn  
260 265 270  
Pro Lys Thr Met Pro Pro Ala Ser Val Met Thr Arg Leu Ile Leu Ile  
275 280 285



WO 00/68389

PCT/US00/12061

Met Val Trp Arg Lys Leu Ile Arg Asn Pro Asn Thr Tyr Ser Ser Leu  
290 295 300

Ile Gly Leu Thr Trp Ser Leu Ile Ser Phe Arg Trp Asn Val Lys Met  
305 310 315 320

Pro Ala Ile Ile Ala Lys Ser Ile Ser Ile Leu Ser Asp Ala Gly Leu  
325 330 335

Gly Met Ala Met Phe Ser Leu Gly Leu Phe Met Ala Leu Gln Pro Arg  
340 345 350

Ile Ile Ala Cys Gly Asn Ser Thr Ala Ala Phe Ser Met Ala Val Arg  
355 360 365

Phe Leu Thr Gly Pro Ala Val Met Ala Ala Ala Ser Ile Ala Val Gly  
370 375 380

Leu Lys Gly Val Leu Leu His Val Ala Ile Val Gln Ala Ala Leu Pro  
385 390 395 400

Gln Gly Ile Val Pro Phe Val Phe Ala Lys Glu Tyr Asn Val His Pro  
405 410 415

Asp Ile Leu Ser Thr Gly Val Ile Phe Gly Met Leu Ile Ala Leu Pro  
420 425 430

Ile Thr Leu Val Tyr Tyr Ile Leu Leu Gly Leu  
435 440

<210> 23  
<211> 531  
<212> DNA  
<213> Glycine max

<220>  
<221> unsure  
<222> (530)

<400> 23  
tctgacactc cctcacttca tccttctaca cattcacatc ttctctgaaa caattacaaa 60  
gtgagtgaaa gtagtgtect agcactagta gtacagtaca gaaaactaga agagcaacca 120  
aaattttcca attagcacta gtagtacagt acaaaaaact agaagagcaa ccaaaatttt 180  
ccaattgaaa aagaaataac aacgagaaca aaatcttatc gtgagatcga ataactgaaa 240  
aaaaaggaaa gaagaacaaa aaatgataac gtggaaagac ctatacacgg tcctgaccgc 300  
agtggtcctt ctctacgtgg cgatgatcct ggcgtacggc tcgggtccggg ggtggaaaga 360  
tcttctcacc ggaccagtgc tccggcataa accgcttcgt ggcgatcttc gccgtgccgc 420  
tctctctcct ccacttcate tccaccaaca acccctacgc catgaacttc cgcttcatcc 480  
gccgcgggac acctccaaga agatcatcat gctcttcgcc cttgcaaccn g 531

<210> 24  
<211> 90  
<212> PRT  
<213> Glycine max

<220>  
<221> UNSURE  
<222> (33)

WO 00/68389

PCT/US00/12061

<220>  
<221> UNSURE  
<222> (78)

<400> 24  
Met Ile Thr Trp Lys Asp Leu Tyr Thr Val Leu Thr Ala Val Val Pro  
1 5 10 15  
Leu Tyr Val Ala Met Ile Leu Ala Tyr Gly Ser Val Arg Trp Trp Lys  
20 25 30  
Xaa Ile Phe Ser Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala  
35 40 45  
Ile Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Thr Asn Asn  
50 55 60  
Pro Tyr Ala Met Asn Phe Arg Phe Ile Arg Arg Arg Thr Xaa Thr Ser  
65 70 75 80  
Lys Lys Ile Ile Met Leu Phe Ala Leu Ala  
85 90

<210> 25  
<211> 2101  
<212> DNA  
<213> Glycine max

<400> 25  
ctttctctga cactccctca cttcatcctt ctacacattc acatcttctc tgaacaatt 60  
acaaagttag tgaaagttag gtcctagcac tagtagtaca gtacagaaaa ctagaagagc 120  
aaccaaaatt ttccaattag cactagtagt acagtacaaa aaactagaag agcaacccaaa 180  
atthttccaa tgaaaaagaa ataacaacga gaacaaaatc ttatcgtgag atcgaataac 240  
tgaaaaaaaa ggaaagaaga acaaaaaatg ataacgtgga aagacctata cacggtcctg 300  
accgcagtgg tccctctcta cgtggcgatg atcctggcgt acggctcggg ccggtgggtg 360  
aagatcttct caccggacca gtgctccggc ataaaccgct tctggtcgat cttcgccgtg 420  
ccgctcctct ccttccactt catctccacc aacaaccctt acgcatgaa cttccgcttc 480  
atcgccgccc acaccctcca gaagatcatc atgctcttcg cccttgccat ctggaccaac 540  
ctcaccaaaa ccggttccct agagtggatg attaccatct tctccctctc aacccttccc 600  
aataccttag tcatgggaat tccactccta atcgccatgt acggcgacta ctccggctcg 660  
ctcatggttc aggtcgtggt ccttcagtgc atcatatggt acacctgtt gctcttctta 720  
ttcgaatacc ggcgcgcgaa aatcctaate atggaacagt tccctgaaac cgctgcctcc 780  
atcgtgtcgt ttaaagtcga ctccgacgtc gtttcgctcg acgggaggga cttcttggag 840  
accgacgccc aagtcggtga cgatgggaag cttcatgtca ccgttagaaa gtcgaacgcc 900  
tcgcgtaggt cgtttatgat gacgcccagg ccttctaate tcaactgggc ggagatttac 960  
agcctcagct cgtctcgtaa cccaacacca cgtggctcaa actttaacca tgccgatttc 1020  
ttctccatga tggggtacca gcctcgccac tccaatttca cggccaatga tttgttctcc 1080  
tcgcgtggac ccactccgag gccttctaate ttcgaagaac cctcaatgcc tcaggcggtg 1140  
acggtagctt ctctcgggtt cgggttctac ccgtcccaaa ccgtgccagc ttctgacctg 1200  
ccgcccaccc cggatttttc ctccgctact aaaaacttga agaatacaag tcagaatcag 1260  
aatccgaacc agagccagag ccagaattcg caggctccgg cgaagggtgc ccacgatgag 1320  
aaggagctcc acatgtttgt gtggagctcc agtgccctcc cgatgtcgga gaatgccgga 1380  
ctcaacgtct ttagcagcac agacctcgga acctccgaac aacctgacca ggtgtctaaa 1440  
gagattagga tgttggtggc tgataataat gcacacttac gaaatggtga agccaacaac 1500  
aaaggtggtt tggaggcagt acttggtgtg gaagacttca agtttctggt gaatggcgaa 1560  
gaacaagttg gggagaagaaa agaagggtc gtacccggcg aggtctccgc cggaaaacac 1620  
tccacgggtg aggtcccaac aaaagccacc gtacccggcg aggtctccgc cggaaaacac 1680  
atgcctccgg caaatgtcat gactcgtctc atactcatca tgggtgtggag aaagcttacc 1740  
cgcaatccca acacatactc tagcctaatt ggtgtagtat ggtccctcgt tgcattcaag 1800  
tggcacgtgc atatgcccac aataatagag aatatcaatt ccatactgct tgatgccggt 1860

cttggaaatg	ctatgttcag	cttaggtgac	tggtcgcaaa	tccattctcc	aaattcatac	1920
tctcgcgaaa	taatttcatt	cttttatcca	aaaacaattt	cgcttccttc	tttcccatag	1980
atcattattt	tattggctcc	aattgttagt	gtaaatgtgg	atttccttat	actaagaaaa	2040
taaaatgcat	gtgtttaatt	atctatttat	ttatttctga	ccccaaaaaa	aaaaaaaaaa	2100
a						2101

```
<210> 26
<211> 540
<212> PRT
<213> Glycine max
```

<400> 26  
Met Ile Thr Trp Lys Asp Leu Tyr Thr Val Leu Thr Ala Val Val Pro  
1 5 10 15

Leu Tyr Val Ala Met Ile Leu Ala Tyr Gly Ser Val Arg Trp Trp Lys  
20 25 30

Ile Phe Ser Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Ile  
35 40 45

Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Thr Asn Asn Pro  
50 55 60

Tyr Ala Met Asn Phe Arg Phe Ile Ala Ala Asp Thr Leu Gln Lys Ile  
65 70 75 80

Ile Met Leu Phe Ala Leu Ala Ile Trp Thr Asn Leu Thr Lys Thr Gly  
85 90 95

Ser Leu Glu Trp Met Ile Thr Ile Phe Ser Leu Ser Thr Leu Pro Asn  
100 105 110

Thr Leu Val Met Gly Ile Pro Leu Leu Ile Ala Met Tyr Gly Asp Tyr  
115 120 125

Ser Gly Ser Leu Met Val Gln Val Val Val Leu Gln Cys Ile Ile Trp  
130 135 140

Tyr Thr Leu Leu Leu Phe Leu Phe Glu Tyr Arg Ala Ala Lys Ile Leu  
145 150 155 160

Ile Met Glu Gln Phe Pro Glu Thr Ala Ala Ser Ile Val Ser Phe Lys  
165 170 175

Val Asp Ser Asp Val Val Ser Leu Asp Gly Arg Asp Phe Leu Glu Thr  
180 185 190

Asp Ala Glu Val Gly Asp Asp Gly Lys Leu His Val Thr Val Arg Lys  
195 200 205

Ser Asn Ala Ser Arg Arg Ser Phe Met Met Thr Pro Arg Pro Ser Asn  
210 215 220

Leu Thr Gly Ala Glu Ile Tyr Ser Leu Ser Ser Ser Arg Asn Pro Thr  
225 230 235 240

Pro	Arg	Gly	Ser	Asn	Phe	Asn	His	Ala	Asp	Phe	Phe	Ser	Met	Met	Gly
				245					250					255	

WO 00/68389

PCT/US00/12061

Tyr Gln Pro Arg His Ser Asn Phe Thr Ala Asn Asp Leu Phe Ser Ser  
260 265 270

Arg Gly Pro Thr Pro Arg Pro Ser Asn Phe Glu Glu Pro Ser Met Pro  
275 280 285

Gln Ala Val Thr Val Ala Ser Pro Arg Phe Gly Phe Tyr Pro Ser Gln  
290 295 300

Thr Val Pro Ala Ser Tyr Pro Pro Pro Asn Pro Asp Phe Ser Ser Ala  
305 310 315 320

Thr Lys Asn Leu Lys Asn Gln Ser Gln Asn Gln Asn Pro Asn Gln Ser  
325 330 335

Gln Ser Gln Asn Ser Gln Ala Pro Ala Lys Gly Ala His Asp Ala Lys  
340 345 350

Glu Leu His Met Phe Val Trp Ser Ser Ser Ala Ser Pro Met Ser Glu  
355 360 365

Asn Ala Gly Leu Asn Val Phe Ser Ser Thr Asp Leu Gly Thr Ser Glu  
370 375 380

Gln Pro Asp Gln Gly Ala Lys Glu Ile Arg Met Leu Val Ala Asp Asn  
385 390 395 400

Asn Ala His Leu Arg Asn Gly Glu Ala Asn Asn Lys Gly Gly Leu Glu  
405 410 415

Ala Val Leu Gly Val Glu Asp Phe Lys Phe Leu Val Asn Gly Glu Glu  
420 425 430

Gln Val Gly Glu Glu Lys Glu Gly Leu Asn Asn Gly Leu Asn Lys Leu  
435 440 445

Gly Ser Ser Ser Thr Val Glu Leu Gln Pro Lys Ala Thr Val Ala Gly  
450 455 460

Glu Ala Ser Ala Gly Lys His Met Pro Pro Ala Asn Val Met Thr Arg  
465 470 475 480

Leu Ile Leu Ile Met Val Trp Arg Lys Leu Ile Arg Asn Pro Asn Thr  
485 490 495

Tyr Ser Ser Leu Ile Gly Val Val Trp Ser Leu Val Ala Phe Arg Trp  
500 505 510

His Val His Met Pro Lys Ile Ile Glu Lys Ser Ile Ser Ile Leu Ser  
515 520 525

Asp Ala Gly Leu Gly Met Ala Met Phe Ser Leu Gly  
530 535 540

<210> 27  
<211> 525  
<212> DNA  
<213> Glycine max

WO 00/68389

PCT/US00/12061

<400> 27  
 cccactctg ccttgtgctt tggagactgc aagtgcaacc ttgcttgag ctctcaaagc 60  
 tgaaaaaata tttgctgtat tctctgctgc acattagcac cattcactca ctactgccc 120  
 caaaaccaca tgctcttcca catccctata taaaatcttt tcaatcttca taatcatcat 180  
 catcaccacc aactccaact caaactctcc aaaacctgcc acttcaacct tcctatatat 240  
 tccttccctc actctcttct gcttctatca tctttctgag aggcttggtg acacacaaaa 300  
 aatgatcacc ttaacagact tctaccatgt gatgactgca atgggtgccac tctatgtggc 360  
 catgatacta gcctatggct cagtgaagtg gtggaagatt ttctccctg ataatgctct 420  
 ggcatacaacc gttttgtggc actctttgca gtgcctcttc tctcctttca cttcatagcc 480  
 tcaaacaacc ctttatgaga tgaacctgaa ggtcctaact ggctg 525

<210> 28  
 <211> 64  
 <212> PRT  
 <213> Glycine max

<220>  
 <221> UNSURE  
 <222> (38)

<400> 28  
 Met Ile Thr Leu Thr Asp Phe Tyr His Val Met Thr Ala Met Val Pro  
 1 5 10 15  
 Leu Tyr Val Ala Met Ile Leu Ala Tyr Gly Ser Val Lys Trp Trp Lys  
 20 25 30  
 Ile Phe Ser Pro Asp Xaa Cys Ser Gly Ile Asn Arg Phe Val Ala Leu  
 35 40 45  
 Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ala Ser Asn Asn Pro  
 50 55 60

<210> 29  
 <211> 2549  
 <212> DNA  
 <213> Glycine max

<400> 29  
 gcacgagccc cactctgcct tgtgctttgg agactgcaag tgcaaccttg cttgcagctc 60  
 tcaaagctga aaaaatattt gctgtattct ctgctgcaca ttagcaccat tcactcactc 120  
 actgccccaa aaccacatgc tcttccacat ccctatataa aatcttttca atcttcataa 180  
 tcatcatcat caccaccaac tccaactcaa actctccaaa acctgccact tcaaccttcc 240  
 tatatatctc ttccctcact ctcttctgct tctatcatct ttctgagagg cttgttgaca 300  
 cacaaaaaat gatcacctta acagacttct accatgtgat gactgcaatg gtgccactct 360  
 atgtggccat gatactagcc tatggctcag tgaagtgggt gaagattttc tccctgac 420  
 aatgctctgg catcaaccgt tttgtggcac tctttgcagt gcctcttctc tccttccact 480  
 tcatagcctc caacaaccct tatgagatga acctgagggt cctagctgct gacaccttc 540  
 aaaagatcat aatactagtc ctcccttgag tttggagcaa catcaccaaa aggggttgtt 600  
 tggaatgggc cataaccttg ttctctctct ccacctccc aaacactttg gttatgggca 660  
 tccctttgct caaagggatg tatggtgact tctcaggag cctcatgggt caaatgtgg 720  
 tctccagctc catcatttgg tacaccttga tgctcttctt gtttgagttt agaggtgcca 780  
 gaatgctcat ctctgagcag ttccctgaca ctgctgcctc cattgtctcc atccatgtgg 840  
 actctgatgt catgtcattg gatggaagac aaccacttga gactgaagct gagatcaagg 900  
 aagatggtaa actccatgtc actgtgagga aatccaatgc ttcaagatca gacatcttct 960  
 ctagaagggtc tcagggtctc tcttccacca ctccacgccc ttccaacctt accaatgctg 1020  
 agatatactc tttgcaatcc tctaggaacc ctacgccgag aggtcttagt ttcaaccaca 1080  
 ctgattttcta tcccatgatg gctgctgggt gcaggaactc aaacttttgt gcctctgatg 1140  
 tttatggcct ttcagcttca agagggccaa ctccaaggcc ttctaactat gatgaagatg 1200  
 gtgggaagcc aaagtttcat taccatgctg ctggtggaac tgggcactac cctgcaccaa 1260

```

accctggcat gttctctccc tctaattgggt ccaaaagtgt tgctgctaata gctaattgcca 1320
agaggcctaa tgggcaggct cagctgaagc ctgaggatgg gaataggagac cttcatatgt 1380
ttgtttggag ttcaagtgtc tcaccagttt ctgatgtgtt tggtgcccat gagtatggag 1440
gaggtcatga tcagaaagaa gtcaaattga atgtatctcc aggaaaagtg gagaataatc 1500
atagagacac tcaagaagac tacctagaga aagatgagtt cagctttggg aatagagaaa 1560
tggacaggga gatgaatcag cttgaagggt agaaggttgg agatgggaaa caaaaaacca 1620
tgcctccagc aagtgtgatg acaaggctta tattgattat ggtgtggaga aaactcatca 1680
gaaaccccaa cacctactct agcctaattg gtctcacttg gtctcttggt tcattcaagt 1740
ggaatgttga gatgcctgcc ataatagcaa agtctatctc catattgtca gacgcagggc 1800
ttggcatggc catgttcagt cttggtctct tcatggcttt gcaaccgagg gtcatagcat 1860
gtggaaattc cacagcagct tttgccatgg ctgtgagatt ccttacaggt ccagctgtca 1920
tggcagctgc ttccattgct gttggactca aagggtgttc cctacacgtt gccattgttc 1980
aggcagctct tccccagga attgtcccat ttgtctttgc taaggaatat aatgtacatc 2040
ctgatattct cagcacagct gttatttttg ggtgctgat tgctttgccc ataactctag 2100
tgtactacat cttgttgggg ttgtgaatga aagaaatgat ggatgataca gaagattcac 2160
gtgtggcatc catgcaaagc ttggttgagg ttgttgagaa tgagagaaaa aaaagggtcat 2220
aaagcaacaa tagaaaagaa gcatcacgag aatttgata ggaagaagaa ccccaggatc 2280
agtttttttt atttatttgt tttcttttct ttttttgaat gaattgccct ttcttagtga 2340
aaattaatgt aaaatcatga tgtagctaata ttacaaaatg attatctcgt taaaatttta 2400
tattataatg acctcgatt ccattgtcact catcaattga aggataagaa agcatgagaa 2460
acttagttga tgaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2520
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2549

```

<210> 30  
 <211> 605  
 <212> PRT  
 <213> Glycine max

<400> 30  
 Met Ile Thr Leu Thr Asp Phe Tyr His Val Met Thr Ala Met Val Pro  
 1 5 10 15  
 Leu Tyr Val Ala Met Ile Leu Ala Tyr Gly Ser Val Lys Trp Trp Lys  
 20 25 30  
 Ile Phe Ser Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Leu  
 35 40 45  
 Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ala Ser Asn Asn Pro  
 50 55 60  
 Tyr Glu Met Asn Leu Arg Phe Leu Ala Ala Asp Thr Leu Gln Lys Ile  
 65 70 75 80  
 Ile Ile Leu Val Leu Leu Ala Val Trp Ser Asn Ile Thr Lys Arg Gly  
 85 90 95  
 Cys Leu Glu Trp Ala Ile Thr Leu Phe Ser Leu Ser Thr Leu Pro Asn  
 100 105 110  
 Thr Leu Val Met Gly Ile Pro Leu Leu Lys Gly Met Tyr Gly Asp Phe  
 115 120 125  
 Ser Gly Ser Leu Met Val Gln Ile Val Val Leu Gln Cys Ile Ile Trp  
 130 135 140  
 Tyr Thr Leu Met Leu Phe Leu Phe Glu Phe Arg Gly Ala Arg Met Leu  
 145 150 155 160

Ile Ser Glu Gln Phe Pro Asp Thr Ala Ala Ser Ile Val Ser Ile His  
 165 170 175  
 Val Asp Ser Asp Val Met Ser Leu Asp Gly Arg Gln Pro Leu Glu Thr  
 180 185 190  
 Glu Ala Glu Ile Lys Glu Asp Gly Lys Leu His Val Thr Val Arg Lys  
 195 200 205  
 Ser Asn Ala Ser Arg Ser Asp Ile Phe Ser Arg Arg Ser Gln Gly Leu  
 210 215 220  
 Ser Ser Thr Thr Pro Arg Pro Ser Asn Leu Thr Asn Ala Glu Ile Tyr  
 225 230 235 240  
 Ser Leu Gln Ser Ser Arg Asn Pro Thr Pro Arg Gly Ser Ser Phe Asn  
 245 250 255  
 His Thr Asp Phe Tyr Ser Met Met Ala Ala Gly Gly Arg Asn Ser Asn  
 260 265 270  
 Phe Gly Ala Ser Asp Val Tyr Gly Leu Ser Ala Ser Arg Gly Pro Thr  
 275 280 285  
 Pro Arg Pro Ser Asn Tyr Asp Glu Asp Gly Gly Lys Pro Lys Phe His  
 290 295 300  
 Tyr His Ala Ala Gly Gly Thr Gly His Tyr Pro Ala Pro Asn Pro Gly  
 305 310 315 320  
 Met Phe Ser Pro Ser Asn Gly Ser Lys Ser Val Ala Ala Asn Ala Asn  
 325 330 335  
 Ala Lys Arg Pro Asn Gly Gln Ala Gln Leu Lys Pro Glu Asp Gly Asn  
 340 345 350  
 Arg Asp Leu His Met Phe Val Trp Ser Ser Ser Ala Ser Pro Val Ser  
 355 360 365  
 Asp Val Phe Gly Ala His Glu Tyr Gly Gly Gly His Asp Gln Lys Glu  
 370 375 380  
 Val Lys Leu Asn Val Ser Pro Gly Lys Val Glu Asn Asn His Arg Asp  
 385 390 395 400  
 Thr Gln Glu Asp Tyr Leu Glu Lys Asp Glu Phe Ser Phe Gly Asn Arg  
 405 410 415  
 Glu Met Asp Arg Glu Met Asn Gln Leu Glu Gly Glu Lys Val Gly Asp  
 420 425 430  
 Gly Lys Pro Lys Thr Met Pro Pro Ala Ser Val Met Thr Arg Leu Ile  
 435 440 445  
 Leu Ile Met Val Trp Arg Lys Leu Ile Arg Asn Pro Asn Thr Tyr Ser  
 450 455 460  
 Ser Leu Ile Gly Leu Thr Trp Ser Leu Val Ser Phe Lys Trp Asn Val  
 465 470 475 480





<220>  
 <221> UNSURE  
 <222> (32)

<220>  
 <221> UNSURE  
 <222> (64)

<400> 32

Met Ile Thr Gly Lys Asp Ile Tyr Asp Val Phe Ala Ala Ile Val Pro  
 1 5 10 15

Leu Tyr Val Ala Met Ile Leu Ser Xaa Tyr Gly Ser Val Arg Trp Xaa  
 20 25 30

Lys Ile Phe Thr Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala  
 35 40 45

Val Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Ser Asn Xaa  
 50 55 60

Pro Tyr Ala Met Asn Tyr His Phe Ile Ala Ala Asp Cys Leu Gln Lys  
 65 70 75 80

Val Val Ile Leu

<210> 33  
 <211> 2324  
 <212> DNA  
 <213> Glycine max

<400> 33

gcacgagctt	tatcgtgaga	gttttgcctt	tatttctcag	ccatgtttcc	ttctttttcca	60
gcttaaaccg	ctaccctaca	aaacctttca	caattctctt	tcttctctagc	tatctctttc	120
tttctgtcta	cattgacctt	gctagctaca	aaccttgcct	taaccatgat	cactggtaag	180
gatatttatg	atgtttttcg	ggctattgtg	ccctctctacg	ttgctatgat	attagcatac	240
ggctcagttc	gggtggtgga	aattttcaca	cctgatcaat	gttctggcat	aaaccgcttc	300
gttctgtgtg	tgcagtttcc	acttctttct	ttccacttca	tctctctcaa	tgacccttat	360
gctatgaact	accacttcat	agcagctgat	tgtcttcaaa	aagttgtcat	tttgggtgct	420
ctctttctat	ggaacacctt	cacaaaacat	ggtagcctag	actggacaat	cacctcttcc	480
tcactttcaa	cccttccaaa	cacacttgct	atggggatcc	ctctattgaa	ggccatgtat	540
ggagactttc	cagggagcct	catggtccaa	attgtggtgt	tgcaaagtgt	gatatgggat	600
accctcatgc	tgttcatggt	tgaatataga	ggtgcaaaac	tcctcatcac	agaacagttc	660
cctgagactg	caggctccat	aacttccttc	aggggtgact	cagatgttgt	ctcactcaat	720
ggtagagagc	cacttcaaac	agatgctgag	ataggagaag	atggaaaact	tcatgtgggt	780
gttaaaagat	cagcagcttc	ttccatgata	tcttcattca	acaagtctca	tttaacttcc	840
atgacaccaa	gagcatctaa	cctcactggg	gttgagatct	attctgttca	gtcatcaaga	900
gaaccaaccc	caagaggttc	gagtttcaac	caaacggatt	tctatgccat	gttcgcaagc	960
aaggcaccga	gtccaaaaca	tggctacaca	aacagtttcc	agagtaataa	tggtgggtatt	1020
gggtgacgtt	actcgttgca	gtcttcaaaa	ggggcaacgc	caaggacttc	taattttgaa	1080
gaggagatgt	tgaagatgca	caagaagaga	ggagggagga	gcatgagtgg	cgagttgttt	1140
aatgggggtt	tggtttcttc	taattacccg	ccaccgaatc	caatgttttc	aggggtctacg	1200
agtgtgtgtg	gtggccccaa	gaagaaagat	agcagtgggtg	gcggtgggtg	tgtagcacct	1260
aacaaggagt	tacacatggt	tgtttggagt	tcaagtgcct	cacctgtttc	tgagggggaat	1320
ttgaggcatg	cagttaatag	agctgcctct	actgactttg	gaactgtcga	tccttctaaag	1380
gctgttccac	acgaaactgt	tgcttcaaaa	gctgtttcacg	aattgattga	gaacatgagc	1440
cctgggtcgt	gagggagtgg	agagagggag	cctgaaatgg	atgaaggagc	caaaattccc	1500
gcaagtggat	ctccatacac	ttgccagaag	aaggtggaca	tggaagatgg	caatgcaaac	1560
aaaaaccaac	agatgccacc	tgcaagtgtc	atgacaagac	ttattctcat	catggttttg	1620



Ser Met Thr Pro Arg Ala Ser Asn Leu Thr Gly Val Glu Ile Tyr Ser  
 225 230 235 240  
 Val Gln Ser Ser Arg Glu Pro Thr Pro Arg Gly Ser Ser Phe Asn Gln  
 245 250 255  
 Thr Asp Phe Tyr Ala Met Phe Ala Ser Lys Ala Pro Ser Pro Lys His  
 260 265 270  
 Gly Tyr Thr Asn Ser Phe Gln Ser Asn Asn Gly Gly Ile Gly Asp Val  
 275 280 285  
 Tyr Ser Leu Gln Ser Ser Lys Gly Ala Thr Pro Arg Thr Ser Asn Phe  
 290 295 300  
 Glu Glu Glu Met Leu Lys Met His Lys Lys Arg Gly Gly Arg Ser Met  
 305 310 315 320  
 Ser Gly Glu Leu Phe Asn Gly Gly Leu Val Ser Ser Asn Tyr Pro Pro  
 325 330 335  
 Pro Asn Pro Met Phe Ser Gly Ser Thr Ser Ala Ala Gly Gly Pro Lys  
 340 345 350  
 Lys Lys Asp Ser Ser Gly Gly Gly Gly Ala Val Ala Pro Asn Lys Glu  
 355 360 365  
 Leu His Met Phe Val Trp Ser Ser Ser Ala Ser Pro Val Ser Glu Gly  
 370 375 380  
 Asn Leu Arg His Ala Val Asn Arg Ala Ala Ser Thr Asp Phe Gly Thr  
 385 390 395 400  
 Val Asp Pro Ser Lys Ala Val Pro His Glu Thr Val Ala Ser Lys Ala  
 405 410 415  
 Val His Glu Leu Ile Glu Asn Met Ser Pro Gly Arg Arg Gly Ser Gly  
 420 425 430  
 Glu Arg Glu Pro Glu Met Asp Glu Gly Ala Lys Ile Pro Ala Ser Gly  
 435 440 445  
 Ser Pro Tyr Thr Cys Gln Lys Lys Val Asp Met Glu Asp Gly Asn Ala  
 450 455 460  
 Asn Lys Asn Gln Gln Met Pro Pro Ala Ser Val Met Thr Arg Leu Ile  
 465 470 475 480  
 Leu Ile Met Val Trp Arg Lys Leu Ile Arg Asn Pro Asn Thr Tyr Ser  
 485 490 495  
 Ser Leu Leu Gly Leu Thr Trp Ser Leu Ile Ser Phe Arg Trp His Ile  
 500 505 510  
 Glu Met Pro Thr Ile Val Lys Gly Ser Ile Ser Ile Leu Ser Asp Ala  
 515 520 525  
 Gly Leu Gly Met Ala Met Phe Ser Leu Gly Leu Phe Met Ala Leu Gln  
 530 535 540

Pro Lys Ile Ile Ala Cys Gly Lys Ser Val Ala Ala Phe Ser Met Ala  
545 550 555 560

Val Arg Phe Leu Thr Gly Pro Ala Val Ile Ala Ala Thr Ser Ile Gly  
565 570 575

Ile Gly Leu Arg Gly Val Leu Leu His Val Ala Ile Val Gln Ala Ala  
580 585 590

Leu Pro Gln Gly Ile Val Pro Phe Val Phe Ala Lys Glu Tyr Asn Leu  
595 600 605

His Ala Asp Ile Leu Ser Thr Ala Val Ile Phe Gly Met Leu Ile Ala  
610 615 620

Leu Pro Ile Thr Ile Leu Tyr Tyr Val Leu Leu Gly Val  
625 630 635

<210> 35  
<211> 473  
<212> DNA  
<213> Triticum aestivum

<220>  
<221> unsure  
<222> (22)

<220>  
<221> unsure  
<222> (46)

<220>  
<221> unsure  
<222> (58)

<220>  
<221> unsure  
<222> (61)

<220>  
<221> unsure  
<222> (91)

<220>  
<221> unsure  
<222> (98)

<220>  
<221> unsure  
<222> (101)

<220>  
<221> unsure  
<222> (122)

<220>  
<221> unsure  
<222> (177)

<220>  
 <221> unsure  
 <222> (201)

<220>  
 <221> unsure  
 <222> (297)

<220>  
 <221> unsure  
 <222> (300)..(301)

<220>  
 <221> unsure  
 <222> (317)

<220>  
 <221> unsure  
 <222> (333)

<220>  
 <221> unsure  
 <222> (336)

<220>  
 <221> unsure  
 <222> (347)

<220>  
 <221> unsure  
 <222> (360)

<220>  
 <221> unsure  
 <222> (367)

<220>  
 <221> unsure  
 <222> (389)

<220>  
 <221> unsure  
 <222> (406)

<220>  
 <221> unsure  
 <222> (435)

<220>  
 <221> unsure  
 <222> (441)

<400> 35  
 cccaccagca gagacgaaga tnccacgagg aaccgttggg atctanctaa ctagctcntc 60  
 ncgatgatta ccgggaagga catctaccac ntgctggngg nggtggtgcc gctgtacgtg 120  
 gncatgttca tggcgtagcg gtcggtgcgg tgggtggggca tcttcacgcc ggaccantgc 180  
 tcgggcatca aacgcttcgt ngccgtcttc gcggtggcgc tcctctcctt ccacttcate 240  
 tccaccaacg aaccctacgc catggactaa cgcttcctgg gcgccgactc gctgcanaan 300  
 ntcgttatcc tcgccgncct cgccgtgtgg ganaangtgc tctcccncca acggtgcccn 360

ggggganaga aggcggcgaa ggctcctcnc tgggctggga caacanactc ttctccttgg 420  
 ggaaagtgcc aaaanactgg ngaaggggaa tccccctgct gggcgcaagt atg 473

<210> 36  
 <211> 89  
 <212> PRT  
 <213> Triticum aestivum

<220>  
 <221> UNSURE  
 <222> (10)

<220>  
 <221> UNSURE  
 <222> (12)..(13)

<220>  
 <221> UNSURE  
 <222> (20)

<220>  
 <221> UNSURE  
 <222> (38)

<220>  
 <221> UNSURE  
 <222> (69)

<220>  
 <221> UNSURE  
 <222> (78)..(79)..(80)

<220>  
 <221> UNSURE  
 <222> (85)

<400> 36  
 Met Ile Thr Gly Lys Asp Ile Tyr His Xaa Leu Xaa Xaa Val Val Pro  
     1                    5                    10                    15  
 Leu Tyr Val Xaa Met Phe Met Ala Tyr Gly Ser Val Arg Trp Trp Gly  
             20                    25                    30  
 Ile Phe Thr Pro Asp Xaa Cys Ser Gly Ile Lys Arg Phe Val Ala Val  
             35                    40                    45  
 Phe Ala Val Ala Leu Leu Ser Phe His Phe Ile Ser Thr Asn Glu Pro  
     50                    55                    60  
 Tyr Ala Met Asp Xaa Arg Phe Leu Gly Ala Asp Ser Leu Xaa Xaa Xaa  
     65                    70                    75                    80  
 Val Ile Leu Ala Xaa Leu Ala Val Trp  
                     85

<210> 37  
 <211> 2293  
 <212> DNA  
 <213> Triticum aestivum

&lt;400&gt; 37

```

ctggatcgat cccagcagc agagacgaga tcccacgagg aaccgttggg atctagctag 60
ctagctcgtc gcgatgatca ccgggaagga catctacgac gtgctggcgg cgggtggcgcc 120
gctgtacgtg gccatgttca tggcgtaagg gtccgtgccc tgggtggggca tcttcacgcc 180
ggaccagtgc tcgggcatca accgcttcgt cgcgctcttc gcggtgcccgc tctctcctt 240
ccacttcacg tccaccaacg acccctacgc catggactac cgcttcctgg ccgcccactc 300
gctgcagaag ctgctcatcc tcgcccgcct cgcggtgtgg cacaacgtgc tctcccgtc 360
ccggtgcccgc ggcggcacgg aggcggcgga ggccctcgct ctggactgga ccatcacgct 420
cttctccctg gcgacgtgct ccaacacgct ggtgatgggc atcccgctgc tgcgcgccat 480
gtacggcgac ttctcggggg cgtcatggt gcagatcggt gtgctgcaga gcgtcatctg 540
gtacacgctc atgctcttcc tcttcgagta ccgcgcgccc aaggcgctca tctccgagca 600
gttcccgcgc gacgtcgggc ccagcatcgc ctcccttcgc gtcgactccg acgtcgtctc 660
gtcaacggg gcgagggcgc tgcacggcgc cgcgagggtc ggccgcgacg gcccggtcca 720
cgtcgtcatc cgcggttcgc cgtcgggggt caccacgggc ggccacggcg ccggcgctc 780
cgggatctac cgtggcgctg ccaacgccat gacgcgcgc gcgtccaacc tcacggcgct 840
ggagatctac tcgctgcaga cgtcgcggga gccacgcgc aggcagcca gcttcaacca 900
gtccgacttc tactccatgt tcaacgggag caagctgggt agtcccaagg gccagccccc 960
cgtcgcggga ggtggtggtg cgcgcgggca ggggctcgac gagcaggtgg ccaacaagtt 1020
caagggcggc gaggcggtg cgcctaccc cgcgcacca cccgggatga tgatgccgc 1080
gccacggaag aaggagctg ggggttccaa ctcaaacgc aacaaggagc tgcacatgtt 1140
cgtgtggagc tccagcgctg cgcgctgtc ggaggccaac ctccgcaacg ccgtcaacca 1200
cgcgcgtcc accgacttcg ccgcccgcac gccggcgga gccacgccac gagacggcg 1260
cacaccaga ggcgtgagc gcagcgtgac gccggtgatg aagaaggacg ccagcagcg 1320
cgcggtggag gtggagatcg aggcggcat gatgaagagc ccgcgacgag ggctggcg 1380
caagttcccg gtgtcggggg cccctacgt ggccccgcgc aagaaggcg ccgacgtgc 1440
tgggctggag gaggcggcgc acccgatgcc gccggcgagc gtgatgacc ggctcatcct 1500
catcatggtg tggcgcaagc tcactccgaa ccccaacacc tactccagcc tcactcgcc 1560
cgtctggtca ctgctctcct tcaggtggaa cattcagatg cctacaataa tcaaggggtc 1620
catatccatc ctgtctgatg cagggtctag gatggctatg ttcagcttag gtctcttcat 1680
ggctctgcaa ccaaagatca tctcttgccg gaagtctgtc gccacatttg caatggcagt 1740
gaggttcttg actgggcccg cgtgatcgc cgcgacctca atcgccgtcg ggctccggg 1800
agtgtccta catgttgcca ttgtccaggc agcacttcca caaggaattg ttccatttgt 1860
gttcgccaag gactacaatt gccatcctca aatacttagc acagcggtta tttttggaat 1920
gctcgtggcg tcccgatca cgatactcta ctacgttctc cttgggatat agattcataa 1980
tcttgaagaa ccaaggctgc aaatcttcgg gtaggagaaa gtagaattct agagagaaaa 2040
tggcaactga acatgcttgt gggctgtcct gaagacctga agatgcatga gaccaagcag 2100
aaggataggg agaactaagt aggaccctag acaggaattc aaaggacaga taaagatatc 2160
cttggttcca tttttttaat tttttatatt atttttacta ctgttttaga tccaaagtaa 2220
aggctagggc tttgagtatg aagagttcaa ccgttaaatac gaaaaaaaaa aaaaaaaaaa 2280
aaaaaaaaa aaa 2293

```

&lt;210&gt; 38

&lt;211&gt; 632

&lt;212&gt; PRT

&lt;213&gt; Triticum aestivum

&lt;400&gt; 38

```

Met Ile Thr Gly Lys Asp Ile Tyr Asp Val Leu Ala Ala Val Val Pro
 1             5             10             15

Leu Tyr Val Ala Met Phe Met Ala Tyr Gly Ser Val Arg Trp Trp Gly
 20             25             30

Ile Phe Thr Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Val
 35             40             45

Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Thr Asn Asp Pro
 50             55             60

```

Tyr Ala Met Asp Tyr Arg Phe Leu Ala Ala Asp Ser Leu Gln Lys Leu  
 65 70 75 80  
 Val Ile Leu Ala Ala Leu Ala Val Trp His Asn Val Leu Ser Arg Tyr  
 85 90 95  
 Arg Cys Arg Gly Gly Thr Glu Ala Gly Glu Ala Ser Ser Leu Asp Trp  
 100 105 110  
 Thr Ile Thr Leu Phe Ser Leu Ala Thr Leu Pro Asn Thr Leu Val Met  
 115 120 125  
 Gly Ile Pro Leu Leu Arg Ala Met Tyr Gly Asp Phe Ser Gly Ser Leu  
 130 135 140  
 Met Val Gln Ile Val Val Leu Gln Ser Val Ile Trp Tyr Thr Leu Met  
 145 150 155 160  
 Leu Phe Leu Phe Glu Tyr Arg Gly Ala Lys Ala Leu Ile Ser Glu Gln  
 165 170 175  
 Phe Pro Pro Asp Val Gly Ala Ser Ile Ala Ser Phe Arg Val Asp Ser  
 180 185 190  
 Asp Val Val Ser Leu Asn Gly Arg Glu Ala Leu His Ala Asp Ala Glu  
 195 200 205  
 Val Gly Arg Asp Gly Arg Val His Val Val Ile Arg Arg Ser Ala Ser  
 210 215 220  
 Gly Ser Thr Thr Gly Gly His Gly Ala Gly Arg Ser Gly Ile Tyr Arg  
 225 230 235 240  
 Gly Ala Ser Asn Ala Met Thr Pro Arg Ala Ser Asn Leu Thr Gly Val  
 245 250 255  
 Glu Ile Tyr Ser Leu Gln Thr Ser Arg Glu Pro Thr Pro Arg Gln Ser  
 260 265 270  
 Ser Phe Asn Gln Ser Asp Phe Tyr Ser Met Phe Asn Gly Ser Lys Leu  
 275 280 285  
 Ala Ser Pro Lys Gly Gln Pro Pro Val Ala Gly Gly Gly Gly Ala Arg  
 290 295 300  
 Gly Gln Gly Leu Asp Glu Gln Val Ala Asn Lys Phe Lys Gly Gly Glu  
 305 310 315 320  
 Ala Ala Ala Pro Tyr Pro Ala Pro Asn Pro Gly Met Met Met Pro Ala  
 325 330 335  
 Pro Arg Lys Lys Glu Leu Gly Gly Ser Asn Ser Asn Ser Asp Lys Glu  
 340 345 350  
 Leu His Met Phe Val Trp Ser Ser Ser Ala Ser Pro Val Ser Glu Ala  
 355 360 365  
 Asn Leu Arg Asn Ala Val Asn His Ala Ala Ser Thr Asp Phe Ala Ala  
 370 375 380



Ala Pro Pro Ala Ala Ala Thr Pro Arg Asp Gly Ala Thr Pro Arg Gly  
 385 390 395 400  
 Val Ser Gly Ser Val Thr Pro Val Met Lys Lys Asp Ala Ser Ser Gly  
 405 410 415  
 Ala Val Glu Val Glu Ile Glu Asp Gly Met Met Lys Ser Pro Ala Thr  
 420 425 430  
 Gly Leu Gly Ala Lys Phe Pro Val Ser Gly Ser Pro Tyr Val Ala Pro  
 435 440 445  
 Arg Lys Lys Gly Ala Asp Val Pro Gly Leu Glu Glu Ala Ala His Pro  
 450 455 460  
 Met Pro Pro Ala Ser Val Met Thr Arg Leu Ile Leu Ile Met Val Trp  
 465 470 475 480  
 Arg Lys Leu Ile Arg Asn Pro Asn Thr Tyr Ser Ser Leu Ile Gly Leu  
 485 490 495  
 Val Trp Ser Leu Val Ser Phe Arg Trp Asn Ile Gln Met Pro Thr Ile  
 500 505 510  
 Ile Lys Gly Ser Ile Ser Ile Leu Ser Asp Ala Gly Leu Gly Met Ala  
 515 520 525  
 Met Phe Ser Leu Gly Leu Phe Met Ala Leu Gln Pro Lys Ile Ile Ser  
 530 535 540  
 Cys Gly Lys Ser Val Ala Thr Phe Ala Met Ala Val Arg Phe Leu Thr  
 545 550 555 560  
 Gly Pro Ala Val Ile Ala Ala Thr Ser Ile Ala Val Gly Leu Arg Gly  
 565 570 575  
 Val Leu Leu His Val Ala Ile Val Gln Ala Ala Leu Pro Gln Gly Ile  
 580 585 590  
 Val Pro Phe Val Phe Ala Lys Glu Tyr Asn Cys His Pro Gln Ile Leu  
 595 600 605  
 Ser Thr Ala Val Ile Phe Gly Met Leu Val Ala Leu Pro Ile Thr Ile  
 610 615 620  
 Leu Tyr Tyr Val Leu Leu Gly Ile  
 625 630

<210> 39  
 <211> 447  
 <212> DNA  
 <213> Triticum aestivum

<220>  
 <221> unsure  
 <222> (366)

<220>  
 <221> unsure  
 <222> (380)

<220>  
 <221> unsure  
 <222> (390)

<220>  
 <221> unsure  
 <222> (418)

<220>  
 <221> unsure  
 <222> (421)

<220>  
 <221> unsure  
 <222> (434)

<400> 39  
 gcacacagag acagtcatac tactccatca aataagatga tagcgttggg cgacatctac 60  
 aaggtggtgg aggcgatggc gccgctttac ttcgcgctag ggctcgggta cgggtccggt 120  
 cgatggtggc ggttcttcac ggcggagcag tgcggcgcca tcaacacgct ggtggtctgc 180  
 ttctccatgc ctttcttcac cttegacttc gtggtccgcg ccgacccta cgccatgaat 240  
 taccggtca tcgccgcga cgcgctgcc aaacttctcg ccgtgctcgc cgcggccgctc 300  
 tgggcgcgct gcgccaaggc caaggccggc gcctactcgt ggtcatcacg gggttctccc 360  
 tgggcncgta caacaacacn ctcgctcgtc gggtgccgct tctgggacgc caatttcngg 420  
 naattggggg gcanggactt tattttt 447

<210> 40  
 <211> 94  
 <212> PRT  
 <213> Triticum aestivum

<400> 40  
 Met Ile Ala Leu Gly Asp Ile Tyr Lys Val Val Glu Ala Met Ala Pro  
 1 5 10 15  
 Leu Tyr Phe Ala Leu Gly Leu Gly Tyr Gly Ser Val Arg Trp Trp Arg  
 20 25 30  
 Phe Phe Thr Ala Glu Gln Cys Gly Ala Ile Asn Thr Leu Val Val Cys  
 35 40 45  
 Phe Ser Met Pro Phe Phe Thr Phe Asp Phe Val Val Arg Ala Asp Pro  
 50 55 60  
 Tyr Ala Met Asn Tyr Arg Val Ile Ala Ala Asp Ala Val Ala Lys Leu  
 65 70 75 80  
 Leu Ala Val Leu Ala Ala Ala Val Trp Ala Arg Cys Ala Lys  
 85 90

<210> 41  
 <211> 415  
 <212> DNA  
 <213> Triticum aestivum

<400> 41  
 ctcgcctaaa taaacctctc cccacgcac tccccactc caccacacac cctcaccagc 60  
 tcgcccgcag agtgagccga ggccgagagc cggagcgcgga gaggaagaag cagaggaggt 120  
 cgggcaagat gatcacgggc acggacttct accacgtgat gacggcggtg gtgccgctgt 180

```

acgtggccat gatcctcgcc tacggctccg tcaagtgggtg gggcatcttc acgccggacc 240
agtgtctcgg gatcaaccgc ttctgtcgcg tcttcgccgt gccgtctctc tctttccact 300
tcattctccac caacaacccc tacaccatga acctgcgctt catcgccgcc gacacgtgc 360
agaagctcat gatgtctgcc atgtcaacg cctggagcaa ctctcccgcc gcggc 415

```

<210> 42  
 <211> 91  
 <212> PRT  
 <213> *Triticum aestivum*

<400> 42  
 Met Ile Thr Gly Thr Asp Phe Tyr His Val Met Thr Ala Val Val Pro  
 1 5 10 15  
 Leu Tyr Val Ala Met Ile Leu Ala Tyr Gly Ser Val Lys Trp Trp Gly  
 20 25 30  
 Ile Phe Thr Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Leu  
 35 40 45  
 Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Thr Asn Asn Pro  
 50 55 60  
 Tyr Thr Met Asn Leu Arg Phe Ile Ala Ala Asp Thr Leu Gln Lys Leu  
 65 70 75 80  
 Met Met Leu Ala Met Leu Asn Ala Trp Ser Asn  
 85 90

<210> 43  
 <211> 647  
 <212> PRT  
 <213> *Arabidopsis thaliana*

<400> 43  
 Met Ile Thr Gly Lys Asp Met Tyr Asp Val Leu Ala Ala Met Val Pro  
 1 5 10 15  
 Leu Tyr Val Ala Met Ile Leu Ala Tyr Gly Ser Val Arg Trp Trp Gly  
 20 25 30  
 Ile Phe Thr Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Val  
 35 40 45  
 Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Ser Asn Asp Pro  
 50 55 60  
 Tyr Ala Met Asn Tyr His Phe Leu Ala Ala Asp Ser Leu Gln Lys Val  
 65 70 75 80  
 Val Ile Leu Ala Ala Leu Phe Leu Trp Gln Ala Phe Ser Arg Arg Gly  
 85 90 95  
 Ser Leu Glu Trp Met Ile Thr Leu Phe Ser Leu Ser Thr Leu Pro Asn  
 100 105 110  
 Thr Leu Val Met Gly Ile Pro Leu Leu Arg Ala Met Tyr Gly Asp Phe  
 115 120 125

WO 00/68389

PCT/US00/12061

Ser Gly Asn Leu Met Val Gln Ile Val Val Leu Gln Ser Ile Ile Trp  
130 135 140

Tyr Thr Leu Met Leu Phe Leu Phe Glu Phe Arg Gly Ala Lys Leu Leu  
145 150 155 160

Ile Ser Glu Gln Phe Pro Glu Thr Ala Gly Ser Ile Thr Ser Phe Arg  
165 170 175

Val Asp Ser Asp Val Ile Ser Leu Asn Gly Arg Glu Pro Leu Gln Thr  
180 185 190

Asp Ala Glu Ile Gly Asp Asp Gly Lys Leu His Val Val Val Arg Arg  
195 200 205

Ser Ser Ala Ala Ser Ser Met Ile Ser Ser Phe Asn Lys Ser His Gly  
210 215 220

Gly Gly Leu Asn Ser Ser Met Ile Thr Pro Arg Ala Ser Asn Leu Thr  
225 230 235 240

Gly Val Glu Ile Tyr Ser Val Gln Ser Ser Arg Glu Pro Thr Pro Arg  
245 250 255

Ala Ser Ser Phe Asn Gln Thr Asp Phe Tyr Ala Met Phe Asn Ala Ser  
260 265 270

Lys Ala Pro Ser Pro Arg His Gly Tyr Thr Asn Ser Tyr Gly Gly Ala  
275 280 285

Gly Ala Gly Pro Gly Gly Asp Val Tyr Ser Leu Gln Ser Ser Lys Gly  
290 295 300

Val Thr Pro Arg Thr Ser Asn Phe Asp Glu Glu Val Met Lys Thr Ala  
305 310 315 320

Lys Lys Ala Gly Arg Gly Gly Arg Ser Met Ser Gly Glu Leu Tyr Asn  
325 330 335

Asn Asn Ser Val Pro Ser Tyr Pro Pro Pro Asn Pro Met Phe Thr Gly  
340 345 350

Ser Thr Ser Gly Ala Ser Gly Val Lys Lys Lys Glu Ser Gly Gly Gly  
355 360 365

Gly Ser Gly Gly Gly Val Gly Val Gly Gly Gln Asn Lys Glu Met Asn  
370 375 380

Met Phe Val Trp Ser Ser Ser Ala Ser Pro Val Ser Glu Ala Asn Ala  
385 390 395 400

Lys Asn Ala Met Thr Arg Gly Ser Ser Thr Asp Val Ser Thr Asp Pro  
405 410 415

Lys Val Ser Ile Pro Pro His Asp Asn Leu Ala Thr Lys Ala Met Gln  
420 425 430

Asn Leu Ile Glu Asn Met Ser Pro Gly Arg Lys Gly His Val Glu Met  
435 440 445

Asp Gln Asp Gly Asn Asn Gly Gly Lys Ser Pro Tyr Met Gly Lys Lys  
 450 455 460  
 Gly Ser Asp Val Glu Asp Gly Gly Pro Gly Pro Arg Lys Gln Gln Met  
 465 470 475 480  
 Pro Pro Ala Ser Val Met Thr Arg Leu Ile Leu Ile Met Val Trp Arg  
 485 490 495  
 Lys Leu Ile Arg Asn Pro Asn Thr Tyr Ser Ser Leu Phe Gly Leu Ala  
 500 505 510  
 Trp Ser Leu Val Ser Phe Lys Trp Asn Ile Lys Met Pro Thr Ile Met  
 515 520 525  
 Ser Gly Ser Ile Ser Ile Leu Ser Asp Ala Gly Leu Gly Met Ala Met  
 530 535 540  
 Phe Ser Leu Gly Leu Phe Met Ala Leu Gln Pro Lys Ile Ile Ala Cys  
 545 550 555 560  
 Gly Lys Ser Val Ala Gly Phe Ala Met Ala Val Arg Phe Leu Thr Gly  
 565 570 575  
 Pro Ala Val Ile Ala Ala Thr Ser Ile Ala Ile Gly Ile Arg Gly Asp  
 580 585 590  
 Leu Leu His Ile Ala Ile Val Gln Ala Ala Leu Pro Gln Gly Ile Val  
 595 600 605  
 Pro Phe Val Phe Ala Lys Glu Tyr Asn Val His Pro Asp Ile Leu Ser  
 610 615 620  
 Thr Ala Val Ile Phe Gly Met Leu Val Ala Leu Pro Val Thr Val Leu  
 625 630 635 640  
 Tyr Tyr Val Leu Leu Gly Leu  
 645

<210> 44  
 <211> 622  
 <212> PRT  
 <213> Arabidopsis thaliana

<400> 44  
 Met Ile Thr Ala Ala Asp Phe Tyr His Val Met Thr Ala Met Val Pro  
 1 5 10 15  
 Leu Tyr Val Ala Met Ile Leu Ala Tyr Gly Ser Val Lys Trp Trp Lys  
 20 25 30  
 Ile Phe Thr Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Leu  
 35 40 45  
 Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ala Ala Asn Asn Pro  
 50 55 60  
 Tyr Ala Met Asn Leu Arg Phe Leu Ala Ala Asp Ser Leu Gln Lys Val  
 65 70 75 80

Ile Val Leu Ser Leu Leu Phe Leu Trp Cys Lys Leu Ser Arg Asn Gly  
 85 90 95  
 Ser Leu Asp Trp Thr Ile Thr Leu Phe Ser Leu Ser Thr Leu Pro Asn  
 100 105 110  
 Thr Leu Val Met Gly Ile Pro Leu Leu Lys Gly Met Tyr Gly Asn Phe  
 115 120 125  
 Ser Gly Asp Leu Met Val Gln Ile Val Val Leu Gln Cys Ile Ile Trp  
 130 135 140  
 Tyr Ile Leu Met Leu Phe Leu Phe Glu Tyr Arg Gly Ala Lys Leu Leu  
 145 150 155 160  
 Ile Ser Glu Gln Phe Pro Asp Thr Ala Gly Ser Ile Val Ser Ile His  
 165 170 175  
 Val Asp Ser Asp Ile Met Ser Leu Asp Gly Arg Gln Pro Leu Glu Thr  
 180 185 190  
 Glu Ala Glu Ile Lys Glu Asp Gly Lys Leu His Val Thr Val Arg Arg  
 195 200 205  
 Ser Asn Ala Ser Arg Ser Asp Ile Tyr Ser Arg Arg Ser Gln Gly Leu  
 210 215 220  
 Ser Ala Thr Pro Arg Pro Ser Asn Leu Thr Asn Ala Glu Ile Tyr Ser  
 225 230 235 240  
 Leu Gln Ser Ser Arg Asn Pro Thr Pro Arg Gly Ser Ser Phe Asn His  
 245 250 255  
 Thr Asp Phe Tyr Ser Met Met Ala Ser Gly Gly Gly Arg Asn Ser Asn  
 260 265 270  
 Phe Gly Pro Gly Glu Ala Val Phe Gly Ser Lys Gly Pro Thr Pro Arg  
 275 280 285  
 Pro Ser Asn Tyr Glu Glu Asp Gly Gly Pro Ala Lys Pro Thr Ala Ala  
 290 295 300  
 Gly Thr Ala Ala Gly Ala Gly Arg Phe His Tyr Gln Ser Gly Gly Ser  
 305 310 315 320  
 Gly Gly Gly Gly Gly Ala His Tyr Pro Ala Pro Asn Pro Gly Met Phe  
 325 330 335  
 Ser Pro Asn Thr Gly Gly Gly Gly Gly Thr Ala Ala Lys Gly Asn Ala  
 340 345 350  
 Pro Val Val Gly Gly Lys Arg Gln Asp Gly Asn Gly Arg Asp Leu His  
 355 360 365  
 Met Phe Val Trp Ser Ser Ser Ala Ser Pro Val Ser Asp Val Phe Gly  
 370 375 380  
 Gly Gly Gly Gly Asn His His Ala Asp Tyr Ser Thr Ala Thr Asn Asp  
 385 390 395 400

His Gln Lys Asp Val Lys Ile Ser Val Pro Gln Gly Asn Ser Asn Asp  
 405 410 415  
 Asn Gln Tyr Val Glu Arg Glu Glu Phe Ser Phe Gly Asn Lys Asp Asp  
 420 425 430  
 Asp Ser Lys Val Leu Ala Thr Asp Gly Gly Asn Asn Ile Ser Asn Lys  
 435 440 445  
 Thr Thr Gln Ala Lys Val Met Pro Pro Thr Ser Val Met Thr Arg Leu  
 450 455 460  
 Ile Leu Ile Met Val Trp Arg Lys Leu Ile Arg Asn Pro Asn Ser Tyr  
 465 470 475 480  
 Ser Ser Leu Phe Gly Ile Thr Trp Ser Leu Ile Ser Phe Lys Trp Asn  
 485 490 495  
 Ile Glu Met Pro Ala Leu Ile Ala Lys Ser Ile Ser Ile Leu Ser Asp  
 500 505 510  
 Ala Gly Leu Gly Met Ala Met Phe Ser Leu Gly Leu Phe Met Ala Leu  
 515 520 525  
 Asn Pro Arg Ile Ile Ala Cys Gly Asn Arg Arg Ala Ala Phe Ala Ala  
 530 535 540  
 Ala Met Arg Phe Val Val Gly Pro Ala Val Met Leu Val Ala Ser Tyr  
 545 550 555 560  
 Ala Val Gly Leu Arg Gly Val Leu Leu His Val Ala Ile Ile Gln Ala  
 565 570 575  
 Ala Leu Pro Gln Gly Ile Val Pro Phe Val Phe Ala Lys Glu Tyr Asn  
 580 585 590  
 Val His Pro Asp Ile Leu Ser Thr Ala Val Ile Phe Gly Met Leu Ile  
 595 600 605  
 Ala Leu Pro Ile Thr Leu Leu Tyr Tyr Ile Leu Leu Gly Leu  
 610 615 620

<210> 45  
 <211> 425  
 <212> DNA  
 <213> Triticum aestivum

<400> 45  
 gcacgagctc gcctaaataa acctctcccc cagcactcc cccactccac cacacaccct 60  
 caccagctcg cccgcagagt gagccgagcg cgagagccgg agcgcgagag gaagaagcag 120  
 aggaggtcgg gcaagatgat cacgggcacg gacttctacc acgtgatgac ggcggtggtg 180  
 ccgctgtacg tggccatgat cctcgccctac ggctccgtca agtgggtggg catcttcacg 240  
 ccggaccagt gctccgggat caaccgcttc gtcgcgtct tgcgcgtgcc gtcctctccc 300  
 ttccaattca tctccaccaa caaccctac accatgaacc tgcgcttcac cgccgccgac 360  
 acgtgcaga agctcatgat gctcgccatg ctcaccgcct ggagccacct ctcccgcgcg 420  
 ggcag 425

<210> 46  
 <211> 96

&lt;212&gt; PRT

&lt;213&gt; Triticum aestivum

&lt;400&gt; 46

Met Ile Thr Gly Thr Asp Phe Tyr His Val Met Thr Ala Val Val Pro  
 1 5 10 15

Leu Tyr Val Ala Met Ile Leu Ala Tyr Gly Ser Val Lys Trp Trp Gly  
 20 25 30

Ile Phe Thr Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Leu  
 35 40 45

Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Thr Asn Asn Pro  
 50 55 60

Tyr Thr Met Asn Leu Arg Phe Ile Ala Ala Asp Thr Leu Gln Lys Leu  
 65 70 75 80

Met Met Leu Ala Met Leu Thr Ala Trp Ser His Leu Ser Arg Arg Gly  
 85 90 95

&lt;210&gt; 47

&lt;211&gt; 855

&lt;212&gt; DNA

&lt;213&gt; Zea mays

&lt;400&gt; 47

ccacgcgtcc ggctgacgt cctggcgctg ctcaactgcat ggagctacct ctcccgcgcg 60  
 ggctgcctcg agtggaccat cagctctctt tccctgtcga cgctgcccac cagctgtgtg 120  
 atgggcatcc cgctgctcaa gggcatgtac ggcgacttct ccggcagcct catggtgcag 180  
 atcgtggtgc tccagtgcac catctggtac acgctgatgc tgttcattgt cgagtaccgc 240  
 ggcgccagga tcctcatcac cgagcagttc cccgacacgg cgggcgccat cgctccatc 300  
 gtggtggacc ccgacgtggt gtcgctggac gggcgcaacg acgccatcga gacggaggcc 360  
 gaggtgaagg aggacggcaa gatacacgtc accgtgcggc gctccaacgc gtcgcgctcg 420  
 gacatctact cccggcggtc catgggggtc tccagcacca cgccgcggcc cagcaacctg 480  
 acaacgcgg agatctactc gctgcagtcg tcgaggaacc ccacgcccgc gggctccagc 540  
 ttcaaccaca ccgacttcta ctccatggte ggcgcgagct ccaacttcgc cgccggggac 600  
 gcgttcggcc tgcgcacggg cgccacgccc aggcgcgtcca actacgagga ggaccgcag 660  
 ggcaaggcga acaagtacgg ccagtaccgc gcgcccaccc cggccatggc ggcgcagccc 720  
 gccaaaggcc tcaagaaggc ggccaatggg caggccaagg gcgaggacgg caaggaccta 780  
 cacatgttcg tgtggagctc cagcgcgctg cccgtgtccg acgtgttcgg caatggcgcc 840  
 gccgagtaca acgac 855

&lt;210&gt; 48

&lt;211&gt; 285

&lt;212&gt; PRT

&lt;213&gt; Zea mays

&lt;400&gt; 48

Pro Arg Val Arg Leu Ile Val Leu Ala Leu Leu Thr Ala Trp Ser Tyr  
 1 5 10 15

Leu Ser Arg Arg Gly Cys Leu Glu Trp Thr Ile Thr Leu Phe Ser Leu  
 20 25 30

Ser Thr Leu Pro Asn Thr Leu Val Met Gly Ile Pro Leu Leu Lys Gly  
 35 40 45







100303774, 1002544

SEQUENCE LISTING

<110> Emil M. Orozco, Jr.  
Zude Weng  
Wesley B. Bruce  
Rebecca E. Cahoon  
Yong Tao

<120> Auxin Transport Proteins

<130> BB1355

<140> 10/030,884

<141>

<150> 60/133,040

<151> 1999-05-07

<160> 48

<170> Microsoft Office 97

<210> 1

<211> 629

<212> DNA

<213> Zea mays

<220>

<221> unsure

<222> (413)

<223> n=a,c,g or t

<220>

<221> unsure

<222> (466)

<223> n=a,c,g or t

<220>

<221> unsure

<222> (526)

<223> n=a,c,g or t

<220>

<221> unsure

<222> (535)

<223> n=a,c,g or t

<220>

<221> unsure

<222> (549)

<223> n=a,c,g or t

<220>

<221> unsure

<222> (560)

<223> n=a,c,g or t

<220>

<221> unsure

<222> (601)..(602)..(603)

<223> n=a,c,g or t

<400> 1						
gctaaaattg	ctaatatattc	tccaaaaggaa	acaagatata	taatgtttat	cttcagacag	60
catgaagcaa	gataagatat	atatatatatc	attcttcgac	cgcagtcagc	atgtttgaca	120
gatcgcgaat	cctcactcac	tgaatcactg	aatagatcgc	tgtcgtcggc	gctatctttc	180
gtttccctac	ctaagctaata	agtaatcgct	aatgctcatc	agaaatttca	tgtggggccg	240
ataaccaca	gcatggcgcc	tctcgcagcg	tgaagaagcg	agcgagagag	gctcacagcc	300
ccagcaagat	gtagtagacc	aggggtgatgg	gcagagcgat	gagcatcccg	aagatcacgg	360
ctgtgctcag	gatgtcggga	tgaacgccgt	actccttggg	cgaacacgaa	cgngcacgat	420
cccctgaggc	agagcagcct	ggacgatggc	gatgtggagg	aggagnccgc	cagaccgacg	480
gcgatggaag	cggcggccat	gaccgcgggg	gctgcgaaga	aaccgnacgc	ccatngcgat	540
ggccgcacanc	ttgtttcccn	aagcgatgat	cctcgggtgc	agcgccatga	acaggccctag	600
nnngcaacatg	gccatccgaq	accgcqtnc				629

```
<210> 2
<211> 171
<212> PRT
<213> Zea mays
```

<400> 2	Pro	Leu	Ala	Ile	Pro	Pro	Ala	Gly	Val	Met	Thr	Arg	Leu	Ile	Leu	Ile
1					5					10					15	
Met	Val	Trp	Arg	Lys	Leu	Ile	Arg	Asn	Pro	Asn	Thr	Tyr	Ser	Ser	Leu	
			20					25					30			
Ile	Gly	Val	Val	Trp	Ser	Leu	Val	Ser	Tyr	Arg	Trp	Gly	Ile	Glu	Met	
		35					40					45				
Pro	Ala	Ile	Ile	Ala	Arg	Ser	Ile	Ser	Ile	Leu	Ser	Asp	Ala	Gly	Leu	
	50					55					60					
Gly	Met	Ala	Met	Phe	Ser	Leu	Gly	Leu	Phe	Met	Ala	Leu	Gln	Pro	Arg	
65					70					75					80	
Ile	Ile	Ala	Cys	Gly	Asn	Lys	Leu	Ala	Ala	Ile	Ala	Met	Gly	Val	Arg	
				85					90					95		
Phe	Val	Ala	Gly	Pro	Ala	Val	Met	Ala	Ala	Ala	Ser	Ile	Ala	Val	Gly	
			100					105					110			
Leu	Arg	Gly	Val	Leu	Leu	His	Ile	Ala	Ile	Val	Gln	Ala	Ala	Leu	Pro	
		115					120					125				
Gln	Gly	Ile	Val	Pro	Phe	Val	Phe	Ala	Lys	Glu	Tyr	Gly	Val	His	Pro	
	130					135					140					
Asp	Ile	Leu	Ser	Thr	Ala	Val	Ile	Phe	Gly	Met	Leu	Ile	Ala	Leu	Pro	
145					150					155					160	
Ile	Thr	Leu	Val	Tyr	Tyr	Ile	Leu	Leu	Gly	Leu						
				165					170							

<210>	3
<211>	1088
<212>	DNA

Asp 1	Gly	Lys	Ala	Ala 5	Ala	Ala	Gly	Gly	Asp 10	Pro	Ser	Thr	Val	Ala 15	Ala
Pro	Thr	Ala	Met 20	Pro	Pro	Thr	Ser	Val 25	Met	Thr	Arg	Leu	Ile 30	Leu	Ile
Met	Val	Trp 35	Arg	Gln	Leu	Ile	Arg 40	Asn	Pro	Asn	Thr	Tyr 45	Ser	Ser	Leu
Ile	Gly 50	Val	Ile	Trp	Ser	Leu 55	Val	Cys	Phe	Arg	Trp 60	Asn	Phe	Gln	Met
Pro 65	Ala	Ile	Val	Leu	Gln 70	Ser	Ile	Ser	Ile	Leu 75	Ser	Asp	Ala	Gly	Leu 80
Gly	Met	Ala	Met	Phe 85	Ser	Leu	Gly	Leu	Phe 90	Met	Ala	Leu	Gln	Pro 95	Arg
Ile	Ile	Ala	Cys 100	Gly	Asn	Lys	Val	Ala 105	Thr	Phe	Ala	Met	Ala 110	Val	Arg
Phe	Leu	Thr 115	Gly	Pro	Ala	Val	Met 120	Ala	Ala	Ala	Ser	Phe 125	Ala	Val	Gly
Leu	Arg 130	Gly	Thr	Leu	Leu	His 135	Val	Ala	Ile	Val	Gln 140	Ala	Ala	Leu	Pro

Gln Gly Ile Val Pro Phe Val Phe Ala Lys Glu Tyr Asn Val His Pro  
145 150 155 160

Asp Ile Leu Ser Thr Ala Val Ile Phe Gly Met Leu Ile Ala Leu Pro  
165 170 175

Ile Thr Leu Val Tyr Tyr Ile Leu Leu Gly Leu  
180 185

<210> 5  
<211> 253  
<212> DNA  
<213> Zea mays

<220>  
<221> unsure  
<222> (150)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (164)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (194)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (229)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (237)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (240)  
<223> n=a,c,g or t

<400> 5  
gccccacccc actcatcaca ctctcccacc gcacctcgcc gccgcggggc accgcgccat 60  
aaagtgcggt cccggcctgc acggacgtcg aggagcagct cgcaagtgtt tcttggtgcg 120  
togatcggca agatgatcac cggcacggan cttctaccac gtentgacgg ccatggtgcc 180  
gttgtaacgtt gccntgatcc tggcgtaacg atccgtcagg tggtggcgna tcttcangcn 240  
gggaccagtgc ctc 253

<210> 6  
<211> 31  
<212> PRT  
<213> Zea mays

<220>  
<221> UNSURE  
<222> (3)  
<223> Xaa = ANY AMINO ACID



<220>  
 <221> unsure  
 <222> (118)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (129)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (137)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (389)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (444)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (456)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (490)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (555)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (622)  
 <223> n=a,c,g or t

<400> 7  
 ggatgggtcca aggagagctt ggggctcgct gccacctcgc gcgccagnnc nnaaataaat 60  
 cactccccacg cacacccacc acccgccgga gcacctccnc cnncccncc tncnncncc 120  
 caccctccnc actagcncta tctagctgag tgaactgaac agcccaactgg ctcgctcttag 180  
 ctaagctcag ctgtaaagct aagggttcgga gttagctagcg tgggtggccgg agagtgtagc 240  
 gagcggcggt cagctcaccg ggggctgctg ggtgagtgag ggaaccagcg tcgtgagagc 300  
 gctccaagat gattacgggg acggacttct accacgtcat gacggccgtg gtgccgctgt 360  
 acgtggcgat gatcctggcc tacgggtcng tgcggtggtg gcgcattctt tcgccggaac 420  
 aatgctccgg gatcaaccgc ttctnggcgc tcttcnccgt gccgctgctg tccttccact 480  
 tcattctccan caacaaccct acaccatgaa cctgcgcttc atcgccgccg aaacctggca 540  
 aaactcatgg tgctnggcat gctcaccgcg tggaaccact caacgccggg ggaacctgga 600  
 aattgaacat caagctcttc tncct 624

<210> 8  
 <211> 78

<212> PRT  
<213> Zea mays

```
<220>  
<221> UNSURE  
<222> (46)  
<223> Xaa = ANY AMINO ACID
```

```
<220>  
<221> UNSURE  
<222> (50)  
<223> Xaa = ANY AMINO ACID
```

```
<220>
<221> UNSURE
<222> (61)
<223> Xaa = ANY AMINO ACID
```

<400> 8  
Met Ile Thr Gly Thr Asp Phe Tyr His Val Met Thr Ala Val Val Pro  
1 5 10 15  
Leu Tyr Val Ala Met Ile Leu Ala Tyr Gly Ser Val Arg Trp Trp Arg  
20 25 30  
Ile Phe Ser Pro Glu Gln Cys Ser Gly Ile Asn Arg Phe Xaa Ala Leu  
35 40 45  
Phe Xaa Val Pro Leu Leu Ser Phe His Phe Ile Ser Xaa Gln Gln Pro  
50 55 60  
Tyr Thr Met Asn Leu Arg Phe Ile Ala Ala Glu Thr Trp Gln  
65 70 75

```
<210> 9
<211> 1426
<212> DNA
<213> Zea mays
```

<400> 9						
ccacgcgctcc	gggatggtcc	aaggagagct	tggggctcgc	tgccacctcg	cgcgccagcg	60
cctaaataaaa	tactcccac	gcacaccac	cacgcgcgc	agcacctcct	ccttcccttc	120
cttctctctc	ccaccctcct	cactagctct	atctagctga	gtgaactgaa	cagcccactg	180
gctcgtctta	gctaagctca	gctgtaaagc	taagggttcg	agtatgtagc	gtggtggccg	240
gagagtgtag	cgagcggctg	tcagctcaac	gggggtctgt	gggtgagtga	gggaaccagc	300
gtcgtgagag	cgtccaaga	tgattacggg	gacggacttc	taccacgtca	tgacggccgt	360
ggtgcgctg	tacgtggcga	tgatcctggc	ctacgggtcg	gtgcggtggt	ggcgcatctt	420
ctcgccggac	cagtgtccg	ggatcaaccg	cttcgtggcg	ctcttcgcgg	tgcgctgtct	480
gtccttccac	ttcatctcca	ccaacaacc	ctacaccatg	aacctgcgct	tcctgcgcgc	540
cgacacgctg	cagaagctca	tgggtgctgg	catgctcaac	gcgtggagcc	acctcagccg	600
ccggggcagc	ctggagtgga	ccatcacgct	cttctccctc	tccacgtgc	ccaacacgct	660
cgtcatgggc	atccccctgc	tcaaggcat	gtacggcgac	ttctcggga	gctcatggt	720
gcagatcgtc	gtgtccagt	gcatactctg	gtacacgtc	atgtcttcca	tgttcgagta	780
ccgcggcgcg	cggatgctca	tcaccgagca	gttcccgga	aacgcgggg	ccatcgcttc	840
catcgtcgtc	gacccggacg	tgggtctcct	cgacggccgc	agggacgcca	tcgagacgga	900
ggccgaggtc	aaggaggacg	gcaggataca	cgtcacctgt	cgccgctcca	acgcctcgcg	960
ctccgacatc	tactcgcgcc	gctccatggg	cttctccagc	accacgcgcg	gccccagcaa	1020
cctgaccaac	gccgagatct	actcgtgca	gtcgtcgcgc	aaccgcacc	cgcggggctc	1080
cagcttcaac	cacaacgact	tctactccac	ggtcgggccg	agctccaact	tcggcgggcg	1140
cgacgcgttc	ggcatccgca	ccgcgcccat	gcgcgcgcgc	tccaactacg	aggacgacgc	1200
gtccaagccc	aagtaccctc	tccccgtggt	gaatgcgacg	tccggggcgg	gggcggctca	1260



SECRET

<210> 10  
<211> 369  
<212> PRT  
<213> Zea mays

<400> 10  
Met Ile Thr Gly Thr Asp Phe Tyr His Val Met Thr Ala Val Val Pro  
1 5 10 15

Leu Tyr Val Ala Met Ile Leu Ala Tyr Gly Ser Val Arg Trp Trp Arg  
20 25 30

Ile Phe Ser Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Leu  
35 40 45

Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Thr Asn Asn Pro  
50 55 60

Tyr Thr Met Asn Leu Arg Phe Ile Ala Ala Asp Thr Leu Gln Lys Leu  
65 70 75 80

Met Val Leu Ala Met Leu Thr Ala Trp Ser His Leu Ser Arg Arg Gly  
85 90 95

Ser Leu Glu Trp Thr Ile Thr Leu Phe Ser Leu Ser Thr Leu Pro Asn  
100 105 110

Thr Leu Val Met Gly Ile Pro Leu Leu Lys Gly Met Tyr Gly Asp Phe  
115 120 125

Ser Gly Ser Leu Met Val Gln Ile Val Val Leu Gln Cys Ile Ile Trp  
130 135 140

Tyr Thr Leu Met Leu Phe Met Phe Glu Tyr Arg Gly Ala Arg Met Leu  
145 150 155 160

Ile Thr Glu Gln Phe Pro Asp Asn Ala Gly Ala Ile Ala Ser Ile Val  
165 170 175

Val Asp Pro Asp Val Val Ser Leu Asp Gly Arg Arg Asp Ala Ile Glu  
180 185 190

Thr Glu Ala Glu Val Lys Glu Asp Gly Arg Ile His Val Thr Val Arg  
195 200 205

Arg Ser Asn Ala Ser Arg Ser Asp Ile Tyr Ser Arg Arg Ser Met Gly  
210 215 220

Phe Ser Ser Thr Thr Pro Arg Pro Ser Asn Leu Thr Asn Ala Glu Ile  
225 230 235 240

Tyr Ser Leu Gln Ser Ser Arg Asn Pro Thr Pro Arg Gly Ser Ser Phe  
245 250 255

Asn His Asn Asp Phe Tyr Ser Met Val Gly Arg Ser Ser Asn Phe Gly  
260 265 270

Ala Ala Asp Ala Phe Gly Ile Arg Thr Gly Ala Thr Pro Arg Pro Ser  
 275 280 285

Asn Tyr Glu Asp Asp Ala Ser Lys Pro Lys Tyr Pro Leu Pro Val Val  
 290 295 300

Asn Ala Thr Ser Gly Ala Gly Ala Ala His Tyr Pro Ala Pro Asn Pro  
 305 310 315 320

Ala Val Ala Ala Ala Pro Lys Gly Ala Arg Lys Ala Ala Thr Asn Gly  
 325 330 335

Gln Ala Lys Gly Glu Asp Leu His Met Phe Val Trp Ser Ser Ser Ala  
 340 345 350

Ser Pro Val Ser Asp Val Phe Gly Gly Gly Ala Pro Asp Tyr Asn Glu  
 355 360 365

Ala

<210> 11  
 <211> 504  
 <212> DNA  
 <213> Zea mays  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (126)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (192)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (205)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (237)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (242)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (244)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (255)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (258)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (263)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (265)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (287)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (430)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (449)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (455)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (488)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (490)  
 <223> n=a,c,g or t

<400> 11  
 ttttttgagc cctacaacca ctctcttctt cattgctcca cactaccate tcctctctcc 60  
 gccattttac accactccct tctcgttgca acccaacaaa ttggcaactgc tcgtcgccga 120  
 cccctnctcc ctccccgcgt cccccgacaa gccatccgcg gccatgatca ccgcgctgga 180  
 cctctaccac gngctgacgg ctggnggtgc cgctgtacgt ggccatgacg ctggcgcnacg 240  
 gntnctgccc ctggnggngc atntncaacgc cggaccagtg ctccggnatc aaccgcttcg 300  
 tggcgctctt cgccgtgccg ctctctctct tccacttcat ctccaccaac gaccccttcg 360  
 ccatgaacct gcgcttctg gccgtcgaca cgctgcagaa ggtggcgctc ctgcgctgc 420  
 tggcgctggc ctcccgcggc ctcttctcnc cgagngcgct cagggctcga ctggagcatt 480  
 aagctctncc ccctctccac gctc 504

<210> 12  
 <211> 114  
 <212> PRT  
 <213> Zea mays

<220>  
 <221> UNSURE  
 <222> (10)  
 <223> Xaa = ANY AMINO ACID

<220>  
 <221> UNSURE  
 <222> (14)  
 <223> Xaa = ANY AMINO ACID

<220>  
 <221> UNSURE  
 <222> (25)  
 <223> Xaa = ANY AMINO ACID

<220>  
 <221> UNSURE  
 <222> (27)  
 <223> Xaa = ANY AMINO ACID

<220>  
 <221> UNSURE  
 <222> (31)..(32)..(33)..(34)  
 <223> Xaa = ANY AMINO ACID

<220>  
 <221> UNSURE  
 <222> (89)  
 <223> Xaa = ANY AMINO ACID

<220>  
 <221> UNSURE  
 <222> (91)  
 <223> Xaa = ANY AMINO ACID

<220>  
 <221> UNSURE  
 <222> (96)  
 <223> Xaa = ANY AMINO ACID

<220>  
 <221> UNSURE  
 <222> (98)  
 <223> Xaa = ANY AMINO ACID

<220>  
 <221> UNSURE  
 <222> (109)..(110)  
 <223> Xaa = ANY AMINO ACID

<400> 12  
 Met Ile Thr Ala Leu Asp Leu Tyr His Xaa Leu Thr Ala Xaa Val Pro  
 1 5 10 15  
 Leu Tyr Val Ala Met Thr Leu Ala Xaa Gly Xaa Val Arg Trp Xaa Xaa  
 20 25 30  
 Xaa Xaa Thr Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Leu  
 35 40 45

Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Thr Asn Asp Pro  
 50 55 60  
 Phe Ala Met Asn Leu Arg Phe Leu Ala Val Asp Thr Leu Gln Lys Val  
 65 70 75 80  
 Ala Val Leu Ala Leu Leu Ala Leu Xaa Ser Xaa Ala Ala Ser Ser Xaa  
 85 90 95  
 Arg Xaa Arg Ser Gly Leu Asp Trp Ser Ile Lys Leu Xaa Xaa Leu Ser  
 100 105 110

Thr Leu

<210> 13  
 <211> 2769  
 <212> DNA  
 <213> Zea mays

<400> 13  
 ccacgcgtcc gctgagccct acaaccactc tcttcttcat tgctccacac taccatctca 60  
 tctctccgcc attttacacc actcccttct cgttgcaacc caacaaattg gcaactgctcg 120  
 tcgcgcagcc ctctccctc cccgcgtccc ccgacaagcc atccgcggcc atgatcaccg 180  
 cgctggacct ctaccacgtg ctgacggcgg tggtgccgct gtacgtggcc atgacgctgg 240  
 cgtacggctc cgtccgctgg tggcgcatct tcacgccgga ccagtgtctc gggatcaacc 300  
 gcttcgtggc gctcttcgcc gtgcgcgtcc tctccttoca cticactctc accaacgacc 360  
 ccttcgccat gaacctgcgc ttcttgcccg ccgacacgct gcagaagggtg gccgtcctcg 420  
 cgctgctggc gctggcctcc cgcggcctct cctccccgcg cgcgctcggg ctgcactgga 480  
 gcateacgct cttctccctc tccacgctcc ccaacacgct cgctcatgggc atcccgctgc 540  
 tgcgaggcat gtacggcgcg tcgtcgcccg gcacgctcat ggtccagggtc gtcgtcctcc 600  
 agtgcacat ctggtacacg ctcatgtctt tctcttcga gtaccgcgcc gcgcgcgcgc 660  
 tcgtcctcga ccagttcccc gacggcgccg ccgcgtccat cgtctccttc cgcgtcgaact 720  
 ccgacgtcgt ctgcgtcggc aggggggacg tcgagctcga ggccgagccc gacggcgtcg 780  
 ccggcgccgg cgccgtctcc tcccgcggcg gggacgccgg gcgggtgcgc gtcaccgtgc 840  
 gcaagtcac cagctcgcgc tccgaggccg cgtgctcgca ctgcactcc cagaccatgc 900  
 agccccgtgt gtccaacctc tccggcgtag agatctactc gctgcagtcg tcgcgcaacc 960  
 ccacccccgc cggtccagc ttcaaccaag ccgacttctt caacatcgte ggcgcgcgcg 1020  
 ccaagggagg cggaggagcg gcgggggacg aggagaagg cgcagtcggc ggcggcgcg 1080  
 gaggacactc gccgcagccg caggccgtcg ccgtgccggc caagaggaag gacctgcaca 1140  
 tgctcgtctg gagctccagc gcctcgcccg tgtccgagcg gcgcgcgtg cactcttcg 1200  
 gcgcgcggcg cgctgacct gccgacgtcc tcgccaaagg agcccaggcc tacgacgagt 1260  
 acgggcgcga cgactacagc agcaggacga agaacgggag cgcgcgcgcg gacaaggcg 1320  
 ggccgacgct gtcgaagctg ggttccaaact cgacggcgca gctgtacccc aaggacgacg 1380  
 gcgaggggag ggccggcgcg gtggcgatgc cgcgcgcgag cgtgatgacg cggctcatcc 1440  
 tcatcatggt gtggaggaag ctgatccgga accccaacac ctactccagc ctcatcgcg 1500  
 tcgtctggtc cctggtctcc tacagggtgg gcatecgagat gccagcgatc atcgcccgg 1560  
 cgatttcgat cctgtcggac gcgggtctcg ggatggccat gttcagccta ggctgttca 1620  
 tggcgctgca gccgaggatc atcgcggtcg ggaacaagct ggcggccatc gcgatggcg 1680  
 tccggttcgt ccagggcccc gcggtcatgg ccgcgcctc catcgccgct ggtctgcgcg 1740  
 gcgtcctcct ccacatcgcc atcgctcagg ctgctctgcc tcagggggatc gtgcggttcg 1800  
 tggtcgccaa ggagtacggc gttcatcccg acatcctgag cacagcgtat ggtccaataa 1860  
 catcgcatgg ttctcatcact tgccatagtt aacgggaaaa aaaagcagaa gcaatcgatg 1920  
 acgacgcact gaattcacta tgattcatta ctaatgatgg tgtgttcatt cagtgcagtc 1980  
 aaagaaccac taataagcac tgatctagga cagcatcagc atgattgatt gcttgttttc 2040  
 tcttgacaat ctgcatttct tactacacag tgtgccttca ctcatccatc cagatgatca 2100  
 tacaacacta ctgatgcate tttttttttt attctgctgc agcgtgatct tcgggatgct 2160  
 catcgctctg cccatcccc tggtctacta catcttgcgt gggctgtgag cctctctcgc 2220  
 tcgcttcttc agcgtgcgga aggcgccatg ctgtggtgta tcggcccccac atgaaatttc 2280  
 tgatgagcat tagcgattac tattagctta gcgaagaatg atgagatggt gtcggcctgt 2340  
 cgggactggg ggagtcagac cagaccccc tcgaacaaaa gtttcttttg gcttctgtcc 2400

gtcagaaaca aaagttttgg cttttggcat gcgcactcga agcacagcag cagcagcagc 2460  
atcatccatg agatgatact cctctcgaat cctagagcta gcgaaggcaa taataagata 2520  
ccacaaggca atggaatcaa caaaagcttc atgcgacgcg ctatcatatc aaggaacaca 2580  
tgcagaatac aacggagtct agtgcgcaat ggcttcttct cttttttttt cttgcgaaaa 2640  
gggtttctag actgattaaa ggattccaaa tagcatctct ggattcgatt tctttcgcag 2700  
acaaattttc tggctttttt agaaaaatcc tctcgttgaa aaaaaaaaaa aaaaaaaaaa 2760  
aaaaaaaaag 2769

<210> 14  
<211> 573  
<212> PRT  
<213> Zea mays

<400> 14  
Met Ile Thr Ala Leu Asp Leu Tyr His Val Leu Thr Ala Val Val Pro  
1 5 10 15  
Leu Tyr Val Ala Met Thr Leu Ala Tyr Gly Ser Val Arg Trp Trp Arg  
20 25 30  
Ile Phe Thr Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Leu  
35 40 45  
Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Thr Asn Asp Pro  
50 55 60  
Phe Ala Met Asn Leu Arg Phe Leu Ala Ala Asp Thr Leu Gln Lys Val  
65 70 75 80  
Ala Val Leu Ala Leu Leu Ala Leu Ala Ser Arg Gly Leu Ser Ser Pro  
85 90 95  
Arg Ala Leu Gly Leu Asp Trp Ser Ile Thr Leu Phe Ser Leu Ser Thr  
100 105 110  
Leu Pro Asn Thr Leu Val Met Gly Ile Pro Leu Leu Arg Gly Met Tyr  
115 120 125  
Gly Ala Ser Ser Ala Gly Thr Leu Met Val Gln Val Val Val Leu Gln  
130 135 140  
Cys Ile Ile Trp Tyr Thr Leu Met Leu Phe Leu Phe Glu Tyr Arg Ala  
145 150 155 160  
Ala Arg Ala Leu Val Leu Asp Gln Phe Pro Asp Gly Ala Ala Ala Ser  
165 170 175  
Ile Val Ser Phe Arg Val Asp Ser Asp Val Val Ser Leu Ala Arg Gly  
180 185 190  
Asp Val Glu Leu Glu Ala Glu Pro Asp Gly Val Ala Gly Ala Gly Ala  
195 200 205  
Val Ser Ser Arg Gly Gly Asp Ala Gly Arg Val Arg Val Thr Val Arg  
210 215 220  
Lys Ser Thr Ser Ser Arg Ser Glu Ala Ala Cys Ser His Ser His Ser  
225 230 235 240  
Gln Thr Met Gln Pro Arg Val Ser Asn Leu Ser Gly Val Glu Ile Tyr  
245 250 255

10034164 10034165

Ser	Leu	Gln	Ser 260	Ser	Arg	Asn	Pro	Thr 265	Pro	Arg	Gly	Ser	Ser	Phe	Asn
His	Ala	Asp 275	Phe	Phe	Asn	Ile	Val 280	Gly	Ala	Ala	Ala	Lys 285	Gly	Gly	Gly
Gly	Ala 290	Ala	Gly	Asp	Glu	Glu 295	Lys	Gly	Ala	Cys	Gly 300	Gly	Gly	Gly	Gly
Gly 305	His	Ser	Pro	Gln	Pro 310	Gln	Ala	Val	Ala	Val 315	Pro	Ala	Lys	Arg	Lys 320
Asp	Leu	His	Met	Leu 325	Val	Trp	Ser	Ser	Ser 330	Ala	Ser	Pro	Val	Ser 335	Glu
Arg	Ala	Ala	Val 340	His	Val	Phe	Gly	Ala 345	Gly	Gly	Ala	Asp	His 350	Ala	Asp
Val	Leu	Ala 355	Lys	Gly	Ala	Gln	Ala 360	Tyr	Asp	Glu	Tyr	Gly 365	Arg	Asp	Asp
Tyr	Ser 370	Ser	Arg	Thr	Lys	Asn 375	Gly	Ser	Gly	Gly	Ala 380	Asp	Lys	Gly	Gly
Pro 385	Thr	Leu	Ser	Lys	Leu 390	Gly	Ser	Asn	Ser	Thr 395	Ala	Gln	Leu	Tyr	Pro 400
Lys	Asp	Asp	Gly	Glu 405	Gly	Arg	Ala	Ala 410	Ala	Val	Ala	Met	Pro	Pro 415	Ala
Ser	Val	Met	Thr 420	Arg	Leu	Ile	Leu	Ile 425	Met	Val	Trp	Arg	Lys 430	Leu	Ile
Arg	Asn	Pro 435	Asn	Thr	Tyr	Ser	Ser 440	Leu	Ile	Gly	Val	Val 445	Trp	Ser	Leu
Val	Ser 450	Tyr	Arg	Trp	Gly	Ile 455	Glu	Met	Pro	Ala	Ile 460	Ile	Ala	Arg	Ser
Ile 465	Ser	Ile	Leu	Ser	Asp 470	Ala	Gly	Leu	Gly	Met 475	Ala	Met	Phe	Ser	Leu 480
Gly	Leu	Phe	Met	Ala 485	Leu	Gln	Pro	Arg	Ile 490	Ile	Ala	Cys	Gly	Asn 495	Lys
Leu	Ala	Ala	Ile 500	Ala	Met	Gly	Val	Arg 505	Phe	Val	Ala	Gly	Pro 510	Ala	Val
Met	Ala	Ala 515	Ala	Ser	Ile	Ala	Val 520	Gly	Leu	Arg	Gly	Val 525	Leu	Leu	His
Ile	Ala 530	Ile	Val	Gln	Ala	Ala 535	Leu	Pro	Gln	Gly	Ile 540	Val	Pro	Phe	Val
Phe 545	Ala	Lys	Glu	Tyr	Gly 550	Val	His	Pro	Asp	Ile 555	Leu	Ser	Thr	Ala	Tyr 560
Gly	Pro	Ile	Thr	Ser 565	His	Gly	Phe	Ile	Thr 570	Cys	His	Ser			

<210> 15  
 <211> 543  
 <212> DNA  
 <213> Oryza sativa

<220>  
 <221> unsure  
 <222> (42)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (374)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (412)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (415)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (431)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (443)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (463)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (475)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (482)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (511)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (514)  
 <223> n=a,c,g or t

<220>



<221> unsure  
<222> (519)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (521)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (530)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (535)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (543)  
<223> n=a,c,g or t

<400> 15  
gagcgacgtc gagatgaacg ggcgcgtcgt cgcggcgccg gngcggcgccg ggcggcggtcc 60  
ggctaccgtt ctgggcgacg gcgaggacgg tggggctgaa gctggcgagg aaccggaacg 120  
tgtacgccag cgttctcggc gtcgtgtggg cgtgcatcgc gtacagggtg cacctgagct 180  
tgccggggat cgtgacgggg tcgctgcagg tgatgtccag gactggcacg gggatgtcca 240  
tgttcagcat ggggttggtc atggggcagc aggagagggt gatagcgtgc ggggcggggc 300  
tgacggcgct ggggatggcg ctgcgggttcg tcgcgggtcc gtcgcccacg ctgctcggcg 360  
ccgcgcgcct cggnctccgc ggcgacgtcc tgcacctcgc catcatacag gncgnactgc 420  
tcaatcgatt nttcttcgtt ttncaaagga gtatggctta ttncgatgac tcagnacggc 480  
gntatattcg gacattatcc tgtgcgatct ntnaatang nggtttgggn ttgtnaaatc 540  
atn 543

<210> 16  
<211> 110  
<212> PRT  
<213> Oryza sativa

<220>  
<221> UNSURE  
<222> (108)..(109)  
<223> Xaa = ANY AMINO ACID

<400> 16  
Val Gly Leu Lys Leu Ala Arg Asn Pro Asn Val Tyr Ala Ser Val Leu  
1 5 10 15  
Gly Val Val Trp Ala Cys Ile Ala Tyr Arg Trp His Leu Ser Leu Pro  
20 25 30  
Gly Ile Val Thr Gly Ser Leu Gln Val Met Ser Arg Thr Gly Thr Gly  
35 40 45  
Met Ser Met Phe Ser Met Gly Leu Phe Met Gly Gln Gln Glu Arg Val  
50 55 60  
Ile Ala Cys Gly Ala Gly Leu Thr Ala Leu Gly Met Ala Leu Arg Phe  
65 70 75 80

[illegible]

Arg Gly Asp Val Leu His Leu Ala Ile Ile Gln Xaa Xaa Leu  
100 105 110

```
<210> 17
<211> 330
<212> DNA
<213> Oryza sativa
```

<400> 17						
ctccactcgg	ccgctcctgc	atgtataact	agctagttct	agctcgctca	ggcactcgat	60
ccaccgccgg	gcgcgttgga	ttgagatagg	ctgaggagat	gatatccggg	cacgacttct	120
acacggtgat	ggcggcgggt	gtgccgctgt	acgtggcgat	gttctctggcg	tacgggtcgg	180
tgcggtggtg	gggcatcttc	acgcgcgcacc	agtgtccgg	catcaaccgc	ttcgtcgcca	240
tcttcgcgct	gcgcgtcttc	tcttcccaact	tcatctccac	caacgaccgg	tacgccatga	300
ccttcgcctt	cctgcgcgcg	ggacacgctg				330

```
<210> 18
<211> 74
<212> PRT
<213> Oryza sativa
```

<400> 18  
Met Ile Ser Gly His Asp Phe Tyr Thr Val Met Ala Ala Val Val Pro  
1 5 10 15

Leu Tyr Val Ala Met Phe Leu Ala Tyr Gly Ser Val Arg Trp Trp Gly  
20 25 30

Ile Phe Thr Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Ile  
35 40 45

Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Thr Asn Asp Pro  
50 55 60

Tyr Ala Met Asn Leu Arg Phe Leu Ala Ala  
65 70

```
<210> 19
<211> 2162
<212> DNA
<213> Oryza sativa
```

<400> 19						
ctccactcgg	ccgctcctgc	atgtataact	agctagttct	agctcgctca	ggcactcgat	60
ccaccgccgg	gcgcgttgga	ttgagatagg	ctgaggagat	gatatccggg	cacgacttct	120
acacggtgat	ggcggcggtg	gtgccgctgt	acgtggcgat	gttcctggcg	tacgggtcgg	180
tgcggtggtg	gggcattctc	acgccggacc	agtgtccgg	catcaaccgc	ttcgtcgcca	240
tcttcgccgt	gcgcgtcctg	tcttccaact	tcattctcac	cgacgaccgc	tacgccatga	300
acctccgctt	cctggcggcg	gacacgctgc	agaagctgct	cgtcctggcg	gggtcgcgcg	360
cgtggtcggt	cctccccctg	cggaccggcg	cgcgcggcgt	ggactgggtc	atcacgctct	420
tctccctctc	cacgctgccc	aacacgctcg	tcattggggat	cccgtgtgtg	atcgccatgt	480
acggggcata	ctccggctcg	ctcatgggtc	agatcgtcgt	gctccagtgc	atcatctggt	540
acacgctgat	gtctttcctc	ttcgagtcc	gcgcgcgcgc	gatgtgatc	gccgaccagt	600
tcccgacac	ggcggcgctc	atcgtgtccc	tgcacgtcga	cccggacgtg	gtgtcgctgg	660
agggcggcca	cgcggagacg	gaggccgagg	tggcggcgga	cgggcgggtg	cacgtcaccg	720
tgcgcgggtc	ctcggttctg	cggcggtcgc	tgttgttcac	gcgcggccgc	tcgaacctga	780
cggagacgga	gatatctcgt	cttaactcgt	cgcggaacct	aacctccggc	ggctccaact	840

[illegible]

```
<210> 20
<211> 589
<212> PRT
<213> Oryza sativa
```

<400> 20  
Met Ile Ser Gly His Asp Phe Tyr Thr Val Met Ala Ala Val Val Pro  
1 5 10 15

Leu Tyr Val Ala Met Phe Leu Ala Tyr Gly Ser Val Arg Trp Trp Gly  
20 25 30

Ile Phe Thr Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Ile  
35 40 45

Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Thr Asn Asp Pro  
50 55 60

Tyr Ala Met Asn Leu Arg Phe Leu Ala Ala Asp Thr Leu Gln Lys Leu  
65 70 75 80

Leu Val Leu Ala Gly Leu Ala Ala Trp Ser Arg Leu Pro Ser Arg Thr  
85 90 95

Gly Ala Pro Arg Leu Asp Trp Ser Ile Thr Leu Phe Ser Leu Ser Thr  
100 105 110

Leu Pro Asn Thr Leu Val Met Gly Ile Pro Leu Leu Ile Ala Met Tyr  
115 120 125

Gly Pro Tyr Ser Gly Ser Leu Met Val Gln Ile Val Val Leu Gln Cys  
130 135 140

Ile Ile Trp Tyr Thr Leu Met Leu Phe Leu Phe Glu Phe Arg Ala Ala  
145 150 155 160

Arg Met Leu Ile Ala Asp Gln Phe Pro Asp Thr Ala Ala Ser Ile Val

165								170				175			
Ser	Leu	His	Val 180	Asp	Pro	Asp	Val	Val 185	Ser	Leu	Glu	Gly	Gly 190	His	Ala
Glu	Thr	Glu	Ala 195	Glu	Val	Ala	Ala 200	Asp	Gly	Arg	Leu	His 205	Val	Thr	Val
Arg	Arg	Ser	Ser	Val	Ser	Arg	Arg	Ser	Leu	Leu	Val 220	Thr	Pro	Arg	Pro
Ser 225	Asn	Leu	Thr	Gly	Ala 230	Glu	Ile	Tyr	Ser	Leu 235	Ser	Ser	Ser	Arg	Asn 240
Pro	Thr	Pro	Arg	Gly 245	Ser	Asn	Phe	Asn	His 250	Ala	Asp	Phe	Phe	Ala 255	Met
Val	Gly	Gly	Gly 260	Pro	Pro	Pro	Pro	Thr 265	Pro	Ala	Ala	Val	Arg 270	Gly	Ser
Ser	Phe	Gly	Ala 275	Ser	Glu	Leu	Tyr 280	Ser	Leu	Gln	Ser	Ser 285	Arg	Gly	Pro
Thr	Pro	Arg	Gln	Ser	Asn	Phe 295	Asp	Glu	His	Ser	Ala 300	Arg	Pro	Pro	Lys
Pro 305	Pro	Ala	Thr	Thr	Thr 310	Gly	Ala	Leu	Asn	His 315	Asp	Ala	Lys	Glu	Leu 320
His	Met	Phe	Val	Trp 325	Ser	Ser	Ser	Ala	Ser 330	Pro	Val	Ser	Glu	Val 335	Ser
Gly	Leu	Pro	Val 340	Phe	Ser	Gly	Gly	Gly 345	Gly	Gly	Gly	Ala 350	Leu	Asp	Val
Gly	Ala	Lys 355	Glu	Ile	His	Met	Val 360	Ile	Pro	Ala	Asp	Leu 365	Pro	Gln	Asn
Asn	Gly 370	Ser	Gly	Lys	Glu	His 375	Glu	Glu	Tyr	Gly	Ala 380	Val	Ala	Leu	Gly
Gly 385	Gly	Gly	Gly	Gly	Glu 390	Asn	Phe	Ser	Phe	Gly 395	Gly	Gly	Lys	Thr	Val 400
Asp	Gly	Ala	Glu	Ala 405	Val	Asp	Glu	Glu	Ala 410	Ala	Leu	Pro	Asp	Gly 415	Leu
Thr	Lys	Met	Gly 420	Ser	Ser	Ser	Thr	Ala 425	Glu	Leu	His	Pro	Lys 430	Val	Val
Asp	Val	Asp 435	Gly	Pro	Asn	Ala	Gly 440	Gly	Gly	Ala	Ala	Gly 445	Ala	Gly	Gln
Tyr	Gln 450	Met	Pro	Pro	Ala	Ser 455	Val	Met	Thr	Arg	Leu 460	Ile	Leu	Ile	Met
Val 465	Trp	Arg	Lys	Leu	Ile 470	Arg	Asn	Pro	Asn	Thr 475	Tyr	Ser	Ser	Leu	Leu 480
Gly	Leu	Ala	Trp	Ser 485	Leu	Val	Ala	Phe	Arg 490	Leu	Phe	Met	Ala	Leu	Gln 495

Pro Ser Ile Ile Ala Cys Gly Lys Ser Ala Ala Val Val Ser Met Ala  
500 505 510

Val Arg Phe Leu Ala Gly Pro Ala Val Met Ala Ala Ala Ser Ile Ala  
515 520 525

Ile Gly Leu Arg Gly Thr Leu Leu His Val Ala Ile Val Gln Ala Ala  
530 535 540

Leu Pro Gln Gly Ile Val Pro Phe Val Phe Ala Lys Glu Tyr Asn Val  
545 550 555 560

His Pro Ala Ile Leu Ser Thr Ala Val Ile Phe Gly Met Leu Ile Ala  
565 570 575

Leu Pro Ile Thr Leu Leu Tyr Tyr Ile Leu Leu Gly Leu  
580 585

```
<210> 21
<211> 1618
<212> DNA
<213> Glycine max
```

<400>	21						
gcacgaggat	ctctgagcag	ttcccagaca	ctgccgggtac	cattgtctcc	atccatgtcg	60	
actctgatgt	catgtctott	gacggacgac	agcaccctct	ggaaccgat	gcccaaatca	120	
aagaggacgg	caagctccac	gtcactgtca	gaaaatccaa	cgcttccaga	tccgacatct	180	
ttcttagaag	gtcccagggc	ttctcttcca	ccaccctctcg	cccttccaat	ctcaccatgt	240	
ctgagattta	ctctctctcag	tctctctcgaa	accctactcc	acgtggctcc	agtttcaacc	300	
acaccgattt	ctactccatg	atggctgctg	gtcgtaattc	taactttggg	gccaacgatg	360	
tttatggcct	ttctgcttcc	agaggaccaa	ctcccagacc	ttccaattac	gacgaggatg	420	
cttctaataa	taacaatggg	aagccgaggt	accactaccc	tgctgctgga	acaggaacag	480	
gaacaggaac	aggaacggga	acgggaacag	ggcactaccc	tgctcctaac	cctggcatgt	540	
tctctcccac	tgcttctaaa	aacgtcgcca	agaagccaga	cgatccaaat	aaggaccttc	600	
atatgttcgt	ttggagttca	agtgtctccc	cggtttcgga	tgtgtttggg	gggtgacatg	660	
aatatgatca	taagaactc	aagtttaactg	tatctccagg	aaaagttggg	ggtaatatta	720	
atagagacac	tcaagaggag	taccagccag	agaaagatga	at tttagttt	ggaaacagag	780	
ggattgagga	tgagcatgaa	ggtgagaaa	ttggaaacgg	aaatccaaaa	acaatgcctc	840	
cagcaagtgt	aatgacgagg	cttattttga	tcatgggtgtg	gaggaaactt	atcagaaacc	900	
ccaacaccta	ctccagccta	atcggcctaa	cttgggtcact	catttccattc	aggtggaacg	960	
taaaaatgcc	agccataatt	gccaagtcta	tttcgatatt	gtcagatgca	gggcttggga	1020	
tggccatggt	tagtctttggt	ctgttcatgg	ctttgcaacc	gaggatcata	gcattgtggaa	1080	
attccacagc	agctttttct	atgcccgtga	gattctcttac	aggtccagct	gtcatggcag	1140	
ctgcttccat	tgctgtttga	ctcaaaaggcg	ttctcttgcg	cggttgcatt	gttcaggcag	1200	
ctcttctctca	aggaattgtc	ccatttgtct	ttgccaaagg	atacaatgta	catcctgata	1260	
ttctcagtac	gggtgttatt	tttgggatgt	tgattgcatt	gcccatctacg	ctcgtgtact	1320	
acatcttgct	gggttattga	gtgaatgaga	agatggaggga	tatgaagatt	acatgtggca	1380	
tggcattgcat	gcaatctcgt	ttgagactcc	ttagagcacg	acaacaaagt	ttcaatgaaa	1440	
tacaaaagca	tcaccataat	tgaattaggag	gaatcgatca	acggatgagt	tttcatTTTT	1500	
cttcttcttt	tttttttaat	gaattgtcct	tgctcagtga	aaatgtaaaa	tcatgtttgt	1560	
agctaatttta	taaaatggct	atctcgttaa	atttcaaatt	aaaaaaaaaa	aaaaaaaaaa	1618	

```
<210> 22
<211> 443
<212> PRT
<213> Glycine max
```

<400> 22  
Ile Ser Glu Gln Phe Pro Asp Thr Ala Gly Thr Ile Val Ser Ile His  
1 5 10 15

SECRET

Val	Asp	Ser	Asp 20	Val	Met	Ser	Leu	Asp 25	Gly	Arg	Gln	His	Pro 30	Leu	Glu
Thr	Asp	Ala 35	Gln	Ile	Lys	Glu	Asp 40	Gly	Lys	Leu	His	Val 45	Thr	Val	Arg
Lys	Ser	Asn 50	Ala	Ser	Arg	Ser 55	Asp	Ile	Phe	Ser	Arg 60	Arg	Ser	Gln	Gly
Phe 65	Ser	Ser	Thr	Thr	Pro 70	Arg	Pro	Ser	Asn	Leu 75	Thr	Asn	Ala	Glu	Ile 80
Tyr	Ser	Leu	Gln	Ser 85	Ser	Arg	Asn	Pro	Thr 90	Pro	Arg	Gly	Ser	Ser 95	Phe
Asn	His	Thr	Asp 100	Phe	Tyr	Ser	Met	Met 105	Ala	Ala	Gly	Arg	Asn 110	Ser	Asn
Phe	Gly	Ala 115	Asn	Asp	Val	Tyr	Gly 120	Leu	Ser	Ala	Ser	Arg 125	Gly	Pro	Thr
Pro	Arg	Pro 130	Ser	Asn	Tyr	Asp 135	Glu	Asp	Ala	Ser	Asn 140	Asn	Asn	Asn	Gly
Lys 145	Pro	Arg	Tyr	His	Tyr 150	Pro	Ala	Ala	Gly	Thr 155	Gly	Thr	Gly	Thr	Gly 160
Thr	Gly	Thr	Gly	Thr 165	Gly	Thr	Gly	His	Tyr 170	Pro	Ala	Pro	Asn	Pro 175	Gly
Met	Phe	Ser	Pro 180	Thr	Ala	Ser	Lys	Asn 185	Val	Ala	Lys	Lys	Pro 190	Asp	Asp
Pro	Asn	Lys 195	Asp	Leu	His	Met	Phe 200	Val	Trp	Ser	Ser	Ser 205	Ala	Ser	Pro
Val	Ser	Asp 210	Val	Phe	Gly	Gly 215	Gly	His	Glu	Tyr	Asp 220	His	Lys	Glu	Leu
Lys 225	Leu	Thr	Val	Ser	Pro 230	Gly	Lys	Val	Glu	Gly 235	Asn	Ile	Asn	Arg	Asp 240
Thr	Gln	Glu	Glu	Tyr 245	Gln	Pro	Glu	Lys	Asp 250	Glu	Phe	Ser	Phe	Gly 255	Asn
Arg	Gly	Ile	Glu 260	Asp	Glu	His	Glu	Gly 265	Glu	Lys	Val	Gly	Asn 270	Gly	Asn
Pro	Lys	Thr 275	Met	Pro	Pro	Ala	Ser 280	Val	Met	Thr	Arg	Leu 285	Ile	Leu	Ile
Met	Val	Trp 290	Arg	Lys	Leu	Ile 295	Arg	Asn	Pro	Asn	Thr 300	Tyr	Ser	Ser	Leu
Ile 305	Gly	Leu	Thr	Trp	Ser 310	Leu	Ile	Ser	Phe	Arg 315	Trp	Asn	Val	Lys	Met 320
Pro	Ala	Ile	Ile	Ala 325	Lys	Ser	Ile	Ser	Ile	Leu	Ser	Asp	Ala	Gly 335	Leu

$\frac{1}{\sqrt{\pi}} \int_{-\infty}^{\infty} f(x) \delta(x-a) dx = f(a)$

Leu Tyr Val Ala Met Ile Leu Ala Tyr Gly Ser Val Arg Trp Trp Lys  
 20 25 30  
 Xaa Ile Phe Ser Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala  
 35 40 45  
 Ile Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Thr Asn Asn  
 50 55 60  
 Pro Tyr Ala Met Asn Phe Arg Phe Ile Arg Arg Arg Thr Xaa Thr Ser  
 65 70 75 80  
 Lys Lys Ile Ile Met Leu Phe Ala Leu Ala  
 85 90

<210> 25  
 <211> 2101  
 <212> DNA  
 <213> Glycine max

<400> 25  
 ctttctctga cactccctca cttcatcctt ctacacattc acatcttctc tgaaacaatt 60  
 acaaagttag tgaaagttag gtcctagcac tagtagtaca gtacagaaaa ctagaagagc 120  
 aacccaaaatt ttccaatttag cactagtagt acagtacaaa aaactagaag agcaacccaaa 180  
 atttttccaat tgaaaaagaa ataacaacga gaacaaaatc ttatcgtgag atcgaataac 240  
 tgaaaaaaaaa ggaaagaaga acaaaaaatg ataacgtgga aagacctata caccgtcctg 300  
 accgcagtgg tccctctcta cgtggcgatg atcctggcgt acggctcggg cgggtggtgg 360  
 aagatcttct caccggacca gtgctccggc ataaaccgct tcgtggcgat cttcgccgtg 420  
 ccgctcctct ccttccactt catctccacc aacaaccct acgccatgaa cttccgcttc 480  
 atcgccgccc acaccctcca gaagatcatc atgctcttcg ccttgccat ctggaccaac 540  
 ctcaccaaaa cgggttccct agagtggatg attaccatct tctccctctc aacccttccc 600  
 aataccttag tcatgggaat tccactccta atcgccatgt acggcgacta ctccggctcg 660  
 ctcattggtt aggtcgtggt ccttcagtgc atcatatggt acaccttggt gctcttctta 720  
 ttcgaatacc gcgcgcgcaa aatcctaate atggaacagt tccctgaaac cgtgcctcc 780  
 atcgtgtcgt ttaaagtcca ctccgacgtc gtttcgctcg acgggaggga cttcttggag 840  
 accgacgccg aagtccgtga cgtatgggaag cttcatgtca ccgttagaaa gtcgaacgcc 900  
 tcgcgtaggt cgtttatgat gacgcgaggg ccttctaate tcaactgggg ggagatttac 960  
 agcctcagct cgtctcgtaa cccaaacacca cgtggctcaa actttaacca tgcggatttc 1020  
 ttctccatga tggggtacca gcctcgccac tccaatttca cggccaatga tttgttctcc 1080  
 tcgcgtggac ccactccgag gccttctaate ttogaagaac cctcaatgcc tcaggcgggtg 1140  
 accgtagctt ctctcgggtt cgggttctac ccgtcccaaa ccgtgccagc ttcgtaaccg 1200  
 ccgcccaccc cggatttttc ctccgctact aaaaacttga agaatacaaag tcagaatcag 1260  
 aatccgaacc agagccagag ccagaattcg caggctccgg cgaagggtgc ccacgatgcg 1320  
 aaggagctcc acatgtttgt gtggagctcc agtgccctcc cgatgtcgga gaatgccgga 1380  
 ctcaacgtct ttagcagcac agacctcgga acctccgaac aacctgacca ggggtgctaaa 1440  
 gagattagga tgttgggtgg tgataataat gcacacttac gaaatgggtga agccaacaac 1500  
 aaaggtggtt tggaggcagt acttggtgtg gaagacttca agtttctggt gaatggcgaa 1560  
 gaacaagttg gggaagaaaa agaagggtc aacaatgggc ttaacaagtt gggctcaagc 1620  
 tccacggtgg agctccaacc aaaagccacc gtagccggcg aggttccgc cggaaaacac 1680  
 atgcctccgg caaatgtcat gactcgtctc atactcatca tgggtgtggag aaagcttata 1740  
 cgcaatccca acacatactc tagcctaatt ggtgtagtat ggtccctcgt tgcattcagg 1800  
 tggcacgtgc atatgcccaa aataatagag aaatcaattt ccatactgtc tgatgccggt 1860  
 cttggaatgg ctatgttcag cttaggtgac tggtcgcaaa tccattctcc aaattcatac 1920  
 tctcgcgaaa taatttcatt cttttatcca aaaacaattt cgttccctc tttcccatag 1980  
 atcattatct tattggctcc aattgttagt gtaaatgtgg atttccctat actaagaaaa 2040  
 taaaatgcat gtgttttaatt atctatttat ttatttctga cccaaaaaaa aaaaaaaaaa 2100  
 a 2101

<210> 26  
 <211> 540  
 <212> PRT



<213> Glycine max

<400> 26

```

Met Ile Thr Trp Lys Asp Leu Tyr Thr Val Leu Thr Ala Val Val Pro
 1           5           10           15

Leu Tyr Val Ala Met Ile Leu Ala Tyr Gly Ser Val Arg Trp Trp Lys
          20           25           30

Ile Phe Ser Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Ile
          35           40           45

Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Thr Asn Asn Pro
          50           55           60

Tyr Ala Met Asn Phe Arg Phe Ile Ala Ala Asp Thr Leu Gln Lys Ile
          65           70           75           80

Ile Met Leu Phe Ala Leu Ala Ile Trp Thr Asn Leu Thr Lys Thr Gly
          85           90           95

Ser Leu Glu Trp Met Ile Thr Ile Phe Ser Leu Ser Thr Leu Pro Asn
          100          105          110

Thr Leu Val Met Gly Ile Pro Leu Leu Ile Ala Met Tyr Gly Asp Tyr
          115          120          125

Ser Gly Ser Leu Met Val Gln Val Val Val Leu Gln Cys Ile Ile Trp
          130          135          140

Tyr Thr Leu Leu Leu Phe Leu Phe Glu Tyr Arg Ala Ala Lys Ile Leu
          145          150          155          160

Ile Met Glu Gln Phe Pro Glu Thr Ala Ala Ser Ile Val Ser Phe Lys
          165          170          175

Val Asp Ser Asp Val Val Ser Leu Asp Gly Arg Asp Phe Leu Glu Thr
          180          185          190

Asp Ala Glu Val Gly Asp Asp Gly Lys Leu His Val Thr Val Arg Lys
          195          200          205

Ser Asn Ala Ser Arg Arg Ser Phe Met Met Thr Pro Arg Pro Ser Asn
          210          215          220

Leu Thr Gly Ala Glu Ile Tyr Ser Leu Ser Ser Ser Arg Asn Pro Thr
          225          230          235          240

Pro Arg Gly Ser Asn Phe Asn His Ala Asp Phe Phe Ser Met Met Gly
          245          250          255

Tyr Gln Pro Arg His Ser Asn Phe Thr Ala Asn Asp Leu Phe Ser Ser
          260          265          270

Arg Gly Pro Thr Pro Arg Pro Ser Asn Phe Glu Glu Pro Ser Met Pro
          275          280          285

Gln Ala Val Thr Val Ala Ser Pro Arg Phe Gly Phe Tyr Pro Ser Gln
          290          295          300

Thr Val Pro Ala Ser Tyr Pro Pro Pro Asn Pro Asp Phe Ser Ser Ala

```

305	310							315							320	
Thr	Lys	Asn	Leu	Lys	Asn	Gln	Ser	Gln	Asn	Gln	Asn	Pro	Asn	Gln	Ser	
				325					330					335		
Gln	Ser	Gln	Asn	Ser	Gln	Ala	Pro	Ala	Lys	Gly	Ala	His	Asp	Ala	Lys	
			340					345					350			
Glu	Leu	His	Met	Phe	Val	Trp	Ser	Ser	Ser	Ala	Ser	Pro	Met	Ser	Glu	
		355					360					365				
Asn	Ala	Gly	Leu	Asn	Val	Phe	Ser	Ser	Thr	Asp	Leu	Gly	Thr	Ser	Glu	
	370					375					380					
Gln	Pro	Asp	Gln	Gly	Ala	Lys	Glu	Ile	Arg	Met	Leu	Val	Ala	Asp	Asn	
385					390					395					400	
Asn	Ala	His	Leu	Arg	Asn	Gly	Glu	Ala	Asn	Asn	Lys	Gly	Gly	Leu	Glu	
				405					410					415		
Ala	Val	Leu	Gly	Val	Glu	Asp	Phe	Lys	Phe	Leu	Val	Asn	Gly	Glu	Glu	
			420					425					430			
Gln	Val	Gly	Glu	Glu	Lys	Glu	Gly	Leu	Asn	Asn	Gly	Leu	Asn	Lys	Leu	
		435					440					445				
Gly	Ser	Ser	Ser	Thr	Val	Glu	Leu	Gln	Pro	Lys	Ala	Thr	Val	Ala	Gly	
	450					455					460					
Glu	Ala	Ser	Ala	Gly	Lys	His	Met	Pro	Pro	Ala	Asn	Val	Met	Thr	Arg	
465					470					475					480	
Leu	Ile	Leu	Ile	Met	Val	Trp	Arg	Lys	Leu	Ile	Arg	Asn	Pro	Asn	Thr	
				485					490					495		
Tyr	Ser	Ser	Leu	Ile	Gly	Val	Val	Trp	Ser	Leu	Val	Ala	Phe	Arg	Trp	
			500					505					510			
His	Val	His	Met	Pro	Lys	Ile	Ile	Glu	Lys	Ser	Ile	Ser	Ile	Leu	Ser	
		515					520					525				
Asp	Ala	Gly	Leu	Gly	Met	Ala	Met	Phe	Ser	Leu	Gly					
	530					535					540					

<210> 27

<211> 525

<212> DNA

<213> Glycine max

<400> 27

cccactctg	ccttgctgt	tggagactgc	aagtgcaccc	ttgcttgag	ctctcaagg	60
tgaaaaaata	tttgctgtat	tctctgctgc	acattagcac	cattcactca	ctcactgcc	120
caaaaccaca	tgtctttcca	catccctata	taaaatcttt	tcaatcttca	taatcatcat	180
catcaccacc	aactccaact	caaactctcc	aaaacctgcc	acttcaacct	tcctatatat	240
tccttccctc	actctcttct	gcttctatca	tctttctgag	aggttgttg	acacacaaaa	300
aatgatcacc	ttaacagact	tctaccatgt	gatgactgca	atggtgccac	tctatgtggc	360
catgataact	gcctatggct	cagtgaagtg	gtggaagatt	tcttccctgt	ataatgctct	420
ggcatacaacc	gttttggtgc	actctttgca	gtgcctcttc	tctcctttca	cttcatagcc	480
tcacaacacc	ctttatgaga	tgaacctgaa	ggctctaact	ggctg		525

<210> 28



<210> 30

&lt;212&gt; PRT

<213> Glycine max

<400> 30

Leu Tyr Val Ala Met Ile Leu Ala Tyr Gly Ser Val Lys Trp Trp Lys  
20 25 30

Ile Phe Ser Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Leu  
35 40 45

Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ala Ser Asn Asn Pro  
50 55 60

Tyr Glu Met Asn Leu Arg Phe Leu Ala Ala Asp Thr Leu Gln Lys Ile  
65 70 75 80

Ile Ile Leu Val Leu Leu Ala Val Trp Ser Asn Ile Thr Lys Arg Gly  
85 90 95

Cys Leu Glu Trp Ala Ile Thr Leu Phe Ser Leu Ser Thr Leu Pro Asn  
100 105 110

Thr Leu Val Met Gly Ile Pro Leu Leu Lys Gly Met Tyr Gly Asp Phe  
115 120 125

Ser Gly Ser Leu Met Val Gln Ile Val Val Leu Gln Cys Ile Ile Trp  
130 135 140

Tyr Thr Leu Met Leu Phe Leu Phe Glu Phe Arg Gly Ala Arg Met Leu  
145 150 155 160

Ile Ser Glu Gln Phe Pro Asp Thr Ala Ala Ser Ile Val Ser Ile His  
165 170 175

Val Asp Ser Asp Val Met Ser Leu Asp Gly Arg Gln Pro Leu Glu Thr  
180 185 190

Glu Ala Glu Ile Lys Glu Asp Gly Lys Leu His Val Thr Val Arg Lys  
195 200 205

Ser Asn Ala Ser Arg Ser Asp Ile Phe Ser Arg Arg Ser Gln Gly Leu  
210 215 220

Ser Ser Thr Thr Pro Arg Pro Ser Asn Leu Thr Asn Ala Glu Ile Tyr  
225 230 235 240

[illegible]

Ser	Leu	Gln	Ser	Ser	Arg	Asn	Pro	Thr	Pro	Arg	Gly	Ser	Ser	Phe	Asn
				245					250					255	
His	Thr	Asp	Phe	Tyr	Ser	Met	Met	Ala	Ala	Gly	Gly	Arg	Asn	Ser	Asn
			260					265					270		
Phe	Gly	Ala	Ser	Asp	Val	Tyr	Gly	Leu	Ser	Ala	Ser	Arg	Gly	Pro	Thr
		275					280					285			
Pro	Arg	Pro	Ser	Asn	Tyr	Asp	Glu	Asp	Gly	Gly	Lys	Pro	Lys	Phe	His
	290					295					300				
Tyr	His	Ala	Ala	Gly	Gly	Thr	Gly	His	Tyr	Pro	Ala	Pro	Asn	Pro	Gly
305				310						315					320
Met	Phe	Ser	Pro	Ser	Asn	Gly	Ser	Lys	Ser	Val	Ala	Ala	Asn	Ala	Asn
				325					330					335	
Ala	Lys	Arg	Pro	Asn	Gly	Gln	Ala	Gln	Leu	Lys	Pro	Glu	Asp	Gly	Asn
			340					345					350		
Arg	Asp	Leu	His	Met	Phe	Val	Trp	Ser	Ser	Ser	Ala	Ser	Pro	Val	Ser
		355					360					365			
Asp	Val	Phe	Gly	Ala	His	Glu	Tyr	Gly	Gly	Gly	His	Asp	Gln	Lys	Glu
	370					375					380				
Val	Lys	Leu	Asn	Val	Ser	Pro	Gly	Lys	Val	Glu	Asn	Asn	His	Arg	Asp
385					390					395					400
Thr	Gln	Glu	Asp	Tyr	Leu	Glu	Lys	Asp	Glu	Phe	Ser	Phe	Gly	Asn	Arg
				405					410					415	
Glu	Met	Asp	Arg	Glu	Met	Asn	Gln	Leu	Glu	Gly	Glu	Lys	Val	Gly	Asp
			420					425					430		
Gly	Lys	Pro	Lys	Thr	Met	Pro	Pro	Ala	Ser	Val	Met	Thr	Arg	Leu	Ile
		435					440					445			
Leu	Ile	Met	Val	Trp	Arg	Lys	Leu	Ile	Arg	Asn	Pro	Asn	Thr	Tyr	Ser
	450					455					460				
Ser	Leu	Ile	Gly	Leu	Thr	Trp	Ser	Leu	Val	Ser	Phe	Lys	Trp	Asn	Val
465					470					475					480
Glu	Met	Pro	Ala	Ile	Ile	Ala	Lys	Ser	Ile	Ser	Ile	Leu	Ser	Asp	Ala
				485					490					495	
Gly	Leu	Gly	Met	Ala	Met	Phe	Ser	Leu	Gly	Leu	Phe	Met	Ala	Leu	Gln
			500					505					510		
Pro	Arg	Val	Ile	Ala	Cys	Gly	Asn	Ser	Thr	Ala	Ala	Phe	Ala	Met	Ala
		515					520					525			
Val	Arg	Phe	Leu	Thr	Gly	Pro	Ala	Val	Met	Ala	Ala	Ala	Ser	Ile	Ala
	530					535					540				
Val	Gly	Leu	Lys	Gly	Val	Leu	Leu	His	Val	Ala	Ile	Val	Gln	Ala	Ala
545					550					555					560

Leu Pro Gln Gly Ile Val Pro Phe Val Phe Ala Lys Glu Tyr Asn Val  
565 570 575

His Pro Asp Ile Leu Ser Thr Ala Val Ile Phe Gly Met Leu Ile Ala  
580 585 590

Leu Pro Ile Thr Leu Val Tyr Tyr Ile Leu Leu Gly Leu  
595 600 605

<210> 31  
<211> 419  
<212> DNA  
<213> Glycine max

<220>  
<221> unsure  
<222> (237)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (250)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (347)  
<223> n=a,c,g or t

<400> 31  
ctttatcgtg agagttttgc ctttatttct cagccatggt tccttctttt ccagcttaaa 60  
ccgctaccct acaaaacctt tcacaattct ctttcttctt agctatctct ttctttctgt 120  
ctacattgac ctagctagct acaaaccctg cattaaccat gatcactggg aaggatattt 180  
atgatgtttt cgcggctatt gtgcccctct acgttgctat gatattaagc atacggncca 240  
gttcggtggn ggaaaatttt cacacctgat caatgttctg gcataaaccg cttcgttgct 300  
gtgttcgcag ttccacttct ttctttccac ttcactctct ccaatgnccc ttatgctatg 360  
aactaccact tcatagcagc tgattgtctt caaaaagttg tcattttggg gggctcccc 419

<210> 32  
<211> 84  
<212> PRT  
<213> Glycine max

<220>  
<221> UNSURE  
<222> (25)  
<223> Xaa = ANY AMINO ACID

<220>  
<221> UNSURE  
<222> (32)  
<223> Xaa = ANY AMINO ACID

<220>  
<221> UNSURE  
<222> (64)  
<223> Xaa = ANY AMINO ACID

<400> 32  
Met Ile Thr Gly Lys Asp Ile Tyr Asp Val Phe Ala Ala Ile Val Pro  
1 5 10 15

Leu Tyr Val Ala Met Ile Leu Ser Xaa Tyr Gly Ser Val Arg Trp Xaa  
20 25 30

Lys Ile Phe Thr Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala  
35 40 45

Val Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Ser Asn Xaa  
50 55 60

Pro Tyr Ala Met Asn Tyr His Phe Ile Ala Ala Asp Cys Leu Gln Lys  
65 70 75 80

Val Val Ile Leu

<210> 33

<211> 2324

<212> DNA

<213> Glycine max

<400> 33

```
gcacgagcgtt tatcgtgaga gttttgcctt tattttctcag ccatgtttcc ttctttttcca 60
gcttaaaccg ctaccctaca aaacctttca caattctctt tcttcctagc tatctctttc 120
tttctgtcta cattgaccta gctagctaca aacctgtcat taacctgat cactggtaag 180
gatatttatg atgttttcgc ggctattgtg cccctctacg ttgctatgat attagcatat 240
ggctcagttc ggtgggtggaa aattttcaca cctgatcaat gttctggcat aaaccgcttc 300
gttgctgtgt tcgcagttcc acttctttct ttcacttca tctcctccaa tgaccttat 360
gctatgaact accacttcat agcagctgat tgtcttcaaa aagttgtcat tttgggtgct 420
ctctttctat ggaacacctt cacaacacat ggtagcctag actggacaat cacctcttc 480
tcactttcaa ccttccaaa cacacttgct atggggatcc ctctattgaa ggccatgtat 540
ggagacttct cagggagcct catggtccaa attgtggtgt tgcaaagtgt gatatgggat 600
accctcatgc tgttcatgtt tgaatataga ggtgcaaaac tcctcatcac agaacagttc 660
cctgagactg caggctccat aacttctctc aggggtgact cagatgttgt ctactcaat 720
ggtagagagc cacttcaaac agatgctgag ataggagaag atggaaaact tcatgtggtt 780
gttaaaagat gagcagcttc ttccatgata tcttcattca acaagtctca ttttaacttc 840
atgacaccaa gagcatctaa cctcaactggg gttgagatct attctgttca gtcacaaaga 900
gaaccaaccc caagaggttc gagtttcaac caaacggatt tctatgccat gttcgcaagc 960
aaggcaccga gtccaaaaca tggctacaca aacagtttcc agagtaataa tgggtggtatt 1020
ggtgacgttt actcgttgca gtcttcaaaa ggggcaacgc caaggacttc taattttgaa 1080
gaggagatgt tgaagatgca caagaagaga ggaggaggga gcatgagtg gtagttgttt 1140
aatggggggt tggtttcttc taattacccg ccaccgaatc caatgttttc aggggtctacg 1200
agtgtgtctg gtggcccaa gaagaaagat agcagtgggt gcggtgggtg tgtagcacct 1260
aacaaggagt tacacatgtt tgtttggagt tcaagtgcac cactgtttc tgaggggaat 1320
ttgaggcatg cagttaatag agctgcctct actgactttg gaactgtcga tcttcttaag 1380
gctgttccac acgaaactgt tgctcaaaa gctgttccag aattgattga gaacatgagc 1440
cctggtcgtg gagggagtgg agagagggag cctgaaatgg atgaaggagc caaaattccc 1500
gcaagtggat ctccatacac ttgccagaag aaggtggaca tggaagatgg caatgcaaac 1560
aaaaaccaac agatgccacc tgcaagtgtc atgacaagac ttattctcat catggttttg 1620
aggaaactca taagaaatcc taatacttac tccagtcttt tgggactcac atggtctctc 1680
atatcattta ggtggcacat tgaaatgcca actattgtaa aaggttccat ctcaatactg 1740
tctgatgctg gtctaggaat ggccatgttc agtctaggtc tattcatggc attacaaccg 1800
aagatcattg cctgtggaaa atctgtggca gcattttcaa tggctgttag gttcttgaca 1860
ggtccagctg tgattgctgc aacctcaata ggcacgggac tccgtggagt tcttttgcac 1920
gttgcaattg tccaggctgc tcttcccaa ggtatcgttc cctttgtgtt tgccaaagaa 1980
tacaatctcc atgcagatat acttagcact gcggttata ttgggatgct aattgcattg 2040
cccataacca tacttacta cgtgctgctt gtagtttaat ttgtcttggg agacaaaagc 2100
aatagaaaaa gaagtatatg ttgctataac tgcactgact atgtaaaccc aatgtcacgc 2160
tcaagcgggg tggatgaagg gaaatgtaga agatattgga ttttagatgt tagagggaaa 2220
gagaaattat ataatagata cggtagaatg ctatatatat taattattta tgattcatat 2280
gaaaattttg gtttgattcg ttccacaaaa aaaaaaaaaa aaaa 2324
```

<210> 34  
 <211> 637  
 <212> PRT  
 <213> Glycine max

<400> 34  
 Met Ile Thr Gly Lys Asp Ile Tyr Asp Val Phe Ala Ala Ile Val Pro  
 1 5 10 15  
 Leu Tyr Val Ala Met Ile Leu Ala Tyr Gly Ser Val Arg Trp Trp Lys  
 20 25 30  
 Ile Phe Thr Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Val  
 35 40 45  
 Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Ser Asn Asp Pro  
 50 55 60  
 Tyr Ala Met Asn Tyr His Phe Ile Ala Ala Asp Cys Leu Gln Lys Val  
 65 70 75 80  
 Val Ile Leu Gly Ala Leu Phe Leu Trp Asn Thr Phe Thr Lys His Gly  
 85 90 95  
 Ser Leu Asp Trp Thr Ile Thr Leu Phe Ser Leu Ser Thr Leu Pro Asn  
 100 105 110  
 Thr Leu Val Met Gly Ile Pro Leu Leu Lys Ala Met Tyr Gly Asp Phe  
 115 120 125  
 Ser Gly Ser Leu Met Val Gln Ile Val Val Leu Gln Ser Val Ile Trp  
 130 135 140  
 Tyr Thr Leu Met Leu Phe Met Phe Glu Tyr Arg Gly Ala Lys Leu Leu  
 145 150 155 160  
 Ile Thr Glu Gln Phe Pro Glu Thr Ala Gly Ser Ile Thr Ser Phe Arg  
 165 170 175  
 Val Asp Ser Asp Val Val Ser Leu Asn Gly Arg Glu Pro Leu Gln Thr  
 180 185 190  
 Asp Ala Glu Ile Gly Glu Asp Gly Lys Leu His Val Val Val Lys Arg  
 195 200 205  
 Ser Ala Ala Ser Ser Met Ile Ser Ser Phe Asn Lys Ser His Leu Thr  
 210 215 220  
 Ser Met Thr Pro Arg Ala Ser Asn Leu Thr Gly Val Glu Ile Tyr Ser  
 225 230 235 240  
 Val Gln Ser Ser Arg Glu Pro Thr Pro Arg Gly Ser Ser Phe Asn Gln  
 245 250 255  
 Thr Asp Phe Tyr Ala Met Phe Ala Ser Lys Ala Pro Ser Pro Lys His  
 260 265 270  
 Gly Tyr Thr Asn Ser Phe Gln Ser Asn Asn Gly Gly Ile Gly Asp Val  
 275 280 285





610	615	620
Leu Pro Ile Thr Ile Leu Tyr Tyr Val Leu Leu Gly Val		
625	630	635

<210> 35  
 <211> 473  
 <212> DNA  
 <213> Triticum aestivum

<220>  
 <221> unsure  
 <222> (22)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (46)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (58)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (61)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (91)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (98)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (101)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (122)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (177)  
 <223> n=a,c,g or t

<220>  
 <221> unsure  
 <222> (201)  
 <223> n=a,c,g or t

<220>



<221> unsure  
<222> (297)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (300)..(301)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (317)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (333)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (336)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (347)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (360)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (367)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (389)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (406)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (435)  
<223> n=a,c,g or t

<220>  
<221> unsure  
<222> (441)  
<223> n=a,c,g or t

<400> 35  
cccaccagca gagacgaaga tncacgagg aaccgttggg atctanctaa ctagctontc 60

ncgatgatta ccggaagga catctaccac ntgctggngg nggtgggtgcc gctgtacgtg 120  
 gncatgttca tggcgtagcg gtggtggcggt tgggtggggca tcttcacgcc ggaccantgc 180  
 tccggcatca aacgcttcgt ngcgtcttc gcggtgggcgc tctctctctt ccacttcac 240  
 tccaccaacg aaccctacgc catggactaa cgcttctctg gcgcgcgactc gctgcanaaa 300  
 ntcgttatcc tcgccgncct cgcgtgtgtg ganaangtgc tctcccncca acggtgccc 360  
 ggggganaga aggcggcgaa ggctcctcnc tgggctggga caacanactc ttctccttgg 420  
 ggaaagtgcc aaaanactgg ngaaggggaa tccccctgct gggcgcaagt atg 473

<210> 36  
 <211> 89  
 <212> PRT  
 <213> Triticum aestivum

<220>  
 <221> UNSURE  
 <222> (10)  
 <223> Xaa = ANY AMINO ACID

<220>  
 <221> UNSURE  
 <222> (12)..(13)  
 <223> Xaa = ANY AMINO ACID

<220>  
 <221> UNSURE  
 <222> (20)  
 <223> Xaa = ANY AMINO ACID

<220>  
 <221> UNSURE  
 <222> (38)  
 <223> Xaa = ANY AMINO ACID

<220>  
 <221> UNSURE  
 <222> (69)  
 <223> Xaa = ANY AMINO ACID

<220>  
 <221> UNSURE  
 <222> (78)..(79)..(80)  
 <223> Xaa = ANY AMINO ACID

<220>  
 <221> UNSURE  
 <222> (85)  
 <223> Xaa = ANY AMINO ACID

<400> 36  
 Met Ile Thr Gly Lys Asp Ile Tyr His Xaa Leu Xaa Xaa Val Val Pro  
 1 5 10 15  
 Leu Tyr Val Xaa Met Phe Met Ala Tyr Gly Ser Val Arg Trp Trp Gly  
 20 25 30  
 Ile Phe Thr Pro Asp Xaa Cys Ser Gly Ile Lys Arg Phe Val Ala Val  
 35 40 45  
 Phe Ala Val Ala Leu Leu Ser Phe His Phe Ile Ser Thr Asn Glu Pro  
 50 55 60

Tyr Ala Met Asp Xaa Arg Phe Leu Gly Ala Asp Ser Leu Xaa Xaa Xaa  
65 70 75 80

Val Ile Leu Ala Xaa Leu Ala Val Trp  
85

<210> 37  
<211> 2293  
<212> DNA  
<213> Triticum aestivum

<400> 37  
ctggatcgat cccagcagc agagacgaga tcccacgagg aaccgttggg atctagctag 60  
ctagctcgtc gcgatgatca ccgggaagga catctacgac gtgctggcgg cgggtggtgcc 120  
gctgtacgtg gccatgttca tggcgtacgg gtcggtgcgg tgggtggggca tcttcacgcc 180  
ggaccagtgc tcgggcatca accgcttcgt cgccgtcttc gcggtgccgc tctctcctt 240  
ccacttcatt tccaccaacg acccctacgc catggactac cgcttccttg ccgccgactc 300  
gctgcagaag ctgctcatcc tcgccgccct cgccgtgtgg cacaacgtgc tctcccgcta 360  
ccggtgccgc ggccggcagc aggcggcgga ggctcgtcgt ctggactgga ccatcacgct 420  
cttctccctg gcgacgctgc ccaacacgct ggtgatgggc atcccgtgc tgcgcgccat 480  
gtacggcgac ttctcggggg cgtcatggt gcagatcgtg gtgctgcaga gcgtcatctg 540  
gtacacgctc atgctcttcc tcttcgagta ccgcgccgcc aaggcgctca tctccgagca 600  
gttcccgccc gacgtcggcg ccagcatcgc ctcttccgc gtcgactccg acgtcgtctc 660  
gctcaacggg cgcgaggcgc tgcacgccga cgcgagggtc ggccgcgacg gccgcgtcca 720  
cgtcgtcatc cgcgggtccg cgtcggggtc caccacgggc ggccacggcg ccgggcgctc 780  
cgggatctac cgtggcgcggt ccaacgccat gacgccgcgc gcgtccaacc tcacgggcgt 840  
ggagatctac tcgctgcaga cgtcggggga gcccacgccg aggcagtcca gcttcaacca 900  
gtccgaattc tactccatgt tcaacgggag caagctggct agtcccaagg gccagcccc 960  
cgtcgcggga ggtggtggtg cgcgcgggca ggggctcgac gagcagggtg ccaacaagt 1020  
caaggcgggc gaggcggtg cgcctaccc cgcgcccaac ccgggatga tgatgccggc 1080  
gccacgggaag aaggagcttg ggggttccaa ctcaaactcg aacaaggagc tgcacatgt 1140  
cgtgtggagc tccagcgcgt cgcgcgtgtc ggaggccaac ctccgcaacg ccgtcaacca 1200  
cgcgcgctcc accgacttcg ccgcgcgacc gccggcgga gccacgccac gagacggcg 1260  
cacaccaga ggctgagcg gcagcgtgac gccggtgatg aagaaggagc ccagcagcg 1320  
cgcggtggag gtggagatcg aggacggcat gatgaagagc ccggcgacgg ggctggcg 1380  
caagttcccg gtgtcgggt cccctacgt ggcggcgcg aagaaggcg ccgacgtgc 1440  
tgggctggag gaggcgcg cccgatgcc gcggcgagc gtgatgacc ggctcatct 1500  
catcatggtg tggcgcaagc tcatccgcaa cccaacacc tactccagc tcatcggct 1560  
cgtctggtca ctgctctct tccaggtgaa cattcagatg cctacaataa tcaaggggtc 1620  
catatccatc ctgtctgatg cagggttagg gatggctatg ttcagcttag gtctcttcat 1680  
ggctctgcaa ccaagatca tctcttgagg gaagtctgtc gccacatttg caatggcagt 1740  
gaggttcttg actgggcgg cgggtgatcg cgcgacctca atcgccgtcg ggctccgggg 1800  
agtgtccta catgttgcca ttgtccaggc agcacttcca caaggaattg ttccatttgt 1860  
gttcgccaag gagtacaatt gccatcctca aatacttagc acagcggtta tttttggaat 1920  
gctcgtggcg ctcccgatca cgatactcta ctacgttctc cttgggatat agattcataa 1980  
tcttgaagaa ccaaggctgc aaatcttcgg gtagggagaa gtagaattct agagagaaaa 2040  
tggaactga acatgcttgt gggctgtcct gaagacctga agatgcatga gaccaagcag 2100  
aaggatagg agaactaagt aggaccctag acaggaattc aaaggacaga taaagatatc 2160  
cttggttcca ttttttaatt tttttatatt atttttacta ctgtttttaga tccaaagtaa 2220  
aggctagggc tttgagtatg aagagttcaa ccgttaaata gaaaaaaaaa aaaaaaaaaa 2280  
aaaaaaaaa aaa 2293

<210> 38  
<211> 632  
<212> PRT  
<213> Triticum aestivum

<400> 38  
Met Ile Thr Gly Lys Asp Ile Tyr Asp Val Leu Ala Ala Val Val Pro  
1 5 10 15



340										345				350			
Leu	His	Met	Phe	Val	Trp	Ser	Ser	Ser	Ala	Ser	Pro	Val	Ser	Glu	Ala		
		355					360					365					
Asn	Leu	Arg	Asn	Ala	Val	Asn	His	Ala	Ala	Ser	Thr	Asp	Phe	Ala	Ala		
370						375					380						
Ala	Pro	Pro	Ala	Ala	Ala	Thr	Pro	Arg	Asp	Gly	Ala	Thr	Pro	Arg	Gly		
385					390					395						400	
Val	Ser	Gly	Ser	Val	Thr	Pro	Val	Met	Lys	Lys	Asp	Ala	Ser	Ser	Gly		
				405					410					415			
Ala	Val	Glu	Val	Glu	Ile	Glu	Asp	Gly	Met	Met	Lys	Ser	Pro	Ala	Thr		
			420					425					430				
Gly	Leu	Gly	Ala	Lys	Phe	Pro	Val	Ser	Gly	Ser	Pro	Tyr	Val	Ala	Pro		
		435					440					445					
Arg	Lys	Lys	Gly	Ala	Asp	Val	Pro	Gly	Leu	Glu	Glu	Ala	Ala	His	Pro		
450						455					460						
Met	Pro	Pro	Ala	Ser	Val	Met	Thr	Arg	Leu	Ile	Leu	Ile	Met	Val	Trp		
465					470					475						480	
Arg	Lys	Leu	Ile	Arg	Asn	Pro	Asn	Thr	Tyr	Ser	Ser	Leu	Ile	Gly	Leu		
				485					490					495			
Val	Trp	Ser	Leu	Val	Ser	Phe	Arg	Trp	Asn	Ile	Gln	Met	Pro	Thr	Ile		
			500					505					510				
Ile	Lys	Gly	Ser	Ile	Ser	Ile	Leu	Ser	Asp	Ala	Gly	Leu	Gly	Met	Ala		
		515					520					525					
Met	Phe	Ser	Leu	Gly	Leu	Phe	Met	Ala	Leu	Gln	Pro	Lys	Ile	Ile	Ser		
530						535					540						
Cys	Gly	Lys	Ser	Val	Ala	Thr	Phe	Ala	Met	Ala	Val	Arg	Phe	Leu	Thr		
545					550					555					560		
Gly	Pro	Ala	Val	Ile	Ala	Ala	Thr	Ser	Ile	Ala	Val	Gly	Leu	Arg	Gly		
				565					570					575			
Val	Leu	Leu	His	Val	Ala	Ile	Val	Gln	Ala	Ala	Leu	Pro	Gln	Gly	Ile		
			580					585					590				
Val	Pro	Phe	Val	Phe	Ala	Lys	Glu	Tyr	Asn	Cys	His	Pro	Gln	Ile	Leu		
		595					600					605					
Ser	Thr	Ala	Val	Ile	Phe	Gly	Met	Leu	Val	Ala	Leu	Pro	Ile	Thr	Ile		
610						615					620						
Leu	Tyr	Tyr	Val	Leu	Leu	Gly	Ile										
625					630												

```
<210> 39
<211> 447
<212> DNA
<213> Triticum aestivum
```

```

<400> 40
Met Ile Ala Leu Gly Asp Ile Tyr Lys Val Val Glu Ala Met Ala Pro
  1             5             10             15

Leu Tyr Phe Ala Leu Gly Leu Gly Tyr Gly Ser Val Arg Trp Trp Arg
          20             25             30

Phe Phe Thr Ala Glu Gln Cys Gly Ala Ile Asn Thr Leu Val Val Cys
          35             40             45

Phe Ser Met Pro Phe Phe Thr Phe Asp Phe Val Val Arg Ala Asp Pro
  50             55             60

Tyr Ala Met Asn Tyr Arg Val Ile Ala Ala Asp Ala Val Ala Lys Leu
  65             70             75             80

```



Leu Ala Val Leu Ala Ala Ala Val Trp Ala Arg Cys Ala Lys  
85 90

```
<210> 41
<211> 415
<212> DNA
<213> Triticum aestivum
```

<400>	41						
ctcgccctaaa	taaacctctc	ccccacgcac	tcccccactc	caccacacac	cctcaccagc	60	
tcgcccgcag	agtgagccga	ggcggagagc	cggagcgcga	gaggaagaag	cagaggaggt	120	
cgggcaagat	gatcacgggc	acggacttct	accacgtgat	gacggcgggtg	gtgccgctgt	180	
acgtggccat	gatcctcgcc	tacggctccg	tcaagtgggtg	gggcatcttc	acgccggacc	240	
agtgtctccg	gatcaaccgc	ttcgctcgcc	tcttcgcgtt	gccgctcttc	tccttccact	300	
tcattctccac	caacaacccc	tacaccatga	acctgcgctt	catcgccgcc	gacacgtgc	360	
agaagctcat	gatgctcgcc	atgctcaacg	cctggagcaa	ctctcccgcc	ggggc	415	

```
<210> 42
<211> 91
<212> PRT
<213> Triticum aestivum
```

```
<400> 42
Met Ile Thr Gly Thr Asp Phe Tyr His Val Met Thr Ala Val Val Pro
  1                   5                10               15
```

Leu Tyr Val Ala Met Ile Leu Ala Tyr Gly Ser Val Lys Trp Trp Gly  
20 25 30

Ile Phe Thr Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Leu  
35 40 45

Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Thr Asn Asn Pro  
50 55 60

Tyr Thr Met Asn Leu Arg Phe Ile Ala Ala Asp Thr Leu Gln Lys Leu  
65 70 75 80

Met Met Leu Ala Met Leu Asn Ala Trp Ser Asn  
85 90

```
<210> 43
<211> 647
<212> PRT
<213> Arabidopsis thaliana
```

<400> 43  
Met Ile Thr Gly Lys Asp Met Tyr Asp Val Leu Ala Ala Met Val Pro  
1 5 10 15

Leu Tyr Val Ala Met Ile Leu Ala Tyr Gly Ser Val Arg Trp Trp Gly  
20 25 30

Ile Phe Thr Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Val  
35 40 45

Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Ser Asn Asp Pro  
50 55 60

Tyr Ala Met Asn Tyr His Phe Leu Ala Ala Asp Ser Leu Gln Lys Val  
65 70 75 80

SECRET

Val	Ile	Leu	Ala	Ala	Leu	Phe	Leu	Trp	Gln	Ala	Phe	Ser	Arg	Arg	Gly
				85					90					95	
Ser	Leu	Glu	Trp	Met	Ile	Thr	Leu	Phe	Ser	Leu	Ser	Thr	Leu	Pro	Asn
			100					105					110		
Thr	Leu	Val	Met	Gly	Ile	Pro	Leu	Leu	Arg	Ala	Met	Tyr	Gly	Asp	Phe
		115					120					125			
Ser	Gly	Asn	Leu	Met	Val	Gln	Ile	Val	Val	Leu	Gln	Ser	Ile	Ile	Trp
	130					135					140				
Tyr	Thr	Leu	Met	Leu	Phe	Leu	Phe	Glu	Phe	Arg	Gly	Ala	Lys	Leu	Leu
145					150					155					160
Ile	Ser	Glu	Gln	Phe	Pro	Glu	Thr	Ala	Gly	Ser	Ile	Thr	Ser	Phe	Arg
				165					170					175	
Val	Asp	Ser	Asp	Val	Ile	Ser	Leu	Asn	Gly	Arg	Glu	Pro	Leu	Gln	Thr
			180					185					190		
Asp	Ala	Glu	Ile	Gly	Asp	Asp	Gly	Lys	Leu	His	Val	Val	Val	Arg	Arg
		195					200					205			
Ser	Ser	Ala	Ala	Ser	Ser	Met	Ile	Ser	Ser	Phe	Asn	Lys	Ser	His	Gly
		210				215					220				
Gly	Gly	Leu	Asn	Ser	Ser	Met	Ile	Thr	Pro	Arg	Ala	Ser	Asn	Leu	Thr
225					230					235					240
Gly	Val	Glu	Ile	Tyr	Ser	Val	Gln	Ser	Ser	Arg	Glu	Pro	Thr	Pro	Arg
				245					250					255	
Ala	Ser	Ser	Phe	Asn	Gln	Thr	Asp	Phe	Tyr	Ala	Met	Phe	Asn	Ala	Ser
			260					265					270		
Lys	Ala	Pro	Ser	Pro	Arg	His	Gly	Tyr	Thr	Asn	Ser	Tyr	Gly	Gly	Ala
		275					280					285			
Gly	Ala	Gly	Pro	Gly	Gly	Asp	Val	Tyr	Ser	Leu	Gln	Ser	Ser	Lys	Gly
	290					295					300				
Val	Thr	Pro	Arg	Thr	Ser	Asn	Phe	Asp	Glu	Glu	Val	Met	Lys	Thr	Ala
305					310					315					320
Lys	Lys	Ala	Gly	Arg	Gly	Gly	Arg	Ser	Met	Ser	Gly	Glu	Leu	Tyr	Asn
				325					330					335	
Asn	Asn	Ser	Val	Pro	Ser	Tyr	Pro	Pro	Pro	Asn	Pro	Met	Phe	Thr	Gly
			340					345					350		
Ser	Thr	Ser	Gly	Ala	Ser	Gly	Val	Lys	Lys	Lys	Glu	Ser	Gly	Gly	Gly
		355					360					365			
Gly	Ser	Gly	Gly	Gly	Val	Gly	Val	Gly	Gly	Gln	Asn	Lys	Glu	Met	Asn
	370					375					380				
Met	Phe	Val	Trp	Ser	Ser	Ser	Ala	Ser	Pro	Val	Ser	Glu	Ala	Asn	Ala
385					390					395					400

[illegible]

Lys Val Ser Ile Pro Pro His Asp Asn Leu Ala Thr Lys Ala Met Gln  
420 425 430

Asn Leu Ile Glu Asn Met Ser Pro Gly Arg Lys Gly His Val Glu Met  
435 440 445

Asp Gln Asp Gly Asn Asn Gly Gly Lys Ser Pro Tyr Met Gly Lys Lys  
450 455 460

Gly Ser Asp Val Glu Asp Gly Gly Pro Gly Pro Arg Lys Gln Gln Met  
465 470 475 480

Pro Pro Ala Ser Val Met Thr Arg Leu Ile Leu Ile Met Val Trp Arg  
485 490 495

Lys Leu Ile Arg Asn Pro Asn Thr Tyr Ser Ser Leu Phe Gly Leu Ala  
500 505 510

Trp Ser Leu Val Ser Phe Lys Trp Asn Ile Lys Met Pro Thr Ile Met  
515 520 525

Ser Gly Ser Ile Ser Ile Leu Ser Asp Ala Gly Leu Gly Met Ala Met  
530 535 540

Phe Ser Leu Gly Leu Phe Met Ala Leu Gln Pro Lys Ile Ile Ala Cys  
545 550 555 560

Gly Lys Ser Val Ala Gly Phe Ala Met Ala Val Arg Phe Leu Thr Gly  
565 570 575

Pro Ala Val Ile Ala Ala Thr Ser Ile Ala Ile Gly Ile Arg Gly Asp  
580 585 590

Leu Leu His Ile Ala Ile Val Gln Ala Ala Leu Pro Gln Gly Ile Val  
595 600 605

Pro Phe Val Phe Ala Lys Glu Tyr Asn Val His Pro Asp Ile Leu Ser  
610 615 620

Thr Ala Val Ile Phe Gly Met Leu Val Ala Leu Pro Val Thr Val Leu  
625 630 635 640

Tyr Tyr Val Leu Leu Gly Leu  
645

<210> 44

<211> 622

&lt;212&gt; PRT

<213> Arabidopsis thaliana

<400> 44

Met Ile Thr Ala Ala Asp Phe Tyr His Val Met Thr Ala Met Val Pro  
1 5 10 15

Leu Tyr Val Ala Met Ile Leu Ala Tyr Gly Ser Val Lys Trp Trp Lys  
20 25 30

Ile Phe Thr Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Leu

35					40					45					
Phe	Ala	Val	Pro	Leu	Leu	Ser	Phe	His	Phe	Ile	Ala	Ala	Asn	Asn	Pro
50						55					60				
Tyr	Ala	Met	Asn	Leu	Arg	Phe	Leu	Ala	Ala	Asp	Ser	Leu	Gln	Lys	Val
65					70					75					80
Ile	Val	Leu	Ser	Leu	Leu	Phe	Leu	Trp	Cys	Lys	Leu	Ser	Arg	Asn	Gly
				85					90					95	
Ser	Leu	Asp	Trp	Thr	Ile	Thr	Leu	Phe	Ser	Leu	Ser	Thr	Leu	Pro	Asn
			100					105					110		
Thr	Leu	Val	Met	Gly	Ile	Pro	Leu	Leu	Lys	Gly	Met	Tyr	Gly	Asn	Phe
			115				120					125			
Ser	Gly	Asp	Leu	Met	Val	Gln	Ile	Val	Val	Leu	Gln	Cys	Ile	Ile	Trp
	130					135					140				
Tyr	Ile	Leu	Met	Leu	Phe	Leu	Phe	Glu	Tyr	Arg	Gly	Ala	Lys	Leu	Leu
145					150					155					160
Ile	Ser	Glu	Gln	Phe	Pro	Asp	Thr	Ala	Gly	Ser	Ile	Val	Ser	Ile	His
				165					170					175	
Val	Asp	Ser	Asp	Ile	Met	Ser	Leu	Asp	Gly	Arg	Gln	Pro	Leu	Glu	Thr
			180					185					190		
Glu	Ala	Glu	Ile	Lys	Glu	Asp	Gly	Lys	Leu	His	Val	Thr	Val	Arg	Arg
		195					200					205			
Ser	Asn	Ala	Ser	Arg	Ser	Asp	Ile	Tyr	Ser	Arg	Arg	Ser	Gln	Gly	Leu
	210					215					220				
Ser	Ala	Thr	Pro	Arg	Pro	Ser	Asn	Leu	Thr	Asn	Ala	Glu	Ile	Tyr	Ser
225					230					235					240
Leu	Gln	Ser	Ser	Arg	Asn	Pro	Thr	Pro	Arg	Gly	Ser	Ser	Phe	Asn	His
				245					250					255	
Thr	Asp	Phe	Tyr	Ser	Met	Met	Ala	Ser	Gly	Gly	Gly	Arg	Asn	Ser	Asn
			260					265					270		
Phe	Gly	Pro	Gly	Glu	Ala	Val	Phe	Gly	Ser	Lys	Gly	Pro	Thr	Pro	Arg
		275					280					285			
Pro	Ser	Asn	Tyr	Glu	Glu	Asp	Gly	Gly	Pro	Ala	Lys	Pro	Thr	Ala	Ala
	290					295					300				
Gly	Thr	Ala	Ala	Gly	Ala	Gly	Arg	Phe	His	Tyr	Gln	Ser	Gly	Gly	Ser
305					310					315					320
Gly	Gly	Gly	Gly	Gly	Ala	His	Tyr	Pro	Ala	Pro	Asn	Pro	Gly	Met	Phe
				325					330					335	
Ser	Pro	Asn	Thr	Gly	Gly	Gly	Gly	Gly	Thr	Ala	Ala	Lys	Gly	Asn	Ala
			340					345					350		
Pro	Val	Val	Gly	Gly	Lys	Arg	Gln	Asp	Gly	Asn	Gly	Arg	Asp	Leu	His
		355					360					365			

Met Phe Val Trp Ser Ser Ser Ala Ser Pro Val Ser Asp Val Phe Gly  
370 375 380

Gly Gly Gly Gly Asn His His Ala Asp Tyr Ser Thr Ala Thr Asn Asp  
385 390 395 400

His Gln Lys Asp Val Lys Ile Ser Val Pro Gln Gly Asn Ser Asn Asp  
405 410 415

Asn Gln Tyr Val Glu Arg Glu Glu Phe Ser Phe Gly Asn Lys Asp Asp  
420 425 430

Asp Ser Lys Val Leu Ala Thr Asp Gly Gly Asn Asn Ile Ser Asn Lys  
435 440 445

Thr Thr Gln Ala Lys Val Met Pro Pro Thr Ser Val Met Thr Arg Leu  
450 455 460

Ile Leu Ile Met Val Trp Arg Lys Leu Ile Arg Asn Pro Asn Ser Tyr  
465 470 475 480

Ser Ser Leu Phe Gly Ile Thr Trp Ser Leu Ile Ser Phe Lys Trp Asn  
485 490 495

Ile Glu Met Pro Ala Leu Ile Ala Lys Ser Ile Ser Ile Leu Ser Asp  
500 505 510

Ala Gly Leu Gly Met Ala Met Phe Ser Leu Gly Leu Phe Met Ala Leu  
515 520 525

Asn Pro Arg Ile Ile Ala Cys Gly Asn Arg Arg Ala Ala Phe Ala Ala  
530 535 540

Ala Met Arg Phe Val Val Gly Pro Ala Val Met Leu Val Ala Ser Tyr  
545 550 555 560

Ala Val Gly Leu Arg Gly Val Leu Leu His Val Ala Ile Ile Gln Ala  
565 570 575

Ala Leu Pro Gln Gly Ile Val Pro Phe Val Phe Ala Lys Glu Tyr Asn  
580 585 590

Val His Pro Asp Ile Leu Ser Thr Ala Val Ile Phe Gly Met Leu Ile  
595 600 605

Ala Leu Pro Ile Thr Leu Leu Tyr Tyr Ile Leu Leu Gly Leu  
610 615 620

<210> 45  
<211> 425  
<212> DNA  
<213> Triticum aestivum

<400> 45  
gcacgagctc gcctaaataa acctctcccc cagcactcc cccactccac cacacaccct 60  
caccagctcg cccgcagagt gagccgaggg cgagagccgg agcgcgagag gaagaagcag 120  
aggaggctcg gcaagatgat caccgggcacg gacttctacc acgtgatgac ggccggtggtg 180  
ccgctgtacg tggccatgat cctcgccctac ggctccgtca agtgggtgggg catcttcacg 240  
ccggaccagt gctccgggat caaccgcttc gtcgcgtctt tcgccgtgcc gctcctctcc 300  
ttccacttca tctccaccaa caaccctac accatgaacc tgcgcttcat cgccgcccagac 360

acgctgcaga agctcatgat gctcgccatg ctcaccgcct ggagccacct ctcccgcgcg 420  
ggcag 425

<210> 46  
<211> 96  
<212> PRT  
<213> Triticum aestivum

<400> 46  
Met Ile Thr Gly Thr Asp Phe Tyr His Val Met Thr Ala Val Val Pro  
1 5 10 15  
Leu Tyr Val Ala Met Ile Leu Ala Tyr Gly Ser Val Lys Trp Trp Gly  
20 25 30  
Ile Phe Thr Pro Asp Gln Cys Ser Gly Ile Asn Arg Phe Val Ala Leu  
35 40 45  
Phe Ala Val Pro Leu Leu Ser Phe His Phe Ile Ser Thr Asn Asn Pro  
50 55 60  
Tyr Thr Met Asn Leu Arg Phe Ile Ala Ala Asp Thr Leu Gln Lys Leu  
65 70 75 80  
Met Met Leu Ala Met Leu Thr Ala Trp Ser His Leu Ser Arg Arg Gly  
85 90 95

<210> 47  
<211> 855  
<212> DNA  
<213> Zea mays

<400> 47  
ccacgcgtcc ggctgacgt cctggcgctg ctcactgcat ggagctacct ctcccgcgcg 60  
ggctgcctcg agtggaccat cacgctcttc tccctgtcga cgctgcccac cacgctggtg 120  
atgggcatcc cgctgctcaa gggcatgtac ggcgacttct ccggcagcct catggtgcag 180  
atcgtggtgc tccagtgcac catctggtac acgctgatgc tgttcatgtt cgagtaccgc 240  
ggcgccagga tctcatcac cgagcagttc cccgacacgg cgggcgccat cgcctccatc 300  
gtggtggacc ccgacgtggt gtcgctggac gggcgcaacg acgccatcga gacggaggcc 360  
gaggtgaagg aggacggcaa gatacacgtc accgtgcggc gctccaacgc gtcgcgtcg 420  
gacatctact cccggcggtc catgggggtc tccagcacca cgccgcggcc cagcaacctg 480  
accaacgccg agatctact gctgcagtcg tccaggaacc ccacgcgcg gggctccagc 540  
ttcaaccaca ccgacttcta ctccatggtc ggcgcgagct ccaacttcgc cgccggggac 600  
gcgttcggcc tgcgcacggg cgccacgccc aggcggtcca actacgagga ggaccgcag 660  
ggcaaggcga acaagtacgg ccagtaccgc gcgcccaccc cggccatggc ggcgcagccc 720  
gccaagggcc tcaagaaggc ggccaatggg caggccaagg gcgaggacgg caaggacct 780  
cacatgttcg tgtggagtc cagcgcgtcg cccgtgtccg acgtgttcg caatggcgcc 840  
gccgagtaca acgac 855

<210> 48  
<211> 285  
<212> PRT  
<213> Zea mays

<400> 48  
Pro Arg Val Arg Leu Ile Val Leu Ala Leu Leu Thr Ala Trp Ser Tyr  
1 5 10 15  
Leu Ser Arg Arg Gly Cys Leu Glu Trp Thr Ile Thr Leu Phe Ser Leu  
20 25 30

Ser Thr Leu Pro Asn Thr Leu Val Met Gly Ile Pro Leu Leu Lys Gly  
35 40 45

Met Tyr Gly Asp Phe Ser Gly Ser Leu Met Val Gln Ile Val Val Leu  
50 55 60

Gln Cys Ile Ile Trp Tyr Thr Leu Met Leu Phe Met Phe Glu Tyr Arg  
65 70 75 80

Gly Ala Arg Ile Leu Ile Thr Glu Gln Phe Pro Asp Thr Ala Gly Ala  
85 90 95

Ile Ala Ser Ile Val Val Asp Pro Asp Val Val Ser Leu Asp Gly Arg  
100 105 110

Asn Asp Ala Ile Glu Thr Glu Ala Glu Val Lys Glu Asp Gly Lys Ile  
115 120 125

His Val Thr Val Arg Arg Ser Asn Ala Ser Arg Ser Asp Ile Tyr Ser  
130 135 140

Arg Arg Ser Met Gly Phe Ser Ser Thr Thr Pro Arg Pro Ser Asn Leu  
145 150 155 160

Thr Asn Ala Glu Ile Tyr Ser Leu Gln Ser Ser Arg Asn Pro Thr Pro  
165 170 175

Arg Gly Ser Ser Phe Asn His Thr Asp Phe Tyr Ser Met Val Gly Arg  
180 185 190

Ser Ser Asn Phe Ala Ala Gly Asp Ala Phe Gly Leu Arg Thr Gly Ala  
195 200 205

Thr Pro Arg Pro Ser Asn Tyr Glu Glu Asp Pro Gln Gly Lys Ala Asn  
210 215 220

Lys Tyr Gly Gln Tyr Pro Ala Pro Asn Pro Ala Met Ala Ala Gln Pro  
225 230 235 240

Ala Lys Gly Leu Lys Lys Ala Ala Asn Gly Gln Ala Lys Gly Glu Asp  
245 250 255

Gly Lys Asp Leu His Met Phe Val Trp Ser Ser Ser Ala Ser Pro Val  
260 265 270

Ser Asp Val Phe Gly Asn Gly Ala Ala Glu Tyr Asn Asp  
275 280 285